WO2002006213A2 - Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids - Google Patents

Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids Download PDF

Info

Publication number
WO2002006213A2
WO2002006213A2 PCT/US2001/022331 US0122331W WO0206213A2 WO 2002006213 A2 WO2002006213 A2 WO 2002006213A2 US 0122331 W US0122331 W US 0122331W WO 0206213 A2 WO0206213 A2 WO 0206213A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenylamino
benzamide
iodo
difluoro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/022331
Other languages
French (fr)
Other versions
WO2002006213A3 (en
Inventor
Stephen Douglas Barrett
Cathlin Biwersi
Michael Kaufman
Haile Tecle
Joseph Scott Warmus
Michael Huai Gu Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HR20030083A priority Critical patent/HRP20030083A2/en
Priority to DK01952778.7T priority patent/DK1301472T3/en
Priority to HK03108249.9A priority patent/HK1055943B/en
Priority to DZ013401A priority patent/DZ3401A1/en
Priority to BRPI0112584-2 priority patent/BRPI0112584B8/en
Priority to EA200300065A priority patent/EA005818B1/en
Priority to CA002416685A priority patent/CA2416685C/en
Priority to US10/333,399 priority patent/US6960614B2/en
Priority to ES01952778.7T priority patent/ES2461854T3/en
Priority to AU2001273498A priority patent/AU2001273498B2/en
Priority to PL365775A priority patent/PL203387B1/en
Priority to SK42-2003A priority patent/SK288317B6/en
Priority to NZ524120A priority patent/NZ524120A/en
Priority to SI200131033T priority patent/SI1301472T1/en
Priority to EP01952778.7A priority patent/EP1301472B1/en
Priority to APAP/P/2003/002742A priority patent/AP2003002742A0/en
Priority to HU0302781A priority patent/HU230251B1/en
Priority to AU7349801A priority patent/AU7349801A/en
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to KR1020037000810A priority patent/KR100773621B1/en
Priority to IL15381701A priority patent/IL153817A0/en
Priority to EEP200300030A priority patent/EE05450B1/en
Priority to JP2002512119A priority patent/JP3811775B2/en
Priority to APAP/P/2001/002217A priority patent/AP2001002217A0/en
Priority to UA2003021455A priority patent/UA76425C2/en
Publication of WO2002006213A2 publication Critical patent/WO2002006213A2/en
Publication of WO2002006213A3 publication Critical patent/WO2002006213A3/en
Priority to IS6666A priority patent/IS6666A/en
Priority to NO20030249A priority patent/NO328436B1/en
Anticipated expiration legal-status Critical
Priority to BG107564A priority patent/BG66386B1/en
Priority to US11/102,307 priority patent/US7411001B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.
  • the present invention also relates to crystalline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.
  • MAPK/ERK Kinase (“MEK”) enzymes are dual specificity kinases involved in, for example, immunomodulation, inflammation, and proliferative diseases such as cancer and restenosis.
  • Proliferative diseases are caused by a defect in the intracellular signaling system, or the signal transduction mechanism of certain proteins.
  • Defects include a change either in the intrinsic activity or in the cellular concentration of one or more signaling proteins in the signaling cascade.
  • the cell may produce a growth factor that binds to its own receptors, resulting in an autocrine loop, which continually stimulates proliferation. Mutations or overexpression of intracellular signaling proteins can lead to spurious mitogenic signals within the cell. Some of the most common mutations occur in genes encoding the protein known as Ras, a
  • Ras-protein that is activated when bound to GTP, and inactivated when bound to GDP.
  • This signal is an absolute prerequisite for proliferation in most cell types. Defects in this signaling system, especially in the deactivation of the Ras-GTP complex, are common in cancers, and lead to the signaling cascade below Ras being chronically activated. Activated Ras leads in turn to the activation of a cascade of serine/threonine kinases.
  • One ofthe groups of kinases known to require an active Ras-GTP for its own activation is the Raf family.
  • MEK e.g., MEKi and MEK2
  • ERK e.g., ERKi and MEK2
  • MAP kinase e.g., MEKi and MEK2
  • ERKi and ERK2 MAP kinase
  • Blockade of downstream Ras signaling for example by use of a dominant negative Raf-1 protein, can completely inhibit mitogenesis, whether induced from cell surface receptors or from oncogenic Ras mutants.
  • Ras is not itself a protein kinase, it participates in the activation of Raf and other kinases, most likely through a phosphorylation mechanism.
  • Raf and other kinases phosphorylate MEK on two closely adjacent serine residues, S ⁇ IS and S ⁇ 22 i n t e case of MEK- 1, which are the prerequisite for activation of MEK as a kinase.
  • MEK in turn phosphorylates MAP kinase on both a tyrosine, Y 1 ⁇ and a threonine residue, T 1 ⁇ separated by a single amino acid. This double phosphorylation activates MAP kinase at least 100-fold.
  • Activated MAP kinase can then catalyze the phosphorylation of a large number of proteins, including several transcription factors and other kinases.
  • MAP kinase phosphorylations are mitogenically activating for the target protein, such as a kinase, a transcription factor, or another cellular protein.
  • target protein such as a kinase, a transcription factor, or another cellular protein.
  • other kinases activate MEK, and MEK itself appears to be a signal integrating kinase.
  • Current understanding is that MEK is highly specific for the phosphorylation of MAP kinase.
  • no substrate for MEK other than the MAP kinase, ERK has been demonstrated to date and MEK does not phosphorylate peptides based on the MAP kinase phosphorylation sequence, or even phosphorylate denatured MAP kinase.
  • MEK also appears to associate strongly with MAP kinase prior to phosphorylating it, suggesting that phosphorylation of MAP kinase by MEK may require a prior strong interaction between the two proteins. Both this requirement and the unusual specificity of MEK are suggestive that it may have enough difference in its mechanism of action to other protein kinases that selective inhibitors of MEK, possibly operating through allosteric mechanisms rather than through the usual blockade ofthe ATP binding site, may be found.
  • the compounds ofthe present invention are inhibitors of MEK and are useful in the treatment of a variety of proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.
  • the present invention provides a compound of formula
  • R ⁇ is hydrogen, halogen, or nitro
  • R2 is hydrogen or fluorine
  • R3 is hydrogen or fluorine
  • R4 is hydrogen, iodine, bromine, chlorine, or fluorine
  • R5 is hydrogen, halogen, hydroxy, Ci _g alkyl, Ci _g alkoxy, trifluoromethyl, or cyano; n is 1 to 5;
  • R ⁇ , R , Rg, R9, and Ri Q are independently hydrogen, C ⁇ g alkyl, C3_g cycloalkyl, hydroxy, Ci .g alkoxy, perhalo(C ⁇ _3)alkyl, hydroxy(C ⁇ _
  • Ra and Rb are independently hydrogen or Ci .4 alkyl
  • W is O orNRa;
  • Ri i is hydrogen, C ⁇ _8 alkyl, C2-6 alkenyl, C3_g cycloalkyl, hydroxy(Ci_s)alkyl,
  • the present invention also provides a compound is of formula
  • Rl is hydrogen or halogen
  • R3 is hydrogen or fluorine
  • R4 is hydrogen, iodine, bromine, chlorine, or fluorine
  • R5 is hydrogen, halogen, or Ci _g alkyl
  • n is 1 to 5;
  • R ⁇ , R , Rg, R9, and Ri 0 are independently hydrogen, Ci _g alkyl, hydroxy, Ci.g alkoxy, perhalo(C ⁇ _3)alkyl, (C2_7)heterocycle(C ⁇ _5)alkyl, or aryloxy(C ⁇ _
  • W is O orNRa;
  • Ri 1 is hydrogen, C ⁇ g alkyl, C2-6 alkenyl, (C ⁇ _5)alkoxy(C ⁇ _5)alkyl, phenyl,
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I or la and a pharmaceutically acceptable carrier.
  • the invention provides a method of treating a proliferative disease in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula I or la.
  • the invention also provides the use of a compound of formula I or la for the manufacture of a medicament for the treatment of a proliferative disease.
  • the invention provides methods of treating cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula I or la.
  • the invention also provides the use of a compound of formula I or la for the manufacture of a medicament for the treatment of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain.
  • the invention provides a method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula I or la in combination with radiation therapy or at least one chemotherapeutic agent.
  • the present invention provides a crystalline Form I N- (2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuK ⁇ radiation: 7.1, 19.2, or 32.1.
  • the present invention also provides a crystalline Form I N-(2,3-
  • the present invention provides a crystalline Form I N-(2,3- Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuK ⁇ radiation: 7.1, 14.1, 15.3, 15.8, 16.9, 18.1, 19.2, 20.3, 21.4, 22.3, 23.4, 24.5, 25.5, 26.2, 26.8, 27.8, 28.3, 29.5, 32.1, 33.2, 33.6, 40.0, 42.9, and 44.1.
  • Also provided by the present invention is a crystalline Form II N-(2,3- Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuK ⁇ radiation: 11.6, 12.6 or 24.9.
  • the present invention also provides a crystalline Form II N-(2,3- Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuK ⁇ radiation: 11.6, 12.6 and 24.9.
  • the present invention provides a crystalline Form II N-(2,3- Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuK ⁇ radiation: 11.6, 12.6, 15.6, 17.3, 17.9, 20.3, 21.1, 22.1, 24.9, 25.9, 26.7, 27.8, 30.1, 30.9, 33.8, 35.4, 38.2, 39.3, 40.8, 41.6, 43.6, and 47.0.
  • the present invention provides a crystalline Form IN-[(R)- 2, 3 -Dihydroxy-propoxy]-3 ,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuK ⁇ radiation: 10.6, 13.7, 19.0 or 23.7.
  • the present invention provides a crystalline Form IN-[(R)-2,3- Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuK ⁇ radiation: 10.6, 13.7, 19.0 and 23.7. Also provided by the present invention is crystalline Form I N-[(R)-2,3-
  • the present invention provides a crystalline Form FI N-[(R)- 2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuK ⁇ radiation: 5.5 or 19.6.
  • the present invention also provides a crystalline Form II N-[(R)-2,3-
  • the present invention provides a crystalline Form II N-[(R)- 2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuK ⁇ radiation: 5.5, 10.7, 16.5, 19.6, 22.0, 22.5, 23.6, 24.1, 25.0, 26.2, 27.6, 29.1, 30.5, 31.7, 33.3, and 39.0.
  • the present invention provides a crystalline Form I N-[(S)-2,3- Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuK ⁇ radiation: 10.5, 13.7, 19.0, or 23.6.
  • crystalline Form IN-[(S)-2,3- Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuK ⁇ radiation: 10.5, 13.7, 19.0, and 23.6.
  • the present invention provides a crystalline Form IN-[(S)- 2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuK ⁇ radiation: 10.548, 13.703, 17.887,
  • the present invention also provides a crystalline Form II N-[(S)-2,3- Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuK ⁇ radiation: 5.6 or 19.6.
  • the present invention provides a crystalline Form II N-[(S)- 2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuK ⁇ radiation: 5.6 and 19.6.
  • the present invention provides a crystalline Form LI N-[(S)-2,3-
  • FIG. 2 Diffractogram of Form I
  • halogen or “halo” in the present invention refer to a fluorine, bromine, chlorine, and iodine atom or fluoro, bromo, chloro, and iodo.
  • fluorine and fluoro for example, are understood to be equivalent herein.
  • Alkyl groups such as "Ci-g alkyl”, include aliphatic chains (i.e., hydrocarbyl or hydrocarbon radical structures containing hydrogen and carbon atoms) with a free valence. Alkyl groups are understood to include straight chain and branched structures.
  • Examples include methyl, ethyl, propyl, isopropyl, butyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, 2,3-dimethylpropyl, hexyl, 2,3- dimethylhexyl, 1,1-dimethylpentyl, heptyl, octyl, and the like.
  • Ci -g alkyl includes within its definition the terms “C ⁇ - ⁇ alkyl”, “C1-5 alkyl”,
  • Alkyl groups can be substituted with 1, 2, 3 or more substituents which are independently selected from halo (fluoro, chloro, bromo, or iodo), cyano, hydroxy, amino, alkoxy, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, arylalkyloxy, heterocyclic radical, and (heterocyclic radical)oxy.
  • substituents are independently selected from halo (fluoro, chloro, bromo, or iodo), cyano, hydroxy, amino, alkoxy, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, arylalkyloxy, heterocyclic radical, and (heterocyclic radical)oxy.
  • Specific examples include fluoromethyl, hydroxyethyl, 2,3-dihydroxyethyl, (2- or 3- furanyl)methyl, cyclopropylmethyl, benzyloxyethyl, (3-pyridinyl)methyl, (2- or 3- furanyl)methyl, (2-thienyl)ethyl, hydroxypropyl, aminocyclohexyl, 2- dimethylaminobutyl, methoxymethyl, N-pyridinylethyl, diethylaminoethyl, and cyclobutylmethyl.
  • alkoxy refers to a straight or branched alkyl chain attached to an oxygen atom.
  • Ci -g alkoxy refers to a straight or branched alkyl chain having from one to eight carbon atoms attached to an oxygen atom.
  • Typical Ci -g alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and the like.
  • Cj-g alkoxy includes within its definition the terms "Ci -g alkoxy” and "Ci -4 alkoxy”.
  • Alkenyl groups are analogous to alkyl groups, but have at least one double bond (two adjacent sp 2 carbon atoms).
  • alkynyl groups have at least one triple bond (two adjacent sp carbon atoms).
  • Unsaturated alkenyl or alkynyl groups may have one or more double or triple bonds, respectively, or a mixture thereof; like alkyl groups, unsaturated groups may be straight chain or branched, and they may be substituted as described both above for alkyl groups and throughout the disclosure by example.
  • alkenyls, alkynyls, and substituted forms include cis-2-butenyl, trans-2-butenyl, 3-butynyl, 3-phenyl-2- propynyl, 3-(2'-fluorophenyl)-2-propynyl, 3-methyl(5-phenyl)-4-pentynyl, 2- hydroxy-2-propynyl, 2-methyl-2-propynyl, 2-propenyl, 4-hydroxy-3-butynyl, 3- (3-fluorophenyl)-2-propynyl, and 2-methyl-2-propenyl.
  • alkenyl includes C2_6 alkenyl or C2.4 alkenyl.
  • Cycloalkyl groups such as C3-1 ⁇ cycloalkyl, refer to a saturated hydrocarbon ring structure containing from 3 to 10 atoms. Typical
  • C3-10 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
  • aryl means an unsubstituted aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl).
  • the aryl group can be optionally substituted with between 1 and 5 substituents independently selected from the group consisting of hydroxy, amino, monoalkylamino, dialkylamino, halogen, cyano, (C ⁇ _3)alkoxy,
  • Ra and Rb are independently hydrogen or C 1.4 alkyl.
  • aryloxy refers to an aryl group attached to an oxygen atom.
  • heterocycle refers to a stable 5-, 6-, or 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated or unsaturated, and consists of carbon atoms and from one to four heteroatoms selected from the group consisting of nitrogen, oxygen, or sulfur.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which affords a stable structure.
  • Heterocyclic radicals which include but are not limited to heteroaryls, include: furyl, (is)oxazolyl, isoxazolyl, thiophenyl, thiazolyl, pynolyl, imidazolyl, 1,3,4-triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, indolyl, and their nonaromatic counterparts.
  • heterocyclic radicals include thienyl, piperidyl, quinolyl, isothiazolyl, piperidinyl, morpholinyl, piperazinyl, tetrahydrofuryl, tetrahydropynolyl, pyrrolidinyl, octahydroindolyl, octahydrobenzothiofuranyl, octahydrobenzofuranyl, (iso)quinolinyl, naphthyridinyl, benzimidazolyl, and benzoxazolyl.
  • substituted hydrocarbon radicals include hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycycloalkyl, hydroxyaryl, and corresponding forms for the prefixes amino-, halo- (e.g., fluoro-, chloro-, or bromo-), nitro-, alkyl-, phenyl-, cycloalkyl- and so on, or combinations of substituents.
  • halo- e.g., fluoro-, chloro-, or bromo-
  • substituted alkyls include, but are not limited to, hydroxyalkyl, alkoxyalkyl, aminoalkyl, nitroalkyl, haloalkyl, cyanoalkyl, alkylalkyl (branched alkyls, such as methylpentyl), (cycloalkyl)alkyl, phenylalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylalkyl, aryloxyalkyl, arylalkyloxyalkyl, (heterocyclic radical)alkyl, and (heterocyclic radical)oxyalkyl.
  • Formula I thus includes hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycycloalkyl, hydroxyaryl, aminoalkyl, aminoalkenyl, aminoalkynyl, aminocycloalkyl, aminoaryl, alkylalkenyl, (alkylaryl)alkyl, (haloaryl)alkyl, (hydroxyaryl)alkynyl, and so forth.
  • R ⁇ , R7, Rg, R9, and Ri 0 include hydroxy(C ⁇ _g)alkyl, (C ⁇ _5)alkoxy(C ⁇ _5)alkyl, aminoalkyl, (e.g., [(Cl-
  • Ri 0 includes hydroxy(C ⁇ _g)alkyl, (Ci _5)alkoxy(C ⁇ _5)alkyl and trifluoro(C ⁇ .
  • Ri 0 to complete a 3-10 member cyclic ring optionally containing additional heteroatoms selected from O, S, NH, or N-alkyl are demonstrated in the fragments shown below.
  • the present invention includes the hydrates and the pharmaceutically acceptable salts and solvates ofthe compounds defined by formula I.
  • the compounds of this invention can possess a sufficiently basic functional group, and accordingly react with any of a number of inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salt refers to salts ofthe compounds of formula I which are substantially non-toxic to living organisms.
  • Typical pharmaceutically acceptable salts include those salts prepared by reaction ofthe compounds ofthe present invention with a pharmaceutically acceptable mineral or organic acid. Such salts are also known as acid addition salts.
  • Such salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science. 66, 2-19 (1977), which are know to the skilled artisan.
  • Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as -toluenesulfonic, methanesulfonic acid, benzenesulfonic acid, oxalic acid, j>-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
  • organic acids such as -toluenesulfonic, methanesulfonic acid, benzenesulfonic acid, oxalic acid, j>-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and
  • Example of such pharmaceutically acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, bromide, hydrobromide, iodide, acetate, propionate, decanoate, caprate, caprylate, acrylate, ascorbate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, glucuronate, glutamate, propionate, phenylpropionate, salicylate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malate, maleate, hydroxymateate, mandelate, mesylate, nicotinate, isonicotinate, cinnamate, hippurate, nitrate, stearate, phthalate,
  • any salt of this inventions is usually not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole. It is further understood that such salts may exist as a hydrate.
  • stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures which are not interchangeable. The three-dimensional structures are called configurations.
  • enantiomer refers to each of two stereoisomers whose molecules are nonsuperimposable mirror images of one another.
  • chiral center refers to a carbon atom to which four different groups are attached.
  • diastereomers refers to stereoisomers which are not enantiomers.
  • racemate or “racemic mixture” refer to a mixture of enantiomers.
  • enantiomers of compounds ofthe present invention can be resolved by one of ordinary skill in the art using standard techniques well-known in the art, such as those described by J. Jacques, et al., "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc. 1981. Examples of resolutions include recrystallization techniques or chiral chromatography.
  • Some ofthe compounds ofthe present invention have one or more chiral centers and may exist in a variety of stereoisomeric configurations. As a consequence of these chiral centers, the compounds ofthe present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope ofthe present invention.
  • the compounds of formula I can be prepared by techniques and procedures readily available to one of ordinary skill in the art, for example by following the procedures as set forth in the following Schemes. These schemes are not intended to limit the scope ofthe invention in any way. All substituents, unless otherwise indicated, are previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art. The compounds of formula I are generally obtained by the union of 2-
  • Preferred coupling agents include diphenylphoshinic chloride (DPP-C1), benzotriazol-yl- oxy-tripyrolidinophosphonium hexafluorophosphate (PyBOP), benzotriazol-1- yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N'- dicyclohexylcarbodiimide (DCC), 1 -ethyl -3 -(3- dimethylaminopropyl)carbodiimide hydrochloride (EDO), or 1,1'- carbonyldimidazole (GDI).
  • DPP-C1 diphenylphoshinic chloride
  • PyBOP benzotriazol-yl- oxy-tripyrolidinophospho
  • Prefened bases include diisopropylethylamine, triethylamine, 4-methylmorpholine, or pyridine or a substituted pyridine, for example, 4-dimethyaminopyridine or 2,6-dimethylpyridine.
  • Preferred solvents are polar aprotic solvents such as dichloromethane, tetrahydrofuran, or dimethylformamide.
  • the reactions are generally carried out at a temperature between about -78 °C to about 25 °C, and are normally complete within about 2 hours to about 5 days.
  • the product amides can be isolated by removing the solvent, for example by evaporation under reduced pressure, and further purified, if desired, by standard methods such as chromatography, crystallization, or distillation.
  • Scheme 1 General Preparation of Benzamides from Benzoic Acids
  • disclosed compounds are also generally prepared as shown in Scheme 2 by the contact of alkoxyamine (2) with "activated” benzoic acid derivatives (3), wherein the activating group "X” completes an acid halide, anhydride, mixed anhydride, or an activated ester, such as a pentafluorophenyl ester, nitrophenyl ester or thioester.
  • Prefened bases include diisopropylethylamine, triethylamine, 4-methylmorpholine, imidazole, pyridine or a substituted pyridine, for example, 4-dimethyaminopyridine or 2,6- dimethylpyridine.
  • Preferced solvents are polar aprotic solvents such as dichloromethane, tetrahydrofuran, or dimethylformamide.
  • Preferred combinatorial methods are outlined in Scheme 3, wherein the compounds of formula I are obtained by the reaction of an excess of pentafluorophenyl esters (4) with alkoxyamines (2) in the presence of polymer supported (PS) 4-methylmorpholine (5) in dimethylformamide with mechanical shaking. After a reaction period of about 16 to 72 hours, polymer supported amine (6) is added with dichloromethane. After an additional several hours of mechanical agitation, targets I are obtained by filtration, solvent evaporation and chromatograhic purification.
  • PS polymer supported
  • general schemes 1-3, above may be modified to include a standard removal ofthe said protecting group.
  • Suitable protecting groups include, but are not limited to, vinyl ethers, silyl ethers, acetals, acetonides, and carbamates. Examples of such modifications are outlined below.
  • preferced compounds of formula Ila may be obtained by the reaction of benzoic acids (1) with vinyl ether (7), a peptide coupling agent (for example, PyBOP) and a base (for example, diisopropylethylamine) to afford vinyl ether amide (8). Further treatment of vinyl ether (8) with acid affords the compounds of formula Ila.
  • Scheme 4 Representative Preparation of Hydroxy lated Benzamides Using a Vinyl Ether as a Hydroxyl Protecting Group
  • preferred compounds of formula lib may also be obtained by the reaction of benzoic acids (1) with a suitable protecting group, such as tert-butyldimethylsilyl ether (9), in the presence a peptide coupling agent (for example, PyBOP) and a tertiary amine base (for example, diisopropylethylamine) to afford tert-butyldimethylsilyl ether amide (10). Further treatment of silyl ether (10) with acid in a protic solvent affords the compounds of formula lib.
  • a suitable protecting group such as tert-butyldimethylsilyl ether (9)
  • a peptide coupling agent for example, PyBOP
  • a tertiary amine base for example, diisopropylethylamine
  • Prefened compounds of formula IVa can be prepared by similar methods, as illustrated in Scheme 6. For example, treatment of benzoic acids (1) with carbamate (11) in the presence of a peptide coupling agent, for example diphenylphosphinic chloride (DPP-Cl), in the presence of a tertiary amine base, for example 4-methylmorpholine (NMM) affords carbamate amide (12). Subsequent treatment of (12) with a suitable acid, for example trifluoracetic acid or hydrogen chloride, gives rise to the amines of general formula IVa, which may be isolated as acid salts or neutralized under standard conditions to afford free bases.
  • a peptide coupling agent for example diphenylphosphinic chloride (DPP-Cl)
  • DPP-Cl diphenylphosphinic chloride
  • NMM 4-methylmorpholine
  • a suitable acid for example trifluoracetic acid or hydrogen chloride
  • a tertiary base for example, 4-methylmorpholine (NMM).
  • NMM 4-methylmorpholine
  • they may be prepared according to Scheme 2 by the treatment of benzoic acid pentafluorophenyl esters (4) with acetonide (13) in the presence of a tertiary amine base (for example, diisopropylethylamine).
  • acetonide- amides (14) to preferred compounds Ilia can be accomplished by treatment under standard acidic hydrolysis conditions, for example p-toluenesulfonic acid in methanol.
  • the compounds of formula I can also be prepared by the modification of other compounds of formula I.
  • alkylating agents for example, iodomethane
  • a base for example, potassium carbonate
  • Additional Compounds described by the invention include:
  • Preferred compounds are those of formula I wherein R ⁇ is hydrogen or halogen; and more preferably, hydrogen, F, Br, or Cl; and most preferably, hydrogen; R2 and R3 are fluoro; R4 is hydrogen, iodine, bromine, chlorine, or fluorine; and more preferably hydrogen, iodine, chlorine, or fluorine; and most preferably is iodo; R5 is fluoro, chloro, or methyl; more preferably is fluoro or chloro; and most preferably is fluoro; n is 1 or 2; or combinations thereof.
  • Preferced compounds are selective MEK inhibitors.
  • the most preferred compounds within are those wherein R ⁇ , R ⁇ , Rg, R9, R ⁇ o, and Ri 1 are hydrogen,
  • W is oxygen, and n is 1 or 2 and also those wherein, Rg, R7, R9, R ⁇ , and R are hydrogen, W is oxygen, n is 2, and Rg(l) is hydrogen and Rg(2) is hydroxy.
  • Ri is hydrogen or halogen
  • R5 is fluorine, chlorine, or methyl; and n is 1 or 2.
  • R is hydrogen or halogen
  • R5 is fluorine, chlorine, or methyl.
  • Other most preferced compounds are those of formula I wherein j is hydrogen or halo such as F, Br, or Cl; R2 and R3 are fluoro; R4 is iodo; R5 is fluoro, chloro, or methyl; n is 1; Rg, R7, Rg, R9, and Ri 0 are hydrogen, W is NRa and Ra is H: R ⁇ is methyl or phenyl; and pharaceutically accepted salts thereof.
  • These compounds have formulae IV and V.
  • Ri is hydrogen or halogen
  • R5 is fluorine, chlorine, or methyl.
  • Rj is hydrogen or halogen
  • R5 is fluorine, chlorine, or methyl.
  • Preferred compounds ofthe present invention include, but are not limited to the following compounds:
  • the present invention provides Crystalline Form I and
  • Form II of N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide hereinafter referred to as "Form I of Compound A" and
  • Form II of Compound A Crystalline Form I and Form II of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide (hereinafter referred to as "Form I of Compound B" and
  • Form I and Form II of N-[(S)-2,3-Dihydroxy-propoxyj-3,4-difluoro-2-(2-fluoro-4- iodo- ⁇ henylamino)-benzamide hereinafter referred to as "Form I of Compound C” and “Form II of Compound C", respectively) or hydrates thereof.
  • the present invention also provides Crystalline Form I and Form II of
  • novel crystalline compounds ofthe present invention are useful as inhibitors ofMEK.
  • Crystal forms provided by the present invention may be characterized by their X-ray powder diffraction patterns. Crystalline Form I and Form II of Compound A, Crystalline Form I and
  • Form II of Compound B and Crystalline Form I and Form II of Compound C were characterized by their X-ray powder diffraction pattern.
  • the X-ray diffraction patterns ofthe crystal forms ofthe present invention were measured on a Rigaku Ultima + diffractometer with CuK a radiation.
  • the silicon standard is run once a week to check the X-ray tube alignment. Continuous ⁇ /2 ⁇ coupled scan: 3.00° to 50.00° in 20, scan rate of 1 min: 1.0 sec/0.04° step. Sample tapped out of vial and pressed onto zero-background silicon in aluminum holder. Sample width 5 mm.
  • Samples are being spun at 40 rpm around vertical axis during data collection.
  • Table 1 lists the X-ray powder diffraction pattern for crystalline Form I of Compound A expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a
  • Table 2 lists the X-ray powder diffraction pattern for crystalline Form II of Compound A, expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuK ⁇ radiation. It should be noted that the computer-generated, unrounded numbers are listed in Table 2.
  • Table 3 lists the X-ray powder diffraction pattern for crystalline Form I of Compound B, expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuK ⁇ radiation. It should be noted that the i computer-generated, unrounded numbers are listed in Table 3.
  • Table 4 lists the X-ray powder diffraction pattern for crystalline Form II of Compound B, expressed in terms ofthe 2-theta ("2 ⁇ "), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a
  • Table 5 lists the X-ray powder diffraction pattern for crystalline Form I of
  • Table 6 lists the X-ray powder diffraction pattern for crystalline Form II of Compound C, expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuK ⁇ radiation. It should be noted that the computer-generated, unrounded numbers are listed in Table 6. TABLE 6
  • the crystal forms ofthe present invention may exist in anhydrous forms as well as hydrated forms. In general, the hydrated forms, are equivalent to unhydrated forms and are intended to be encompassed within the scope ofthe present invention.
  • the present invention provides a process for the preparation of crystalline
  • Form I of Compound A which comprises crystallizing Compound A from a solution in solvents under conditions which yield crystalline Form I of Compound A.
  • the precise conditions under which crystalline Form I of Compound A is formed may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
  • the desired Form I may be obtained by suspending the solid in a suitable solvent, such as ethanol and precipitating with water; by dissolving the solid in a minimum amount of a boiling solvent, such as ethanol and adding water to the boiling solvent; and by dissolving the solid in a minimum amount of boiling solvent, such as ethyl acetate, and adding a suitable solvent, such as heptane to the boiling solvent, as is more fully set forth in Example 39A below.
  • the present invention provides a process for the preparation of crystalline Form II of Compound A which comprises crystallizing Compound A from a solution in solvents under conditions which yield crystalline Form II of
  • the precise conditions under which crystalline Form II of Compound A is formed may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
  • the desired Form II may be obtained by suspending the solid in a suitable solvent, such as ethyl acetate/hexanes or suspending the solid in a suitable solvent, such as heptane - CH 2 C1 (1 : 1), as is more fully set forth in Example 39 below.
  • the present invention provides a process for the preparation of crystalline Form I of Compound B which comprises crystallizing Compound B from a solution in solvents under conditions which yield crystalline Form I of Compound
  • the present invention provides a process for the preparation of crystalline Form II of Compound B which comprises crystallizing Compound B from a solution in solvents under conditions which yield crystalline Form II of Compound B.
  • the precise conditions under which crystalline Form II of Compound B is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice.
  • the desired Form II may be obtained by suspending the solid in ethyl acetate and heptane or by suspending the solid in by suspending the solid in hexane-AcOEt, as is more fully set forth in Examples 49 and 49A below.
  • the present invention provides a process for the preparation of crystalline Form I of Compound C which comprises crystallizing Compound C from a solution in solvents under conditions which yield crystalline Form I of Compound C.
  • the precise conditions under which crystalline Form I of Compound C is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice.
  • the desired Form I may be obtained by suspending the solid in hexane-AcOEt. A more detailed procedure is set forth in Example 50 below.
  • the present invention provides a process for the preparation of crystalline Form I of Compound C which comprises crystallizing Compound C from a solution in solvents under conditions which yield crystalline Form I of Compound C.
  • the precise conditions under which crystalline Form I of Compound C is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice.
  • the desired Form I may be obtained by suspending the solid in hexane-AcOEt. A more detailed procedure is set forth in Example 50
  • Form II of Compound C which comprises crystallizing Compound C from a solution in solvents under conditions which yield crystalline Form II of Compound C.
  • the precise conditions under which crystalline Form II of Compound C is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice.
  • the desired Form II may be obtained by suspending the solid in ethyl acetate and heptane, or by suspending the solid in hexane-AcOEt, as is more fully set forth in Examples 50 and 50 A below.
  • the term "patient” refers to any warm-blooded animal such as, but not limited to, a human, horse, dog, guinea pig, or mouse. Preferably, the patient is human.
  • treating for purposes ofthe present invention refers to prophylaxis or prevention, amelioration or elimination of a named condition once the condition has been established.
  • Selective MEK 1 or MEK 2 inhibitors are those compounds which inhibit the MEK 1 or MEK 2 enzymes, respectively, without substantially inhibiting other enzymes such as MKK3, PKC, Cdk2A, phosphorylase kinase, EGF, and
  • a selective MEK 1 or MEK 2 inhibitor has an IC 50 for MEK 1 or MEK 2 that is at least one-fiftieth (1/50) that of its IC50 for one ofthe above-named other enzymes.
  • a selective inhibitor has an IC 50 that is at least 1/100, more preferably 1/500, and even more preferably 1/1000, 1/5000, or less than that of its IC5 0 or one or more ofthe above- named enzymes.
  • compositions are useful as both prophylactic and therapeutic treatments for diseases or conditions related to the hyperactivity of MEK, as well as diseases or conditions modulated by the MEK cascade.
  • diseases or conditions related to the hyperactivity of MEK include, but are not limited to, stroke, septic shock, heart failure, osteoarthritis, rheumatoid arthritis, organ transplant rejection, and a variety of tumors such as ovarian, lung, pancreatic, brain, prostatic, and colorectal.
  • the invention further relates to a method for treating proliferative diseases, such as cancer, restenosis, psoriasis, autoimmune disease, and atherosclerosis.
  • proliferative diseases such as cancer, restenosis, psoriasis, autoimmune disease, and atherosclerosis.
  • Other aspects ofthe invention include methods for treating MEK-related
  • cancers include brain, breast, lung, such as non-small cell lung, ovarian, pancreatic, prostate, renal, colorectal, cervical, acute leukemia, and gastric cancer.
  • Further aspects ofthe invention include methods for treating or reducing the symptoms of enograft (cell(s), skin, limb, organ or bone marrow transplant) rejection, osteoarthritis, rheumatoid arthritis, cystic fibrosis, complications of diabetes (including diabetic retinopathy and diabetic nephropathy), hepatomegaly, cardiomegaly, stroke (such as acute focal ischemic stroke and global cerebral ischemia), heart failure, septic shock, asthma, Alzheimer's disease, and chronic or neuropathic pain.
  • enograft cell(s), skin, limb, organ or bone marrow transplant
  • osteoarthritis rheumatoid arthritis
  • cystic fibrosis cystic fibrosis
  • complications of diabetes including diabetic retinopathy and diabetic nephropathy
  • hepatomegaly such as acute focal ischemic stroke and global cerebral ischemia
  • stroke such as acute focal ischemic stroke and global cerebral ischemia
  • heart failure such as acute focal
  • Compounds ofthe invention are also useful as antiviral agents for treating viral infections such as HJV, hepatitis (B) virus (HBN), human papilloma virus (HPV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV).
  • HJV hepatitis virus
  • HPV human papilloma virus
  • CMV cytomegalovirus
  • EBV Epstein-Barr virus
  • chronic pain for purposes ofthe present invention includes, but is not limited to, neuropathic pain, idiopathic pain, and pain associated with chronic alcoholism, vitamin deficiency, uremia, or hypothyroidism.
  • Chronic pain is associated with numerous conditions including, but not limited to, inflammation, arthritis, and post-operative pain.
  • neurodegeneration pain is associated with numerous conditions which include, but are not limited to, inflammation, postoperative pain, phantom limb pain, burn pain, gout, trigeminal neuralgia, acute herpetic and postherpetic pain, causalgia, diabetic neuropathy, plexus avulsion, neuroma, vasculitis, viral infection, crush injury, constriction injury, tissue injury, limb amputation, post-operative pain, arthritis pain, and nerve injury between the peripheral nervous system and the central nervous system.
  • the invention also features methods of combination therapy, such as a method for treating cancer, wherein the method further includes providing radiation therapy or chemotherapy, for example, with mitotic inhibitors such as a taxane or a vinca alkaloid.
  • mitotic inhibitors include paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, and vinflunine.
  • Other therapeutic combinations include a MEK inhibitor ofthe invention and an anticancer agent such as cisplatin, 5-fluorouracil or 5-fluoro-2-4(lH,3H)-pyrimidinedione (5FU), flutamide, and gemcitabine.
  • the chemotherapy or radiation therapy may be administered before, concurrently, or after the administration of a disclosed compound according to the needs ofthe patient.
  • an effective amount or a therapeutically-effective amount will be between about 0.1 and about 1000 mg/kg per day, preferably between about 1 and about 300 mg/kg body weight, and daily dosages will be between about 10 and about 5000 mg for an adult subject of normal weight.
  • Commercially available capsules or other formulations such as liquids and film-coated tablets) of 100 mg, 200 mg, 300 mg, or 400 mg can be administered according to the disclosed methods.
  • compositions ofthe present invention are preferably formulated prior to administration. Therefore, another aspect ofthe present invention is a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier.
  • the active ingredient such as a compound of formula I
  • the carrier or diluted by a carrier or enclosed within a carrier.
  • Dosage unit forms or pharmaceutical compositions include tablets, capsules, pills, powders, granules, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers adapted for subdivision into individual doses.
  • Dosage unit forms can be adapted for various methods of administration, including controlled release formulations, such as subcutaneous implants.
  • Administration methods include oral, rectal, parenteral (intravenous, intramuscular, subcutaneous), intracisternal, intravaginal, intraperitoneal, intravesical, local (drops, powders, ointments, gels, or cream), and by inhalation
  • Parenteral formulations include pharmaceutically acceptable aqueous or nonaqueous solutions, dispersion, suspensions, emulsions, and sterile powders for the preparation thereof.
  • carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained by the use of a coating such as lecithin, a surfactant, or maintaining appropriate particle size.
  • Carriers for solid dosage forms include (a) fillers or extenders, (b) binders, (c) humectants, (d) disintegrating agents, (e) solution retarders, (f) absorption acccelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and (j) propellants.
  • Compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents; antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid; isotonic agents such as a sugar or sodium chloride; absorption-prolonging agents such as aluminum monostearate and gelatin; and absorption-enhancing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispensing agents
  • antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid
  • isotonic agents such as a sugar or sodium chloride
  • absorption-prolonging agents such as aluminum monostearate and gelatin
  • absorption-enhancing agents such as aluminum monostearate and gelatin.
  • the resultant solution was stirred at ambient temperature for 18 h.
  • the reaction mixture was diluted with ether (100 mL) and washed with water (40 mL), 0.1 M aqueous hydrochloric acid (40 mL), saturated aqueous sodium bicarbonate (40 mL), and saturated brine (40 mL).
  • the organics were dried over anhydrous magnesium sulfate and concentrated under reduced pressure to afford a foam that was purified on silica gel.
  • Preparations 48-51 were prepared by the general procedure of preparation 47, part A.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

Description

OXYGENATED ESTERS OF 4-IODO PHENYLAJVUNO
BENZHYDROXAMIC ACIDS
FLELD OF THE INVENTION
The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystalline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.
BACKGROUND OF THE INVENTION
MAPK/ERK Kinase ("MEK") enzymes are dual specificity kinases involved in, for example, immunomodulation, inflammation, and proliferative diseases such as cancer and restenosis.
Proliferative diseases are caused by a defect in the intracellular signaling system, or the signal transduction mechanism of certain proteins. Defects include a change either in the intrinsic activity or in the cellular concentration of one or more signaling proteins in the signaling cascade. The cell may produce a growth factor that binds to its own receptors, resulting in an autocrine loop, which continually stimulates proliferation. Mutations or overexpression of intracellular signaling proteins can lead to spurious mitogenic signals within the cell. Some of the most common mutations occur in genes encoding the protein known as Ras, a
G-protein that is activated when bound to GTP, and inactivated when bound to GDP. The above-mentioned growth factor receptors, and many other mitogenic receptors, when activated, lead to Ras being converted from the GDP-bound state to the GTP-bound state. This signal is an absolute prerequisite for proliferation in most cell types. Defects in this signaling system, especially in the deactivation of the Ras-GTP complex, are common in cancers, and lead to the signaling cascade below Ras being chronically activated. Activated Ras leads in turn to the activation of a cascade of serine/threonine kinases. One ofthe groups of kinases known to require an active Ras-GTP for its own activation is the Raf family. These in turn activate MEK (e.g., MEKi and MEK2) which then activates the MAP kinase, ERK (ERKi and ERK2). Activation of MAP kinase by mitogens appears to be essential for proliferation; constitutive activation of this kinase is sufficient to induce cellular transformation. Blockade of downstream Ras signaling, for example by use of a dominant negative Raf-1 protein, can completely inhibit mitogenesis, whether induced from cell surface receptors or from oncogenic Ras mutants. Although Ras is not itself a protein kinase, it participates in the activation of Raf and other kinases, most likely through a phosphorylation mechanism. Once activated, Raf and other kinases phosphorylate MEK on two closely adjacent serine residues, S^IS and S^22 in t e case of MEK- 1, which are the prerequisite for activation of MEK as a kinase. MEK in turn phosphorylates MAP kinase on both a tyrosine, Y1^ and a threonine residue, T1^ separated by a single amino acid. This double phosphorylation activates MAP kinase at least 100-fold. Activated MAP kinase can then catalyze the phosphorylation of a large number of proteins, including several transcription factors and other kinases. Many of these MAP kinase phosphorylations are mitogenically activating for the target protein, such as a kinase, a transcription factor, or another cellular protein. In addition to Raf-1 and MEKK, other kinases activate MEK, and MEK itself appears to be a signal integrating kinase. Current understanding is that MEK is highly specific for the phosphorylation of MAP kinase. In fact, no substrate for MEK other than the MAP kinase, ERK, has been demonstrated to date and MEK does not phosphorylate peptides based on the MAP kinase phosphorylation sequence, or even phosphorylate denatured MAP kinase. MEK also appears to associate strongly with MAP kinase prior to phosphorylating it, suggesting that phosphorylation of MAP kinase by MEK may require a prior strong interaction between the two proteins. Both this requirement and the unusual specificity of MEK are suggestive that it may have enough difference in its mechanism of action to other protein kinases that selective inhibitors of MEK, possibly operating through allosteric mechanisms rather than through the usual blockade ofthe ATP binding site, may be found.
It has been found that the compounds ofthe present invention are inhibitors of MEK and are useful in the treatment of a variety of proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.
SUMMARY OF THE INVENTION
The present invention provides a compound of formula
Figure imgf000004_0001
wherein
R\ is hydrogen, halogen, or nitro;
R2 is hydrogen or fluorine;
R3 is hydrogen or fluorine;
R4 is hydrogen, iodine, bromine, chlorine, or fluorine;
R5 is hydrogen, halogen, hydroxy, Ci _g alkyl, Ci _g alkoxy, trifluoromethyl, or cyano; n is 1 to 5;
Rβ, R , Rg, R9, and Ri Q are independently hydrogen, Cμg alkyl, C3_g cycloalkyl, hydroxy, Ci .g alkoxy, perhalo(Cι _3)alkyl, hydroxy(Cι_
8)alkyl, (Cι _5)alkoxy(Cι _5)alkyl, [(C1_4)alkyl]2aminomethyl, (C2_
7)heterocycle(Cι _5)alkyl, or aryloxy(Cι _5)alkyl, or may be independently joined to complete a 3-10 member cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, NH, and N-alkyl, wherein R7 and Rg are independently selected for n>l;
Ra and Rb are independently hydrogen or Ci .4 alkyl;
W is O orNRa; Ri i is hydrogen, Cι _8 alkyl, C2-6 alkenyl, C3_g cycloalkyl, hydroxy(Ci_s)alkyl,
(Cι _5)alkoxy(Cι_5)alkyl, phenyl, C2_7 heteroaryl, (Cι _8)alkylcarbonyl,
(phenyl)carbonyl, (phenyl)(Cι _3 alkyl)carbonyl, ortrifluoro(Cι_6)alkyl; wherein the above alkyl, alkoxy, cycloalkyl, heteroaryl, and phenyl groups can be optionally substituted with between 1 and 5 substituents independently selected from the group consisting of hydroxy, amino, monoalkylamino, dialkylamino, halogen, cyano, (Cι _3)atkoxy, COOR, OCORa, CONRaRb,
NRaCORb, SO, SO2, SO4, and SO2NRaRb; and pharmaceutically acceptable salts, (Ci _6) amides and (Ci _g) esters thereof; provided that when R \ is phenyl and n is 1, W cannot be O; further provided that the compound is not
5-Bromo-N-(2-diethylamino-ethoxy)-3,4-difluoro-(4-iodo-2-methyl- phenylamino)-benzamide;
5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; or 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-
3 ,4-difluoro-benzamide.
The present invention also provides a compound is of formula
Figure imgf000005_0001
wherein Rl is hydrogen or halogen;
R3 is hydrogen or fluorine;
R4 is hydrogen, iodine, bromine, chlorine, or fluorine; R5 is hydrogen, halogen, or Ci _g alkyl; n is 1 to 5;
Rβ, R , Rg, R9, and Ri 0 are independently hydrogen, Ci _g alkyl, hydroxy, Ci.g alkoxy, perhalo(Cι_3)alkyl, (C2_7)heterocycle(Cι _5)alkyl, or aryloxy(Cι _
5)alkyl, or may be independently joined to complete a 3-10 member cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, NH, and N-alkyl, wherein R7 and Rg are independently selected for n>l; Ra and Rb are independently hydrogen or Ci .4 alkyl;
W is O orNRa; Ri 1 is hydrogen, Cμg alkyl, C2-6 alkenyl, (Cι _5)alkoxy(Cι_5)alkyl, phenyl,
(Ci _g)alkylcarbonyl, or trifluoro(Cι _g)alkyl; wherein the above alkyl, alkoxy, cycloalkyl, heteroaryl, and phenyl groups can be optionally substituted with between 1 and 5 substituents independently selected from the group consisting of hydroxy, amino, monoalkylamino, dialkylamino, halogen, cyano, (Cι_3)alkoxy, COOR, OCORa, CONRaRb,
NRaCORb, SO, SO2, SO4, and SO2NRaRb; and pharmaceutically acceptable salts, (Cι _6) amides and (C\.β) esters thereof; provided that when R is phenyl and n is 1, W cannot be O; further provided that the compound is not 5-Bromo-N-(2-diethylamino-ethoxy)-3,4-difluoro-(4-iodo-2-methyl- phenylamino)-benzamide;
5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; or
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)- 3,4-difluoro-benzamide. The invention also provides a pharmaceutical composition comprising a compound of formula I or la and a pharmaceutically acceptable carrier.
Additionally, the invention provides a method of treating a proliferative disease in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula I or la.
The invention also provides the use of a compound of formula I or la for the manufacture of a medicament for the treatment of a proliferative disease.
Furthermore, the invention provides methods of treating cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula I or la.
The invention also provides the use of a compound of formula I or la for the manufacture of a medicament for the treatment of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain.
In addition, the invention provides a method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula I or la in combination with radiation therapy or at least one chemotherapeutic agent.
In another aspect, the present invention provides a crystalline Form I N- (2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 7.1, 19.2, or 32.1. The present invention also provides a crystalline Form I N-(2,3-
Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 7.1, 19.2, and 32.1.
Additionally, the present invention provides a crystalline Form I N-(2,3- Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 7.1, 14.1, 15.3, 15.8, 16.9, 18.1, 19.2, 20.3, 21.4, 22.3, 23.4, 24.5, 25.5, 26.2, 26.8, 27.8, 28.3, 29.5, 32.1, 33.2, 33.6, 40.0, 42.9, and 44.1.
Also provided by the present invention is a crystalline Form II N-(2,3- Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 11.6, 12.6 or 24.9. The present invention also provides a crystalline Form II N-(2,3- Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 11.6, 12.6 and 24.9.
Additionally, the present invention provides a crystalline Form II N-(2,3- Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 11.6, 12.6, 15.6, 17.3, 17.9, 20.3, 21.1, 22.1, 24.9, 25.9, 26.7, 27.8, 30.1, 30.9, 33.8, 35.4, 38.2, 39.3, 40.8, 41.6, 43.6, and 47.0.
Additionally, the present invention provides a crystalline Form IN-[(R)- 2, 3 -Dihydroxy-propoxy]-3 ,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 10.6, 13.7, 19.0 or 23.7.
In addition, the present invention provides a crystalline Form IN-[(R)-2,3- Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 10.6, 13.7, 19.0 and 23.7. Also provided by the present invention is crystalline Form I N-[(R)-2,3-
Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 10.6, 13.7, 14.6, 17.3, 18.0, 18.2, 98.0, 19.3, 20.1, 21.0, 21.9, 22.4, 23.7, 24.0, 24.9, 26.3, 27.6, 28.0, 30.1, 32.1, 32.3, 32.9, 35.8, and 37.7. Furthermore, the present invention provides a crystalline Form FI N-[(R)- 2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 5.5 or 19.6. The present invention also provides a crystalline Form II N-[(R)-2,3-
Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 5.5 and 19.6.
Additionally, the present invention provides a crystalline Form II N-[(R)- 2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 5.5, 10.7, 16.5, 19.6, 22.0, 22.5, 23.6, 24.1, 25.0, 26.2, 27.6, 29.1, 30.5, 31.7, 33.3, and 39.0.
In addition, the present invention provides a crystalline Form I N-[(S)-2,3- Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 10.5, 13.7, 19.0, or 23.6.
Also provided by the present invention is crystalline Form IN-[(S)-2,3- Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 10.5, 13.7, 19.0, and 23.6.
Furthermore, the present invention provides a crystalline Form IN-[(S)- 2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 10.548, 13.703, 17.887,
18.958, 20.122, 21.950, 22.321, 23.640, 24.803, 26.244, 27.570, 28.000, 29.566, 32.234, 32.769, 35.804, 37.641, 41.402, 41.956, and 44.600.
The present invention also provides a crystalline Form II N-[(S)-2,3- Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 5.6 or 19.6. Additionally, the present invention provides a crystalline Form II N-[(S)- 2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 5.6 and 19.6. In addition, the present invention provides a crystalline Form LI N-[(S)-2,3-
Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 2Θ values measured using CuKα radiation: 5.6, 10.7, 16.5, 19.6, 20.9, 22.0, 23.7, 24.2, 25.0, 26.2, 27.7, 28.0, 29.1, 31.7, 32.8, 33.3, 34.1, 42.0, and 42.3.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention is further described by the following nonlimiting examples which refer to the accompanying Figures 1 to 6, short particulars of which are given below. FIG. 1 Diffractogram of Form I N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide (Y-axis = 0 to maximum intensity of about 350 counts per second (cps)) FIG. 2
Diffractogram of Form II N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide (Y-axis = 0 to maximum intensity of about 1200 cps) FIG. 3
Diffractogram of Form I N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2- (2-fluoro-4-iodo-phenylamino)-benzamide (Y-axis = 0 to maximum intensity of about 600 cps).
FIG. 4
Diffractogram of Form II N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2- (2-fluoro-4-iodo-phenylamino)-benzamide (Y-axis = 0 to maximum intensity of about 1250 cps). FIG. 5
Diffractogram of Form I YY-[(S)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2- (2-fluoro-4-iodo-phenylamino)-benzamide (Y-axis = 0 to maximum intensity of about 2600 cps). FIG. 6
Diffractogram of Form II N-[(S)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2- (2-fluoro-4-iodo-phenylamino)-benzamide (Y-axis = 0 to maximum intensity of about 700 cps).
DETAILED DESCRIPTION OF THE INVENTION
Certain terms are defined below and by their usage throughout this disclosure.
The terms "halogen" or "halo" in the present invention refer to a fluorine, bromine, chlorine, and iodine atom or fluoro, bromo, chloro, and iodo. The terms fluorine and fluoro, for example, are understood to be equivalent herein. Alkyl groups, such as "Ci-g alkyl", include aliphatic chains (i.e., hydrocarbyl or hydrocarbon radical structures containing hydrogen and carbon atoms) with a free valence. Alkyl groups are understood to include straight chain and branched structures. Examples include methyl, ethyl, propyl, isopropyl, butyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, 2,3-dimethylpropyl, hexyl, 2,3- dimethylhexyl, 1,1-dimethylpentyl, heptyl, octyl, and the like. The term
"Ci -g alkyl" includes within its definition the terms "C\-β alkyl", "C1-5 alkyl",
"C1-4 alkyl" and "Cr alkyl".
Alkyl groups can be substituted with 1, 2, 3 or more substituents which are independently selected from halo (fluoro, chloro, bromo, or iodo), cyano, hydroxy, amino, alkoxy, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, arylalkyloxy, heterocyclic radical, and (heterocyclic radical)oxy. Specific examples include fluoromethyl, hydroxyethyl, 2,3-dihydroxyethyl, (2- or 3- furanyl)methyl, cyclopropylmethyl, benzyloxyethyl, (3-pyridinyl)methyl, (2- or 3- furanyl)methyl, (2-thienyl)ethyl, hydroxypropyl, aminocyclohexyl, 2- dimethylaminobutyl, methoxymethyl, N-pyridinylethyl, diethylaminoethyl, and cyclobutylmethyl.
The term "alkoxy" as used herein refers to a straight or branched alkyl chain attached to an oxygen atom. The term "Ci -g alkoxy" as used herein refers to a straight or branched alkyl chain having from one to eight carbon atoms attached to an oxygen atom. Typical Ci -g alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and the like. The term "Cj-g alkoxy" includes within its definition the terms "Ci -g alkoxy" and "Ci -4 alkoxy". Alkenyl groups are analogous to alkyl groups, but have at least one double bond (two adjacent sp2 carbon atoms). Depending on the placement of a double bond and substituents, if any, the geometry ofthe double bond may be entgegen (E), or zusammen (Z), cis, or trans. Similarly, alkynyl groups have at least one triple bond (two adjacent sp carbon atoms). Unsaturated alkenyl or alkynyl groups may have one or more double or triple bonds, respectively, or a mixture thereof; like alkyl groups, unsaturated groups may be straight chain or branched, and they may be substituted as described both above for alkyl groups and throughout the disclosure by example. Examples of alkenyls, alkynyls, and substituted forms include cis-2-butenyl, trans-2-butenyl, 3-butynyl, 3-phenyl-2- propynyl, 3-(2'-fluorophenyl)-2-propynyl, 3-methyl(5-phenyl)-4-pentynyl, 2- hydroxy-2-propynyl, 2-methyl-2-propynyl, 2-propenyl, 4-hydroxy-3-butynyl, 3- (3-fluorophenyl)-2-propynyl, and 2-methyl-2-propenyl. In formula I, the term "alkenyl" includes C2_6 alkenyl or C2.4 alkenyl.
Cycloalkyl groups, such as C3-1 υ cycloalkyl, refer to a saturated hydrocarbon ring structure containing from 3 to 10 atoms. Typical
C3-10 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
The term "aryl" means an unsubstituted aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl). The aryl group can be optionally substituted with between 1 and 5 substituents independently selected from the group consisting of hydroxy, amino, monoalkylamino, dialkylamino, halogen, cyano, (Cι_3)alkoxy,
COOR, OCORa, CONRaRb, NRaCORb, SO, SO2, SO , and SO2NraRb, where
Ra and Rb are independently hydrogen or C 1.4 alkyl.
The term "aryloxy" as used herein refers to an aryl group attached to an oxygen atom.
As used herein, the terms "heterocycle", "C2.-7 heterocycle", "C2..9 heterocycle", or "C2-.7 heteroaryl" in the present invention refers to a stable 5-, 6-, or 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated or unsaturated, and consists of carbon atoms and from one to four heteroatoms selected from the group consisting of nitrogen, oxygen, or sulfur.
The heterocyclic ring may be attached at any heteroatom or carbon atom which affords a stable structure.
Heterocyclic radicals, which include but are not limited to heteroaryls, include: furyl, (is)oxazolyl, isoxazolyl, thiophenyl, thiazolyl, pynolyl, imidazolyl, 1,3,4-triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, indolyl, and their nonaromatic counterparts. Further examples of heterocyclic radicals include thienyl, piperidyl, quinolyl, isothiazolyl, piperidinyl, morpholinyl, piperazinyl, tetrahydrofuryl, tetrahydropynolyl, pyrrolidinyl, octahydroindolyl, octahydrobenzothiofuranyl, octahydrobenzofuranyl, (iso)quinolinyl, naphthyridinyl, benzimidazolyl, and benzoxazolyl.
More general forms of substituted hydrocarbon radicals include hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycycloalkyl, hydroxyaryl, and corresponding forms for the prefixes amino-, halo- (e.g., fluoro-, chloro-, or bromo-), nitro-, alkyl-, phenyl-, cycloalkyl- and so on, or combinations of substituents. According to formula (I), therefore, substituted alkyls include, but are not limited to, hydroxyalkyl, alkoxyalkyl, aminoalkyl, nitroalkyl, haloalkyl, cyanoalkyl, alkylalkyl (branched alkyls, such as methylpentyl), (cycloalkyl)alkyl, phenylalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylalkyl, aryloxyalkyl, arylalkyloxyalkyl, (heterocyclic radical)alkyl, and (heterocyclic radical)oxyalkyl. Formula I thus includes hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycycloalkyl, hydroxyaryl, aminoalkyl, aminoalkenyl, aminoalkynyl, aminocycloalkyl, aminoaryl, alkylalkenyl, (alkylaryl)alkyl, (haloaryl)alkyl, (hydroxyaryl)alkynyl, and so forth. R^, R7, Rg, R9, and Ri 0 include hydroxy(Cι _g)alkyl, (Cι _5)alkoxy(Cι _5)alkyl, aminoalkyl, (e.g., [(Cl-
4)alkyl]2aminomethyl), perhalo(Cι_3)alkyl (e.g., trifluoromethyl or trifluoroethyl), (C2_7)heterocycle(Cι_5)alkyl, and aryloxy(Cι _5)alkyl. Similarly, Ri 0 includes hydroxy(Cι _g)alkyl, (Ci _5)alkoxy(Cι_5)alkyl and trifluoro(Cι .
6)alkyl.
Representative examples ofthe independent union of R , R7, Rg, R9, and
Ri 0 to complete a 3-10 member cyclic ring optionally containing additional heteroatoms selected from O, S, NH, or N-alkyl are demonstrated in the fragments shown below.
Figure imgf000015_0001
Figure imgf000015_0002
Figure imgf000015_0003
Figure imgf000015_0004
Representative examples of formula I where R7 and Rg are independently selected for n>l are illustrated in the fragments shown below. The fragments below also show that where n>l, R7 and Rg are independently selected for each
(CR7Rg) unit.
Figure imgf000016_0001
Figure imgf000016_0002
The present invention includes the hydrates and the pharmaceutically acceptable salts and solvates ofthe compounds defined by formula I. The compounds of this invention can possess a sufficiently basic functional group, and accordingly react with any of a number of inorganic and organic acids, to form a pharmaceutically acceptable salt.
The term "pharmaceutically acceptable salt" as used herein, refers to salts ofthe compounds of formula I which are substantially non-toxic to living organisms. Typical pharmaceutically acceptable salts include those salts prepared by reaction ofthe compounds ofthe present invention with a pharmaceutically acceptable mineral or organic acid. Such salts are also known as acid addition salts. Such salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science. 66, 2-19 (1977), which are know to the skilled artisan. Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as -toluenesulfonic, methanesulfonic acid, benzenesulfonic acid, oxalic acid, j>-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Example of such pharmaceutically acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, bromide, hydrobromide, iodide, acetate, propionate, decanoate, caprate, caprylate, acrylate, ascorbate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, glucuronate, glutamate, propionate, phenylpropionate, salicylate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malate, maleate, hydroxymateate, mandelate, mesylate, nicotinate, isonicotinate, cinnamate, hippurate, nitrate, stearate, phthalate, teraphthalate, butyne-l,4-dioate, butyne-1,4- dicarboxylate, hexyne-l,4-dicarboxylate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, hydrozybenzoate, methoxybenzoate, dinitrobenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, phthalate, p- toluenesulfonate, >-bromobenzenesulfonate, 7-chlorobenzenesulfonate, xylenesulfonate, phenylacetate, trifluoroacetate, phenylpropionate, phenylbutyrate, citrate, lactate, α-hydroxybutyrate, glycolate, tartrate, hemi- tartrate, benzenesulfonate, methanesulfonate, ethanesulfonate, propanesulfonate, hydroxyethanesulfonate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, 1,5- naphthalenedisulfonate, mandelate, tartarate, and the like. A preferred pharmaceutically acceptable salt is hydrochloride.
It should be recognized that the particular counterion forming a part of any salt of this inventions is usually not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole. It is further understood that such salts may exist as a hydrate.
As used herein, the term "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures which are not interchangeable. The three-dimensional structures are called configurations. As used herein, the term "enantiomer" refers to each of two stereoisomers whose molecules are nonsuperimposable mirror images of one another. The term "chiral center" refers to a carbon atom to which four different groups are attached. As used herein, the term "diastereomers" refers to stereoisomers which are not enantiomers. The terms "racemate" or "racemic mixture" refer to a mixture of enantiomers. The enantiomers of compounds ofthe present invention can be resolved by one of ordinary skill in the art using standard techniques well-known in the art, such as those described by J. Jacques, et al., "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc. 1981. Examples of resolutions include recrystallization techniques or chiral chromatography.
Some ofthe compounds ofthe present invention have one or more chiral centers and may exist in a variety of stereoisomeric configurations. As a consequence of these chiral centers, the compounds ofthe present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope ofthe present invention.
The compounds of formula I can be prepared by techniques and procedures readily available to one of ordinary skill in the art, for example by following the procedures as set forth in the following Schemes. These schemes are not intended to limit the scope ofthe invention in any way. All substituents, unless otherwise indicated, are previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art. The compounds of formula I are generally obtained by the union of 2-
(arylamino)-benzoic acids (1) with alkoxyamines (2) by the action of a peptide coupling agent in the presence of a base, as shown in Scheme 1. Preferred coupling agents include diphenylphoshinic chloride (DPP-C1), benzotriazol-yl- oxy-tripyrolidinophosphonium hexafluorophosphate (PyBOP), benzotriazol-1- yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N'- dicyclohexylcarbodiimide (DCC), 1 -ethyl -3 -(3- dimethylaminopropyl)carbodiimide hydrochloride (EDO), or 1,1'- carbonyldimidazole (GDI). Prefened bases include diisopropylethylamine, triethylamine, 4-methylmorpholine, or pyridine or a substituted pyridine, for example, 4-dimethyaminopyridine or 2,6-dimethylpyridine. Preferred solvents are polar aprotic solvents such as dichloromethane, tetrahydrofuran, or dimethylformamide. The reactions are generally carried out at a temperature between about -78 °C to about 25 °C, and are normally complete within about 2 hours to about 5 days. The product amides can be isolated by removing the solvent, for example by evaporation under reduced pressure, and further purified, if desired, by standard methods such as chromatography, crystallization, or distillation. Scheme 1 : General Preparation of Benzamides from Benzoic Acids
Figure imgf000019_0001
Alternately, disclosed compounds are also generally prepared as shown in Scheme 2 by the contact of alkoxyamine (2) with "activated" benzoic acid derivatives (3), wherein the activating group "X" completes an acid halide, anhydride, mixed anhydride, or an activated ester, such as a pentafluorophenyl ester, nitrophenyl ester or thioester. Prefened bases include diisopropylethylamine, triethylamine, 4-methylmorpholine, imidazole, pyridine or a substituted pyridine, for example, 4-dimethyaminopyridine or 2,6- dimethylpyridine. Preferced solvents are polar aprotic solvents such as dichloromethane, tetrahydrofuran, or dimethylformamide. These synthetic strategies, which are suitable for both conventional or combinatorial (parallel synthesis) synthetic methods are further exemplified in examples below.
Scheme 2: General Preparation of Benzamides from "Activated" Benzoic Acid Derivatives
Figure imgf000019_0002
Preferred combinatorial methods are outlined in Scheme 3, wherein the compounds of formula I are obtained by the reaction of an excess of pentafluorophenyl esters (4) with alkoxyamines (2) in the presence of polymer supported (PS) 4-methylmorpholine (5) in dimethylformamide with mechanical shaking. After a reaction period of about 16 to 72 hours, polymer supported amine (6) is added with dichloromethane. After an additional several hours of mechanical agitation, targets I are obtained by filtration, solvent evaporation and chromatograhic purification.
Scheme 3: General Combinatorial Preparation of Benzamides from Benzoic Acid Pentafluorophenyl Esters
Figure imgf000020_0001
For the preparation of compounds of formula I wherein R\ \ = hydrogen, preferred synthetic modes may utilize a reagent of formula (2), wherein Rβ, R7, Rg, R9, Ri 0 are defined as for formula I, above, and Ri 1 is a standard hydroxyl (W = O) or amino (W = NRa) protecting group. In such instances, general schemes 1-3, above may be modified to include a standard removal ofthe said protecting group. Suitable protecting groups include, but are not limited to, vinyl ethers, silyl ethers, acetals, acetonides, and carbamates. Examples of such modifications are outlined below. As illustrated in Scheme 4, preferced compounds of formula Ila may be obtained by the reaction of benzoic acids (1) with vinyl ether (7), a peptide coupling agent (for example, PyBOP) and a base (for example, diisopropylethylamine) to afford vinyl ether amide (8). Further treatment of vinyl ether (8) with acid affords the compounds of formula Ila. Scheme 4: Representative Preparation of Hydroxy lated Benzamides Using a Vinyl Ether as a Hydroxyl Protecting Group
Figure imgf000021_0001
Ila
As shown below in Scheme 5, preferred compounds of formula lib may also be obtained by the reaction of benzoic acids (1) with a suitable protecting group, such as tert-butyldimethylsilyl ether (9), in the presence a peptide coupling agent (for example, PyBOP) and a tertiary amine base (for example, diisopropylethylamine) to afford tert-butyldimethylsilyl ether amide (10). Further treatment of silyl ether (10) with acid in a protic solvent affords the compounds of formula lib.
Scheme 5: Representative Preparation of Hydroxylated Benzamides Using a Silyl Ether as a Hydroxyl Protecting Group
Figure imgf000022_0001
lib
Prefened compounds of formula IVa can be prepared by similar methods, as illustrated in Scheme 6. For example, treatment of benzoic acids (1) with carbamate (11) in the presence of a peptide coupling agent, for example diphenylphosphinic chloride (DPP-Cl), in the presence of a tertiary amine base, for example 4-methylmorpholine (NMM) affords carbamate amide (12). Subsequent treatment of (12) with a suitable acid, for example trifluoracetic acid or hydrogen chloride, gives rise to the amines of general formula IVa, which may be isolated as acid salts or neutralized under standard conditions to afford free bases.
Scheme 6: Representative Preparation of Amino-Substituted Benzamides Using a tert-Butyl Carbamate as an Amino Protecting Group
Figure imgf000023_0001
IVa Further examples ofthe use of protecting group stategies are illustrated in the synthesis of preferred compounds of formula Ilia shown in Scheme 7. Acetonide-amides (14) are readily obtained by the union of acetonide (13) with benzoic acid (1) in the presence of a peptide coupling agent (for example, DPP-
Cl) and a tertiary base, for example, 4-methylmorpholine (NMM). Alternately, they may be prepared according to Scheme 2 by the treatment of benzoic acid pentafluorophenyl esters (4) with acetonide (13) in the presence of a tertiary amine base (for example, diisopropylethylamine). Conversion of acetonide- amides (14) to preferred compounds Ilia can be accomplished by treatment under standard acidic hydrolysis conditions, for example p-toluenesulfonic acid in methanol.
Scheme 7: Representative Preparation of Dihydroxylated Benzamides Using an Acetonide as a Diol Protecting Group
Figure imgf000024_0001
The compounds of formula I can also be prepared by the modification of other compounds of formula I. For example, compounds of formula I, where R6=H (15) may be converted to compounds of formula I, where R^ alkyl (16) by treatment with alkylating agents (for example, iodomethane) in the presence of a base (for example, potassium carbonate). Alternately, compounds of formula I, where Ri i = H (17) may be converted to compounds of formula I, where Rj i = alkyl carbonyl (18) by treatment with an acid chloride (for example, acetyl chloride) and a base, such as triethylamine. Additionally, a compound of formula
I, where R4=H (19) can be prepared from a compound of formula I, where
R4=Iodo (20). Illustrations of these examples are found in Schemes 8-10. Scheme 8: Representative Preparation of Tertiary Benzamides by N-Alkylation
Figure imgf000025_0001
Scheme 9: Representative Preparation of Acetates by Acetylation
Figure imgf000025_0002
Scheme 10: Representative Hydrogenolysis of Aryl Iodides
Figure imgf000025_0003
Specific compounds provided by the invention include: Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3-phenoxy-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-butoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(2-hydroxy- 1 -methyl-ethoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(2-methoxy-ethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3-morpholin-4-yl- propoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-butoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-l-methyl- ethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-methoxy-ethoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-3-morpholin-4-yl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-propoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide
3,4,5-Trifluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4,5-Trifluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 3 ,4, 5 -Trifluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)- benzamide
3,4,5-Trifluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenyIamino)- benzamide
3,4,5-Trifluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 3,4,5-Trifluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-butoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-l-methyl- ethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-methoxy-ethoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-propoxy)- benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide
5 -Bromo-3 ,4-difluoro-N-(2-hydroxy-3 -phenoxy-proρoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5 -Bromo-3 ,4-difluoro-N-(2 -hydroxy- 1 -methyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)- benzamide 5-Bromo-3,4-difluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Bromo-3,4-difluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4-Difluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4-Difluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide 3,4-Difluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)-benzamide
3,4-Difluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4-Difluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4-Difluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 3 ,4-Difluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-butoxy)- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-l-methyl- ethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-methoxy-ethoxy)- benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(2-hydroxy-3 - morpholin-4-yl-propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-propoxy)- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-2,2- dimethyl-propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide
5-Chloro-3,4-difluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-3 ,4-difluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Chloro-3,4-difluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)- benzamide
5-Chloro-3,4-difluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide 5-Chloro-3,4-difluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Chloro-3,4-difluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-propoxy)- benzamide 3,4,5-Trifluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-propoxy)- benzamide
5-Bromo-3,4-difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4-Difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxy] -b enzamide 3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxy] -b enzamide
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy- ethoxy)-ethoxy]-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-[2-(2-methoxy-ethoxy)-ethoxy]- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-[2-(2-methoxy-ethoxy)- ethoxyj-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-[2-(2-methoxy- ethoxy)-ethoxy]-benzamide
Additionally, the claims provide for the following compounds:
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)- benzamide,
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)- benzamide, 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-ethoxy)- benzamide,
5-Bromo-3,4-difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide,
5-Chloro-3,4-difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide,
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-propoxy)- benzamide,
5-Chloro-3,4-difluoro-iV-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide, 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide,
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-2,2- dimethyl-propoxy)-benzamide,
5 -Bromo-3 ,4-difluoro-N-(3 -hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide,
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-2-methyl-propoxy)- benzamide,
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-3,4- difluoro-benzamide, 5-Chloro-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide,
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-3,4- difluoro-benzamide, 5-Chloro-N-(3,4-dihydroxy-butoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide,
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-[2-(2-methoxy- ethoxy)-ethoxy]-benzamide, 5-Chloro-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy- ethoxy)-ethoxy]-benzamide.
Additional Compounds described by the invention include:
4-Fluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide 4-Fluoro-N-(3 -hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy-ethoxy)-ethoxyj- benzamide
4-Fluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide
4-Fluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide 4-Fluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)-benzamide N-(3,4-Dihydroxy-butoxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
N-(2,3-Dihydroxy-propoxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4-Fluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-ethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-[2-(2-methoxy-ethoxy)-ethoxy]- benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-butoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-propoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-2-methyl-propoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy- 1 -methyl-ethoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-methoxy-ethoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-4-fluoro-benzamide 2-(2-Chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-4-fluoro- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-morpholin-4-yl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-phenoxy-propoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3 -hydroxy-2,2-dimethyl- propoxy)-benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)-benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(2-methoxy-ethoxy)-ethoxy]- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)-benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)-benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl-propoxy)- benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- 1 -methyl-ethoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy-ethoxy)-benzamide N-(3,4-Dihydroxy-butoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide N-(2,3-Dihydroxy-propoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-morpholin-4-yl- propoxy)-benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-phenoxy-propoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2-dimethyl-propoxy)- benzamide 4,5-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4,5-Difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4,5-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxy]-benzamide
4,5-Difluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4,5-Difluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 4, 5-Difluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4,5-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)- benzamide
N-(3,4-Dihydroxy-butoxy)-4,5-difluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
N-(2,3-Dihydroxy-propoxy)-4,5-difluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide 4,5-Difluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-ethoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3-hydroxy-propoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-[2-(2-methoxy-ethoxy)- ethoxyj-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-butoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4, 5-difluoro-N-(2-hydroxy- 1 -methyl-ethoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-methoxy-ethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-4,5-difluoro- benzamide
2-(2-Chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-4,5-difluoro- benzamide 2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-3-morpholin-4-yl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-benzamide 4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)- benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxy] -benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)-benzamide 4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl-propoxy)- benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l-methyl-ethoxy)- benzamide 4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy-ethoxy)-benzamide N-(3,4-Dihydroxy-butoxy)-4,5-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
N-(2,3-Dihydroxy-propoxy)-4,5-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide 4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-morpholin-4-yl- propoxy)-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide
5-Chloro-4-fluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Chloro-4-fluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 5-Chloro-4-fiuoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxyj-benzamide
5-Chloro-4-fluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Chloro-4-fluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Chloro-4-fluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)- benzamide
5-Chloro-N-(3,4-dihydroxy-butoxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Chloro-N-(2,3-dihydroxy-propoxy)-4-fluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-4-fluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-ethoxy)- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-propoxy)- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-[2-(2-methoxy-ethoxy)- ethoxyj-benzamide
5-Chloro-2-(2-chloro-4-iodo-ρhenylamino)-4-fluoro-N-(2-hydroxy-butoxy)- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-propoxy)- benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-l-methyl- ethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-methoxy-ethoxy)- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-4-fluoro- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-4-fluoro- benzamide 5 -Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3 -morpholin-
4-yl-propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-phenoxy- proρoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide 5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)- benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxy]-benzamide 5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)- benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl- propoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l-methyl- ethoxy)-b enzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy-ethoxy)- benzamide 5-Chloro-N-(3,4-dihydroxy-butoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
5-Chloro-N-(2,3-dihydroxy-propoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-morpholin- 4-yl-propoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide
5-Chloro-4-fiuoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide 5-Bromo-4-fluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 5-Bromo-4-fluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Bromo-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxyj-benzamide
5-Bromo-4-fluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 5-Bromo-4-fluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Bromo-4-fluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Bromo-4-fluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)- benzamide
5-Bromo-N-(3,4-dihydroxy-butoxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Bromo-N-(2,3-dihydroxy-propoxy)-4-fluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Bromo-4-fluoro-N-(2-hydroxy-3 -phenoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-ethoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-propoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-[2-(2-methoxy-ethoxy)- ethoxy] -b enzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-butoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-propoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-l-methyl- ethoxy)-b enzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-methoxy-ethoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-4-fluoro- benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-4-fluoro- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-morpholin- 4-yl-propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fiuoro-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide 5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)- benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxyj-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)- benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl- propoxy)-benzamide 5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l-methyl- ethoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy-ethoxy)- benzamide
5-Bromo-N-(3,4-dihydroxy-butoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
5-Bromo-N-(2,3-dihydroxy-propoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide 5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-morpholin- 4-yl-propoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide 5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-benzamide 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)- benzamide 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxy] -b enzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)-benzamide 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl-propoxy)- benzamide
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2 -hydroxy- 1 -methyl-ethoxy)- benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy-ethoxy)-benzamide N-(3,4-Dihydroxy-butoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-morpholin-4-yl- propoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide 3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)- benzamide 3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(2-methoxy-ethoxy)- ethoxyj-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)- benzamide 3 ,4, 5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl- propoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l-methyl- ethoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy-ethoxy)- benzamide
N-(3,4-Dihydroxy-butoxy)-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide N-(2,3-Dihydroxy-propoxy)-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-morpholin-4- yl-propoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2-dimethyl- propoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)- benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(2-methoxy- ethoxy)-ethoxy]-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)- benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl- propoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l-methyl- ethoxy)-benzamide 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy-ethoxy)- benzamide
5-Chloro-N-(3,4-dihydroxy-butoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
5-Chloro-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2- dimethyl-propoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)- benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(2-methoxy- ethoxy)-ethoxy] -benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)- benzamide 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide 5-Bromo-3,4-difiuoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl- propoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l-methyl- ethoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy-ethoxy)- benzamide 5-Bromo-N-(3,4-dihydroxy-butoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
5-Bromo-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2- dimethyl-propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3-methoxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-pentyloxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-ρhenylamino)-3,4-difluoro-N-(2-hydroxy-3-methyl-butoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-l,l-dimethyl- ethoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-( 1 -hydroxymethyl- cyclopropoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-N-(2-ethoxy-ethoxy)-3,4-difluoro-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-2-methoxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-pentyloxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-butoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-3-methyl-butoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-[2-(l-hydroxy-cyclopropyl)- ethoxy] -b enzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(3 -hydroxy- 1 , 1 -dimethyl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-l-methyl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-N-(2,3 -dihydroxy- 1 , 1 -dimethyl-propoxy)-3 ,4- difluoro-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-3-methoxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-pentyloxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3 ,4, 5 -trifιuoro-N-(3 ,3 ,3-trifluoro-2-hydroxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-3-methyl- butoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3 ,4, 5 -trifluoro-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3 ,A, 5-trifluoro-N-( 1 -hydroxy- cyclopropylmethoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3 ,4, 5 -trifluoro-N-( 1 -hydroxy- cyclobutylmethoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(l-hydroxymethyl-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-l,l-dimethyl- ethoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-N-(2-ethoxy-ethoxy)-3,4,5-trifluoro- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-2-methoxy- propoxy)-b enzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-pentyloxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-butoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-3 ,4, 5 -trifluoro-N-(3 -hydroxy-3 -methyl- butoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-[2-(l-hydroxy-cyclopropyl)- ethoxy] -b enzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-l,l-dimethyl- propoxy)-b enzamide 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-l-methyl- propoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-N-(2,3 -dihydroxy-1 , 1 -dimethyl-propoxy)-
3,4,5-trifluoro-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- methoxy-propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy- pentyloxy)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3-methyl- butoxy)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl- propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-l,l- dimethyl-ethoxy)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2-ethoxy-ethoxy)-3,4-difluoro- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-2- methoxy-propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy- pentyloxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-butoxy)- benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-3-methyl- butoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-[2-(l-hydroxy- cyclopropyl)-ethoxy]-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-l,l- dimethyl-propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-l-methyl- propoxy)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-l,l-dimethyl- propoxy)-3 ,4-difluoro-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- methoxy-propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy- pentyloxy)-benzamide
5 -Bromo-2-(2-chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(3 ,3 ,3 -trifluoro-2- hydroxy-propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3-methyl- butoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl- proρoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-l,l- dimethyl-ethoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-ethoxy-ethoxy)-3,4-difluoro- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-2- methoxy-propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy- pentyloxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-butoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-3-methyl- butoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-[2-(l-hydroxy- cyclopropyl)-ethoxy]-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-l,l- dimethyl-propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-l-methyl- propoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-l,l-dimethyl- propoxy)-3 ,4-difluoro-benzamide
3,4-Difluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4-Difluoro-N-(2-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3 ,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3 ,3 ,3-trifluoro-2-hydroxy- propoxy)-benzamide
3,4-Difluoro-N-(2-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 3,4-Difluoro-N-(2-hydroxy-4-methyl-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 3,4-Difluoro-N-(l-hydroxy-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3 , 4-Difluoro-N-( 1 -hydroxy-cy clobutyl methoxy)-2-(4-io do-2-methyl- phenylamino)-benzamide
3,4-Difluoro-N-(l-hydroxymethyl-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 3 ,4-Difluoro-N-(2-hydroxy- 1 , 1 -dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4-Difluoro-N-(l-hydroxymethyl-cyclopropoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide N-(2-Ethoxy-ethoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
3,4-Difluoro-N-(3-hydroxy-2-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4-Difluoro-N-(3-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 3,4-Difluoro-N-(3-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4-Difluoro-N-(3-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4-Difluoro-N-[2-(l-hydroxy-cyclopropyl)-ethoxy]-2-(4-iodo-2-methyl- phenylamino)-benzamide
3 ,4-Difluoro-N-( 1 -hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4-Difluoro-N-(2-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 3,4-Difluoro-N-(3-hydroxy-l,l-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3 ,4-Difluoro-N-(3 -hydroxy- 1 -methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
N-(2,3 -Dihydroxy- 1 , 1 -dimethyl-propoxy)-3 ,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 3,4,5-Trifluoro-N-(2-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide 3,4,5-Trifluoro-N-(2-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 3,4,5-Trifluoro-N-(2-hydroxy-4-methyl-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3 ,4, 5-Trifluoro-N-( 1 -hydroxy-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 3,4,5-Trifluoro-N-(l-hydroxy-cyclobutylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-(l-hydroxymethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-(2-hydroxy-l,l-dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-(l-hydroxymethyl-cyclopropoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
N-(2-Ethoxy-ethoxy)-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide 3,4,5-Trifluoro-N-(3-hydroxy-2-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-(3-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4,5-Trifluoro-N-(3-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
3,4,5-Trifluoro-N-(3-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-[2-(l-hydroxy-cyclopropyl)-ethoxy]-2-(4-iodo-2-methyl- phenylamino)-benzamide 3 ,4, 5-Trifluoro-N-( 1 -hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3,4,5-Trifluoro-N-(2-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3 ,4, 5-Trifluoro-N-(3 -hydroxy- 1 , 1 -dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
3 ,4, 5-Trifluoro-N-(3 -hydroxy- 1 -methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide N-(2,3 -Dihydroxy- 1 , 1 -dimethyl-propoxy)-3 ,4, 5-trifluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-3,4-difluoro-N-(2-hydroxy-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide
5-Chloro-3,4-difluoro-N-(2-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(2-hydroxy-4-methyl-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5 -Chloro-3 ,4-difluoro-N-( 1 -hydroxy-cy clopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-3,4-difluoro-N-(l-hydroxy-cyclobutylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(l-hydroxymethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(2-hydroxy- 1 , 1 -dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(l-hydroxymethyl-cyclopropoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-N-(2-ethoxy-ethoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide 5-Chloro-3,4-difluoro-N-(3-hydroxy-2-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(3-hydroxy-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(3-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Chloro-3,4-difluoro-N-(3-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-3,4-difluoro-N-[2-(l-hydroxy-cyclopropyl)-ethoxy]-2-(4-iodo-2- methyl-phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(l-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide 5-Chloro-3,4-difluoro-N-(2-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(3 -hydroxy- 1 , 1 -dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-3,4-difluoro-N-(3-hydroxy-l-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-N-(2,3-dihydroxy-l,l-dimethyl-propoxy)-3,4-difluoro-2-(4-iodo-2- methyl-phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Bromo-3,4-difluoro-N-(2-hydroxy-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide
5-Bromo-3,4-difluoro-N-(2-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(2-hydroxy-4-methyl-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(l-hydroxy-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Bromo-3,4-difluoro-N-(l-hydroxy-cyclobutylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(l-hydroxymethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3 ,4-difluoro-N-(2-hydroxy- 1 , 1 -dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(l-hydroxymethyl-cyclopropoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Bromo-N-(2-ethoxy-ethoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Bromo-3,4-difluoro-N-(3-hydroxy-2-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5 -Bromo-3 ,4-difluoro-N-(3 -hydroxy-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5 -Bromo-3 ,4-difiuoro-N-(3 -hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Bromo-3,4-difluoro-N-(3-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-[2-(l-hydroxy-cyclopropyl)-ethoxy]-2-(4-iodo-2- methyl-phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(l-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide 5-Bromo-3,4-difluoro-N-(2-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide
5-Bromo-3 ,4-difluoro-N-(3 -hydroxy- 1 , 1 -dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-3,4-difluoro-N-(3-hydroxy-l-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5 -Bromo-N-(2,3-dihydroxy- 1 , 1 -dimethyl -propoxy)-3 ,4-difluoro-2-(4-iodo-2- methyl-phenylamino)-benzamide
4-Fluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 4-Fluoro-N-(2-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide
4-Fluoro-N-(2-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 4-Fluoro-N-(2-hydroxy-4-methyl-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-N-(l-hydroxy-cyclopropylmethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 4-Fluoro-N-(l-hydroxy-cyclobutylmethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-N-(l-hydroxymethyl-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 4-Fluoro-N-(2-hydroxy-1,1-dimethyl-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-N-(l-hydroxymethyl-cyclopropoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
N-(2-Ethoxy-ethoxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 4-Fluoro-N-(3-hydroxy-2-methoxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-N-(3-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide 4-Fluoro-N-(3-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide 4-Fluoro-N-(3-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4-Fluoro-N-[2-(l-hydroxy-cyclopropyl)-ethoxy]-2-(4-iodo-2-methyl- phenylamino)-benzamide
4-Fluoro-N-(l-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 4-Fluoro-N-(2-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4-Fluoro-N-(3 -hydroxy- 1 , 1 -dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4-Fluoro-N-(3-hydroxy-l-methyl-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
N-(2,3 -Dihydroxy- 1 , 1 -dimethyl-propoxy)-4-fluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-methoxy-propoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-pentyloxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3 ,3 ,3 -trifluoro-2-hydroxy- propoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-methyl-butoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-4-methyl-pentyloxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-( 1 -hydroxy-cyclopropylmethoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxy-cyclobutylmethoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxymethyl-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy- 1 , 1 -dimethyl-ethoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxymethyl-cyclopropoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-N-(2-ethoxy-ethoxy)-4-fluoro-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-2-methoxy-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-pentyloxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-butoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3 -hydroxy-3 -methyl-butoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-[2-(l-hydroxy-cyclopropyl)- ethoxy] -b enzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-( 1 -hydroxymethyl- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3 -hydroxy- 1 , 1 -dimethy 1- propoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3 -hydroxy- 1 -methyl-propoxy)- benzamide 2-(2-Chloro-4-iodo-phenylamino)-N-(2,3 -dihydroxy- 1 , 1 -dimethyl-propoxy)-4- fluoro-benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methoxy-propoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydrόxy-pentyloxy)-benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methyl-butoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-4-methyl-pentyloxy)- benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy-cyclopropylmethoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy-cyclobutylmethoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl-propoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-1,1-dimethyl-ethoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl-cyclopropoxy)- benzamide N-(2-Ethoxy-ethoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2-methoxy-propoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-pentyloxy)-benzamide
4-Fluoro-2-(2rfluoro-4-iodo-phenylamino)-N-(3-hydroxy-butoxy)-benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-3-methyl-butoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(l-hydroxy-cyclopropyl)- ethoxy] -b enzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hydroxymethyl- cyclopropylmethoxy)-benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy- 1 , 1 -dimethyl-propoxy)- benzamide
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy- 1 -methyl-propoxy)- benzamide N-(2,3-Dihydroxy-l,l-dimethyl-propoxy)-4-fluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
4,5-Difluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(2-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4,5-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide
4,5-Difluoro-N-(2-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 4,5-Difluoro-N-(2-hydroxy-4-methyl-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4, 5 -Difluoro-N-( 1 -hydroxy-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(l-hydroxy-cyclobutylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(l-hydroxymethyl-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4,5-Difluoro-N-(2-hydroxy-l,l-dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 4,5-Difluoro-N-(l-hydroxymethyl-cyclopropoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
N-(2-Ethoxy-ethoxy)-4,5-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
4,5-Difluoro-N-(3-hydroxy-2-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 4,5-Difluoro-N-(3-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 4,5-Difluoro-N-(3-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 4,5-Difluoro-N-(3-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
4,5-Difluoro-N-[2-(l-hydroxy-cyclopropyl)-ethoxy]-2-(4-iodo-2-methyl- phenylamino)-benzamide 4,5-Difluoro-N-(l-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(2-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(3-hydroxy-l,l-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
4,5-Difluoro-N-(3-hydroxy-l-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
N-(2, 3 -Dihydroxy- 1 , 1 -dimethyl-propoxy)-4, 5-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4, 5-difluoro-N-(2-hydroxy-3 -methoxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-pentyloxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-3-methyl-butoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(l-hydroxymethyl-propoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-l,l-dimethyl- ethoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-N-(2-ethoxy-ethoxy)-4,5-difluoro-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3-hydroxy-2-methoxy- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3-hydroxy-pentyloxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3-hydroxy-butoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3-hydroxy-3-methyl-butoxy)- benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-[2-(l-hydroxy-cyclopropyl)- ethoxy] -b enzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide 2-(2-Chloro-4-iodo-phenylamino)-4, 5-difluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3-hydroxy-l,l-dimethyl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(3-hydroxy-l-methyl- propoxy)-benzamide
2-(2-Chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-l,l-dimethyl-propoxy)-4,5- difluoro-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methoxy- propoxy)-benzamide 4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-pentyloxy)- benzamide 4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide
4, 5 -Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3 -methyl-butoxy)- benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide 4, 5 -Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hy droxy- cyclopropylmethoxy)-benzamide
4, 5 -Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hydroxy- cyclobutylmethoxy)-benzamide 4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl-propoxy)- benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l,l-dimethyl- ethoxy)-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
N-(2-Ethoxy-ethoxy)-4,5-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
4, 5 -Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy-2-methoxy- propoxy)-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-pentyloxy)- benzamide
4, 5 -Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy-butoxy)-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-3-methyl-butoxy)- benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(l-hydroxy-cyclopropyl)- ethoxyj-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide A, 5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy- 1 , 1 -dimethyl- propoxy)-benzamide
4,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-l-methyl-propoxy)- benzamide
N-(2,3-Dihydroxy-l,l-dimethyl-propoxy)-4,5-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-4-fluoro-N-(2-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5 -Chloro-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3 ,3,3 -trifluoro-2- hydroxy-propoxy)-benzamide 5-Chloro-4-fluoro-N-(2-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(2-hydroxy-4-methyl-pentyloxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(l-hydroxy-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5 -Chloro-4-fluoro-N-( 1 -hydroxy-cyclobutylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(l-hydroxymethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5 -Chloro-4-fluoro-N-(2-hydroxy- 1 , 1 -dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(l-hydroxymethyl-cyclopropoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-N-(2-ethoxy-ethoxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Chloro-4-fluoro-N-(3-hydroxy-2-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-(3-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 5-Chloro-4-fluoro-N-(3-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 5-Chloro-4-fluoro-N-(3-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-4-fluoro-N-[2-(l-hydroxy-cyclopropyl)-ethoxy]-2-(4-iodo-2-methyl- phenylamino)-benzamide -,
5-Chloro-4-fluoro-N-(l-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide 5-Chloro-4-fluoro-N-(2-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide
5-Chloro-4-fluoro-N-(3-hydroxy-l,l-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Chloro-4-fluoro-N-(3-hydroxy-l-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-N-(2,3-dihydroxy-l,l-dimethyl-propoxy)-4-fluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-methoxy- propoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-pentyloxy)- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-methyl- butoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxy- cyciobutylmethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxymethyl- propoxy)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-l,l-dimethyl- ethoxy)-b enzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2-ethoxy-ethoxy)-4-fluoro- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-2-methoxy- propoxy)-benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-pentyloxy)- benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-butoxy)- benzamide 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-3-methyl- butoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-[2-(l-hydroxy- cyclopropyl)-ethoxy]-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-l,l-dimethyl- propoxy)-benzamide 5 -Chloro-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3 -hydroxy- 1 -methyl- propoxy)-benzamide
5 -Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2,3 -dihydroxy- 1 , 1 -dimethyl- propoxy)-4-fluoro-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methoxy- propoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-pentyloxy)- benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide 5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methyl- butoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclobutylmethoxy)-benzamide 5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- propoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l,l-dimethyl- ethoxy)-benzamide 5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hydroxymethyl- cyclopropoxy)-benzamide
5-Chloro-N-(2-ethoxy-ethoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2-methoxy- propoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-pentyloxy)- benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-butoxy)- benzamide 5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-3-methyl- butoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(l-hydroxy- cyclopropyl)-ethoxy] -b enzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-l,l-dimethyl- propoxy)-benzamide 5-Chloro-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy- 1 -methyl- propoxy)-benzamide
5-Chloro-N-(2,3-dihydroxy-l,l-dimethyl-propoxy)-4-fluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(2-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 5-Bromo-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide
5-Bromo-4-fluoro-N-(2-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Bromo-4-fluoro-N-(2-hydroxy-4-methyl-pentyloxy)-2-(4-iodo-2-methyl- ρhenylamino)-benzamide
5-Bromo-4-fluoro-N-(l-hydroxy-cyclopropylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(l-hydroxy-cyclobutylmethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5 -Bromo-4-fluoro-N-( 1 -hydroxy methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(2-hydroxy-l,l-dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Bromo-4-fluoro-N-(l-hydroxymethyl-cyclopropoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-N-(2-ethoxy-ethoxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Bromo-4-fluoro-N-(3-hydroxy-2-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(3-hydroxy-pentyloxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide
5-Bromo-4-fluoro-N-(3-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide 5-Bromo-4-fluoro-N-(3-hydroxy-3-methyl-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-[2-(l-hydroxy-cyclopropyl)-ethoxy]-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(l-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide
5-Bromo-4-fluoro-N-(2-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide 5-Bromo-4-fluoro-N-(3-hydroxy-l,l-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-4-fluoro-N-(3-hydroxy-l-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide 5-Bromo-N-(2,3-dihydroxy-l,l-dimethyl-propoxy)-4-fluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-methoxy- propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-pentyloxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-3-methyl- butoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-4-methyl- ρentyloxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxymethyl- propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-l,l-dimethyl- ethoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-ethoxy-ethoxy)-4-fluoro- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-2-methoxy- propoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-pentyloxy)- benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-butoxy)- benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-3-methyl- butoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-[2-(l-hydroxy- cyclopropyl)-ethoxy]-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fiuoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3 -hydroxy- 1 , 1 -dimethyl- propoxy)-benzamide
5 -Bromo-2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(3 -hydroxy- 1 -methyl- propoxy)-benzamide 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-l,l-dimethyl- propoxy)-4-fluoro-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methoxy- propoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-pentyloxy)- benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methyl- butoxy)-benzamide 5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- propoxy)-benzamide 5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l,l-dimethyl- ethoxy)-b enzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropoxy)-benzamide 5-Bromo-N-(2-ethoxy-ethoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2-methoxy- propoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-pentyloxy)- benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-butoxy)- benzamide
5 -Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy-3 -methy 1- butoxy)-benzamide 5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(l-hydroxy- cyclopropyl)-ethoxy]-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-l,l-dimethyl- propoxy)-benzamide
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-l-methyl- propoxy)-benzamide 5-Bromo-N-(2,3-dihydroxy-l,l-dimethyl-propoxy)-4-fluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methoxy- propoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-pentyloxy)- benzamide
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 ,3,3 -trifluoro-2-hydroxy- propoxy)-benzamide 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methyl-butoxy)- benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hydroxy- cyclopropylmethoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hydroxymethyl-propoxy)- benzamide
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- 1 , 1 -dimethyl- ethoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropoxy)-benzamide N-(2-Ethoxy-ethoxy)-3 ,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy-2-methoxy- propoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-pentyloxy)- benzamide 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy-butoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-3-methyl-butoxy)- benzamide
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-( 1 -hydroxy-cy clopropyl)- ethoxy] -b enzamide 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hydroxymethyl- cyclopropylmethoxy)-benzamide
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy- 1 , 1 -dimethyl- propoxy)-benzamide
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy- 1 -methyl-propoxy)- benzamide N-(2, 3 -Dihydroxy- 1 , 1 -dimethyl-propoxy)-3 ,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methoxy- propoxy)-benzamide 3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-pentyloxy)- benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methyl- butoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
3 ,4, 5 -Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l -hydroxy- cyclopropylmethoxy)-benzamide 3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl-propoxy)- benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l3l-dimethyl- ethoxy)-b enzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
N-(2-Ethoxy-ethoxy)-3 ,4, 5 -trifluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2-methoxy- propoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-pentyloxy)- benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-butoxy)- benzamide 3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-3-methyl- butoxy)-benzamide 3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(l-hydroxy-cyclopropyl)- ethoxy] -b enzamide 3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide 3,4,5 -Trifluoro-2-(2-fluoro-4-iodo-pheny lamino)-N-(3 -hydroxy- 1 , 1 -dimethyl- propoxy)-benzamide
3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-l-methyl- propoxy)-benzamide
N-(2,3-Dihydroxy-l,l-dimethyl-propoxy)-3,4,5-trifluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- methoxy-propoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- pentyloxy)-benzamide 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methyl- butoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclopropylmethoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclobutylmethoxy)-benzamide 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- propoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l,l- dimethyl-ethoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
5-Chloro-N-(2-ethoxy-ethoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2- methoxy-propoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy- pentyloxy)-benzamide 5-Chloro-3,4-difiuoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-butoxy)- benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-3-methyl- butoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(l-hydroxy- cy clopr opyl)-ethoxy] -b enzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-l,l- dimethyl-propoxy)-benzamide
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-l-methyl- propoxy)-benzamide
5-Chloro-N-(2,3-dihydroxy-l,l-dimethyl-propoxy)-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- methoxy-propoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- pentyloxy)-benzamide 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-methyl- butoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-4-methyl- pentyloxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclopropylmethoxy)-benzamide 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxy- cyclobutylmethoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- propoxy)-benzamide 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l,l- dimethyl-ethoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropoxy)-benzamide
5-Bromo-N-(2-ethoxy-ethoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2- methoxy-propoxy)-benzamide
5 -Bromo-3, 4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy- pentyloxy)-benzamide 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-butoxy)- benzamide
5 -Bromo-3 , 4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy-3 -methyl- butoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-[2-(l-hydroxy- cyclopropyl)-ethoxy] -benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide
5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-l,l- dimethyl-propoxy)-benzamide
5-Bromo-3 ,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 -hydroxy- 1 -methyl- propoxy)-benzamide, and
5-Bromo-N-(2,3-dihydroxy-l,l-dimethyl-proρoxy)-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide.
Preferred compounds are those of formula I wherein R\ is hydrogen or halogen; and more preferably, hydrogen, F, Br, or Cl; and most preferably, hydrogen; R2 and R3 are fluoro; R4 is hydrogen, iodine, bromine, chlorine, or fluorine; and more preferably hydrogen, iodine, chlorine, or fluorine; and most preferably is iodo; R5 is fluoro, chloro, or methyl; more preferably is fluoro or chloro; and most preferably is fluoro; n is 1 or 2; or combinations thereof. Preferced compounds are selective MEK inhibitors. The most preferred compounds within are those wherein Rβ, Rη, Rg, R9, Rχo, and Ri 1 are hydrogen,
W is oxygen, and n is 1 or 2 and also those wherein, Rg, R7, R9, R ø, and R are hydrogen, W is oxygen, n is 2, and Rg(l) is hydrogen and Rg(2) is hydroxy.
Such compounds have the formulae IT and III.
Figure imgf000074_0001
wherein
Ri is hydrogen or halogen;
R5 is fluorine, chlorine, or methyl; and n is 1 or 2.
Figure imgf000074_0002
wherein R is hydrogen or halogen; and
R5 is fluorine, chlorine, or methyl. Other most preferced compounds are those of formula I wherein j is hydrogen or halo such as F, Br, or Cl; R2 and R3 are fluoro; R4 is iodo; R5 is fluoro, chloro, or methyl; n is 1; Rg, R7, Rg, R9, and Ri 0 are hydrogen, W is NRa and Ra is H: R \ is methyl or phenyl; and pharaceutically accepted salts thereof. These compounds have formulae IV and V.
Figure imgf000075_0001
wherein
Ri is hydrogen or halogen; and
R5 is fluorine, chlorine, or methyl.
Figure imgf000075_0002
wherein
Rj is hydrogen or halogen; and
R5 is fluorine, chlorine, or methyl.
Preferred compounds ofthe present invention include, but are not limited to the following compounds:
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-3,4- difluoro-benzamide;
3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-benzamide; N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fiuoro-4-iodo-phenylamino)- benzamide; 5-Chloro-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide;
5-Chloro-N-((R)-2,3-dihydroxy-proρoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methylamino-ethoxy)- benzamide; hydrochloride;
N-((R)-2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide;
N-((S)-2, 3 -Dihydroxy-propoxy)-3 ,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide;
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-((S)-2,3-dihydroxy-propoxy)-3,4- difluoro-benzamide;
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-((R)-2,3-dihydroxy-propoxy)-3,4- difluoro-benzamide; 5-Chloro-N-((S) 2,3-dihydroxy-proρoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide;
3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- 1 -hydroxymethyl- ethoxy)-b enzamide; and
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l- hydroxymethyl-ethoxy)-benzamide.
In another aspect, the present invention provides Crystalline Form I and
Form II ofN-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide (hereinafter referred to as "Form I of Compound A" and
"Form II of Compound A", respectively) or hydrates thereof, Crystalline Form I and Form II of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide (hereinafter referred to as "Form I of Compound B" and
"Form II of Compound B", respectively) or hydrates thereof, and Crystalline
Form I and Form II of N-[(S)-2,3-Dihydroxy-propoxyj-3,4-difluoro-2-(2-fluoro-4- iodo-ρhenylamino)-benzamide (hereinafter referred to as "Form I of Compound C" and "Form II of Compound C", respectively) or hydrates thereof.
The present invention also provides Crystalline Form I and Form II of
Compound A or hydrates thereof, Crystalline Form I and Form II of Compound B or hydrates thereof, and Crystalline Form I or Form II of Compound C or hydrates thereof (hereinafter referred to collectively as "crystal forms" or "crystal forms" ofthe present invention, unless specified otherwise) which are useful as pharmaceutical "agents, to methods for their production and isolation, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to pharmaceutical methods of treatment.
The novel crystalline compounds ofthe present invention are useful as inhibitors ofMEK.
The crystal forms provided by the present invention may be characterized by their X-ray powder diffraction patterns. Crystalline Form I and Form II of Compound A, Crystalline Form I and
Form II of Compound B, and Crystalline Form I and Form II of Compound C were characterized by their X-ray powder diffraction pattern. Thus, the X-ray diffraction patterns ofthe crystal forms ofthe present invention were measured on a Rigaku Ultima + diffractometer with CuKa radiation. Equipment
Rigaku Ultima + Diffractometer with an LBM-compatible interface equipped with 6 position autosampler, software = RigMeas v2.0 (Rigaku, December 1995) and JADE 3.1 (Materials Data, Inc.). CuKa radiation (40 mA, 40 kV, λ= 1.5419 A). Slits I and II at 0.5°, slit III at 0.3°. Methodology
The silicon standard is run once a week to check the X-ray tube alignment. Continuous Θ/2Θ coupled scan: 3.00° to 50.00° in 20, scan rate of 1 min: 1.0 sec/0.04° step. Sample tapped out of vial and pressed onto zero-background silicon in aluminum holder. Sample width 5 mm.
Samples are stored and run at room temperature.
Samples are being spun at 40 rpm around vertical axis during data collection.
Table 1 lists the X-ray powder diffraction pattern for crystalline Form I of Compound A expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a
Rigaku Ultima + diffractometer with CuKα radiation. It should be noted that the computer-generated, unrounded numbers are listed in Table 1. TABLE 1
2-Theta d(A) Relative Intensity (>10%)
7.078 12.4779 15.2
14.123 6.2659 15.4
15.280 5.7939 58.7
15.836 5.5917 31.4
16.880 5.2481 42.2
18.082 4.9019 41.4
19.162 4.6280 67.4
20.279 4.3754 21.1
21.360 4.1565 73.6
22.325 3.9789 14.4
23.400 3.7984 79.3
24.522 3.6271 11.0
25.480 3.4929 24.6
26.159 3.4037 100.0
26.801 3.3237 48.9
27.842 3.2017 22.8
28.280 3.1531 45.4
29.475 3.0280 16.0
32.118 2.7845 19.7
33.248 2.6924 10.6
33.645 2.6615 16.3
40.008 2.2517 10.6
42.885 2.1071 12.1
44.095 2.0520 12.8 Table 2 lists the X-ray powder diffraction pattern for crystalline Form II of Compound A, expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuKα radiation. It should be noted that the computer-generated, unrounded numbers are listed in Table 2.
TABLE 2
2-Theta d(A) Relative Intensity (>10%)
11.582 7.6344 11.2 *
12.598 7.0205 13.0 *
15.622 5.6678 17.1
17.302 5.1211 29.3
17.886 4.9551 13.3
20.345 4.3614 49.8
21.140 4.1991 31.0
22.137 4.0123 81.7
24.855 3.5793 100.0 *
25.885 3.4391 15.1
26.699 3.3362 23.3
27.842 3.2018 23.7
30.059 2.9704 11.8
30.948 2.8871 33.4
33.799 2.6498 24.8
35.399 2.5336 16.2
38.242 2.3516 33.9
39.282 2.2916 11.3
40.755 2.2122 12.6
41.641 2.1671 11.7
43.570 2.0756 24.5
46.958 1.9334 19.5 Table 3 lists the X-ray powder diffraction pattern for crystalline Form I of Compound B, expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuKα radiation. It should be noted that the i computer-generated, unrounded numbers are listed in Table 3.
TABLE 3
2-Theta d(A) Relative Intensity (>10%)
10.560 8.3702 14.9 *
13.720 6.4488 10.3 *
14.619 6.0543 13.9
17.258 5.1340 12.4
17.958 4.9354 44.5
18.219 4.8654 15.8
18.998 4.6675 38.1 *
19.258 4.6052 12.3
20.142 4.4050 17.7
21.002 4.2264 18.5
21.940 4.0479 53.2
22.360 3.9727 19.3
23.680 3.7541 100.0 *
24.043 3.6983 16.9
24.919 3.5702 67.3
26.278 3.3886 20.1
27.603 3.2289 40.6
28.024 3.1813 30.7
30.100 2.9665 14.6
32.142 2.7825 15.8
32.298 2.7694 14.6
32.938 2.7171 14.7
35.841 2.5034 16.3
37.660 2.3865 15.6 Table 4 lists the X-ray powder diffraction pattern for crystalline Form II of Compound B, expressed in terms ofthe 2-theta ("2Θ"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a
Rigaku Ultima + diffractometer with CuKα radiation. It should be noted that the computer-generated, unrounded numbers are listed in Table 4.
TABLE 4
2-Theta (A) Relative Intensity (>10%)
5.482 16.1076 39.6 *
10.721 8.2453 20.3
16.478 5.3751 21.9
19.563 4.5340 73.2 *
22.019 4.0334 100.0
22.478 3.9521 16.1
23.621 3.7634 11.1
24.100 3.6896 31.9
24.959 3.5647 98.2
26.181 3.4010 15.1
27.621 3.2269 31.7
29.081 3.0681 17.7
30.476 2.9307 11.4
31.698 2.8204 38.9
33.263 2.6913 19.4
39.020 2.3064 10.2
Table 5 lists the X-ray powder diffraction pattern for crystalline Form I of
Compound C, expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuKα radiation. It should be noted that the computer-generated, unrounded numbers are listed in Table 5. TABLE 5
2-Theta d(A) Relative Intensity (>10%)
10.548 8.3798 14.6 *
13.703 6.4568 11.3 *
17.887 4.9549 19.9
18.958 4.6772 27.3 *
20.122 4.4093 10.9
21.950 4.0460 58.3
22.321 3.9796 13.4
23.640 3.7604 100.0 *
24.803 3.5867 66.6
26.244 3.3929 12.1
27.570 3.2327 21.6
28.000 3.1840 31.9
29.566 3.0189 23.1
32.234 2.7748 18.3
32.769 2.7307 16.4
35.804 2.5059 13.8
37.641 2.3877 16.8
41.402 2.1791 14.4
41.956 2.1516 10.0
44.600 2.0300 13.9
Table 6 lists the X-ray powder diffraction pattern for crystalline Form II of Compound C, expressed in terms ofthe 2-theta ("20"), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuKα radiation. It should be noted that the computer-generated, unrounded numbers are listed in Table 6. TABLE 6
2-Theta d(A) Relative Intensity (>10%)
5.550 15.91107 21.8 *
10.763 8.2128 22.3
16.485 5.3729 11.8
19.636 4.5173 73.5 *
20.922 4.2425 20.6
22.043 4.0291 54.0
23.683 3.7538 18.0
24.153 3.6817 52.6
24.996 3.5595 100.0
26.236 3.3939 11.4
27.680 3.2201 25.2
28.037 3.1799 22.4
29.120 3.0641 21.5
31.718 2.8187 36.4
32.794 2.7287 13.3
33.314 2.6872 10.8
34.085 2.6282 13.6
41.999 2.1494 14.6
42.278 2.1359 10.3
The crystal forms ofthe present invention may exist in anhydrous forms as well as hydrated forms. In general, the hydrated forms, are equivalent to unhydrated forms and are intended to be encompassed within the scope ofthe present invention. The present invention provides a process for the preparation of crystalline
Form I of Compound A which comprises crystallizing Compound A from a solution in solvents under conditions which yield crystalline Form I of Compound A.
The precise conditions under which crystalline Form I of Compound A is formed may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice. The desired Form I may be obtained by suspending the solid in a suitable solvent, such as ethanol and precipitating with water; by dissolving the solid in a minimum amount of a boiling solvent, such as ethanol and adding water to the boiling solvent; and by dissolving the solid in a minimum amount of boiling solvent, such as ethyl acetate, and adding a suitable solvent, such as heptane to the boiling solvent, as is more fully set forth in Example 39A below.
The present invention provides a process for the preparation of crystalline Form II of Compound A which comprises crystallizing Compound A from a solution in solvents under conditions which yield crystalline Form II of
Compound A.
The precise conditions under which crystalline Form II of Compound A is formed may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice. The desired Form II may be obtained by suspending the solid in a suitable solvent, such as ethyl acetate/hexanes or suspending the solid in a suitable solvent, such as heptane - CH2C1 (1 : 1), as is more fully set forth in Example 39 below.
The present invention provides a process for the preparation of crystalline Form I of Compound B which comprises crystallizing Compound B from a solution in solvents under conditions which yield crystalline Form I of Compound
B. The precise conditions under which crystalline Form I of Compound B is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice. The desired Form I may be obtained by suspending the solid in hexane-AcOEt. A more detailed procedure is set forth in Example 49 below.
The present invention provides a process for the preparation of crystalline Form II of Compound B which comprises crystallizing Compound B from a solution in solvents under conditions which yield crystalline Form II of Compound B. The precise conditions under which crystalline Form II of Compound B is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice. The desired Form II may be obtained by suspending the solid in ethyl acetate and heptane or by suspending the solid in by suspending the solid in hexane-AcOEt, as is more fully set forth in Examples 49 and 49A below.
The present invention provides a process for the preparation of crystalline Form I of Compound C which comprises crystallizing Compound C from a solution in solvents under conditions which yield crystalline Form I of Compound C. The precise conditions under which crystalline Form I of Compound C is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice. The desired Form I may be obtained by suspending the solid in hexane-AcOEt. A more detailed procedure is set forth in Example 50 below. The present invention provides a process for the preparation of crystalline
Form II of Compound C which comprises crystallizing Compound C from a solution in solvents under conditions which yield crystalline Form II of Compound C. The precise conditions under which crystalline Form II of Compound C is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice. The desired Form II may be obtained by suspending the solid in ethyl acetate and heptane, or by suspending the solid in hexane-AcOEt, as is more fully set forth in Examples 50 and 50 A below.
As used herein, the term "patient" refers to any warm-blooded animal such as, but not limited to, a human, horse, dog, guinea pig, or mouse. Preferably, the patient is human. The term "treating" for purposes ofthe present invention refers to prophylaxis or prevention, amelioration or elimination of a named condition once the condition has been established.
Selective MEK 1 or MEK 2 inhibitors are those compounds which inhibit the MEK 1 or MEK 2 enzymes, respectively, without substantially inhibiting other enzymes such as MKK3, PKC, Cdk2A, phosphorylase kinase, EGF, and
PDGF receptor kinases, and C-src. In general, a selective MEK 1 or MEK 2 inhibitor has an IC50 for MEK 1 or MEK 2 that is at least one-fiftieth (1/50) that of its IC50 for one ofthe above-named other enzymes. Preferably, a selective inhibitor has an IC50 that is at least 1/100, more preferably 1/500, and even more preferably 1/1000, 1/5000, or less than that of its IC50 or one or more ofthe above- named enzymes.
The disclosed compositions are useful as both prophylactic and therapeutic treatments for diseases or conditions related to the hyperactivity of MEK, as well as diseases or conditions modulated by the MEK cascade. Examples include, but are not limited to, stroke, septic shock, heart failure, osteoarthritis, rheumatoid arthritis, organ transplant rejection, and a variety of tumors such as ovarian, lung, pancreatic, brain, prostatic, and colorectal.
The invention further relates to a method for treating proliferative diseases, such as cancer, restenosis, psoriasis, autoimmune disease, and atherosclerosis. Other aspects ofthe invention include methods for treating MEK-related
(including ras-related) cancers, whether solid or hematopoietic. Examples of cancers include brain, breast, lung, such as non-small cell lung, ovarian, pancreatic, prostate, renal, colorectal, cervical, acute leukemia, and gastric cancer. Further aspects ofthe invention include methods for treating or reducing the symptoms of enograft (cell(s), skin, limb, organ or bone marrow transplant) rejection, osteoarthritis, rheumatoid arthritis, cystic fibrosis, complications of diabetes (including diabetic retinopathy and diabetic nephropathy), hepatomegaly, cardiomegaly, stroke (such as acute focal ischemic stroke and global cerebral ischemia), heart failure, septic shock, asthma, Alzheimer's disease, and chronic or neuropathic pain. Compounds ofthe invention are also useful as antiviral agents for treating viral infections such as HJV, hepatitis (B) virus (HBN), human papilloma virus (HPV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV). These methods include the step of administering to a patient in need of such treatment, or suffering from such a disease or condition, a therapeutically effective amount of a disclosed compound, including crystal forms, or pharmaceutical composition thereof.
The term "chronic pain" for purposes ofthe present invention includes, but is not limited to, neuropathic pain, idiopathic pain, and pain associated with chronic alcoholism, vitamin deficiency, uremia, or hypothyroidism. Chronic pain is associated with numerous conditions including, but not limited to, inflammation, arthritis, and post-operative pain.
As used herein, the term "neuropathic pain" is associated with numerous conditions which include, but are not limited to, inflammation, postoperative pain, phantom limb pain, burn pain, gout, trigeminal neuralgia, acute herpetic and postherpetic pain, causalgia, diabetic neuropathy, plexus avulsion, neuroma, vasculitis, viral infection, crush injury, constriction injury, tissue injury, limb amputation, post-operative pain, arthritis pain, and nerve injury between the peripheral nervous system and the central nervous system.
The invention also features methods of combination therapy, such as a method for treating cancer, wherein the method further includes providing radiation therapy or chemotherapy, for example, with mitotic inhibitors such as a taxane or a vinca alkaloid. Examples of mitotic inhibitors include paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, and vinflunine. Other therapeutic combinations include a MEK inhibitor ofthe invention and an anticancer agent such as cisplatin, 5-fluorouracil or 5-fluoro-2-4(lH,3H)-pyrimidinedione (5FU), flutamide, and gemcitabine. The chemotherapy or radiation therapy may be administered before, concurrently, or after the administration of a disclosed compound according to the needs ofthe patient.
Those skilled in the art will be able to determine, according to known methods, the appropriate therapeutically-effective amount or dosage of a compound ofthe present invention to administer to a patient, taking into account factors such as age, weight, general health, the compound administered, the route of administration, the type of pain or condition requiring treatment, and the presence of other medications. In general, an effective amount or a therapeutically-effective amount will be between about 0.1 and about 1000 mg/kg per day, preferably between about 1 and about 300 mg/kg body weight, and daily dosages will be between about 10 and about 5000 mg for an adult subject of normal weight. Commercially available capsules or other formulations (such as liquids and film-coated tablets) of 100 mg, 200 mg, 300 mg, or 400 mg can be administered according to the disclosed methods.
The compounds ofthe present invention, including crystal forms, are preferably formulated prior to administration. Therefore, another aspect ofthe present invention is a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier. In making the compositions ofthe present invention, the active ingredient, such as a compound of formula I, will usually be mixed with a carrier, or diluted by a carrier or enclosed within a carrier. Dosage unit forms or pharmaceutical compositions include tablets, capsules, pills, powders, granules, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers adapted for subdivision into individual doses.
Dosage unit forms can be adapted for various methods of administration, including controlled release formulations, such as subcutaneous implants. Administration methods include oral, rectal, parenteral (intravenous, intramuscular, subcutaneous), intracisternal, intravaginal, intraperitoneal, intravesical, local (drops, powders, ointments, gels, or cream), and by inhalation
(a buccal or nasal spray).
Parenteral formulations include pharmaceutically acceptable aqueous or nonaqueous solutions, dispersion, suspensions, emulsions, and sterile powders for the preparation thereof. Examples of carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained by the use of a coating such as lecithin, a surfactant, or maintaining appropriate particle size. Carriers for solid dosage forms include (a) fillers or extenders, (b) binders, (c) humectants, (d) disintegrating agents, (e) solution retarders, (f) absorption acccelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and (j) propellants.
Compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents; antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid; isotonic agents such as a sugar or sodium chloride; absorption-prolonging agents such as aluminum monostearate and gelatin; and absorption-enhancing agents.
The following examples represent typical syntheses ofthe compounds of the present invention as described generally above. These examples are illustrative only and are not intended to limit the invention in any way. The reagents and starting materials are readily available to one of ordinary skill in the art.
Figure imgf000089_0001
PREPARATION 1 5-Bromo-3.4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid
To a stirred solution comprised of 1.88 g (0.00791 mol) of 2-amino- 5-iodotoluene in 10 mL of tetrahydrofuran at -78°C was added 6 mL (0.012 mol) of a 2.0 M lithium diisopropylamide in tetrahydrofuran/heptane/ethylbenzene (Aldrich) solution. The resulting green suspension was stirred vigorously for 10 minutes, after which time a solution of 1.00 g (0.00392 mol) of 5-bromo-
2,3,4-trifluorobenzoic acid in 15 mL of tetrahydrofuran was added. The cold bath was subsequently removed, and the reaction mixture stirred for 18 hours. The mixture was concentrated, and the concentrate was treated with 100 mL of dilute (10%) aqueous hydrochloric acid. The resulting suspension was extracted with ether (2 x 150 mL), and the combined organic extractions were dried (MgSO4) and concentrated in vacuo to give an orange solid. The solid was triturated with boiling dichloromethane, cooled to ambient temperature, and collected by filtration. The solid was rinsed with dichloromethane, and dried in the vacuum- oven (80°C) to afford 1.39 g (76%) of a yellow-green powder; mp 259.5-262°C; ^ MR (400 MHz, DMSO): δ 9.03 (s, 1H), 7.99 (dd, 1H, J=7.5, 1.9 Hz),
7.57 (dd, 1H, J=1.5 Hz), 7.42 (dd, 1H, J=8.4, 1.9 Hz), 6.70 (dd, 1H, J=8.4,
6.0 Hz), 2.24 (s, 3H); 19F NMR (376 MHz, DMSO): δ -123.40 to -123.47 (m); -139.00 to -139.14 (m); IR (KBr) 1667 (C=O stretc^cm"1; MS (CI) M+1 = 469. Anal. Calcd/found for C14H9BrF2rNO2: C, 35.93/36.15; H, 1.94/1.91; N, 2.99/2.70; Br, 17.07/16.40; F, 8.12/8.46;
I, 27.11/26.05.
PREPARATIONS
Preparations 2 to 25 in Table 7 below were prepared by the general procedure of Example 1.
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000093_0002
PREPARATION 26 5-Bromo-3.4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid pentafluorophenyl ester To a solution of 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (prepared as described in WO 99/01426) (1.61 g, 3.4 mmol) and pyridine (0.31 mL, 3.83 mmol) in anhydrous dimethylformamide (7 mL) was added pentafluorophenyl trifluoroacetate (0.71 mL, 4.13 mmol). The resultant solution was stirred at ambient temperature for 18 h. The reaction mixture was diluted with ether (100 mL) and washed with water (40 mL), 0.1 M aqueous hydrochloric acid (40 mL), saturated aqueous sodium bicarbonate (40 mL), and saturated brine (40 mL). The organics were dried over anhydrous magnesium sulfate and concentrated under reduced pressure to afford a foam that was purified on silica gel. Elution with hexanes-ethyl acetate (19:1) afforded 5-Bromo-3,4-difluoro-2- (4-iodo-2-methyl-phenylamino)-benzoic acid pentafluorophenyl ester (1.95 g, 89%) as a pale-yellow powder: 1HNMR (400 MHz, CDC13) δ 8.59 (s, 1 H), 8.24 (d, J = 5.8 Hz, 1 H), 7.54 (s, 1 H), 7.45 (d, J = 8.4 Hz, 1 H), 6.70 (dd, J = 8.4, 5.3 Hz, 1 H), 2.26 (s, 3 H).
Preparations 27-46 were prepared by the general procedure of Preparation 26.
Figure imgf000094_0001
PREPARATION 27
5-Chloro-3.4-difluoro-2-(4-iodo-2-methyl-phenylamino -benzoic acid pentafluorophenyl ester 1H-NMR (400 MHz, CDC13) δ 8.58 (s, 1 H), 8.12 (dd, J = 7.5, 2.0 Hz, 1 H), 7.54 (s, 1 H), 7.46 (dd, J = 8.3, 1.5 Hz, 1 H), 6.70 (dd, J = 8.3, 5.4 Hz, 1 H), 2.28 (s, 3 H); 19F-NMR (376 MHz, CDC13) δ -125.1 (dd, J = 17.7, 5.0 Hz, 1 F), -139.1 (d, J
= 17.7 Hz, 1 F), -152.6 (d, J = 17.7 Hz, 2 F), -156.9 (t, J = 20.3 Hz, 1 H), -161.9 (t, J = 20.2 Hz, 2 H); MS (APCI-) = 587.9.
Figure imgf000094_0002
PREPARATION 28
3 ,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid pentafluorophenyl ester 1H-NMR (400 MHz, CDC13) δ 8.59 (s, 1 H), 8.04 (dd, J = 7.5, 7.0 Hz, 1 H), 7.53 (s, 1 H), 7.45 (d, J = 8.4 Hz, 1 H), 6.77 (m, 1 H), 6.70 (dd, J = 7.2, 6.9 Hz, 1 H), 2.27 (s, 3 H); MS (APCI-) = 554.0
Figure imgf000095_0001
PREPARATION 29 3A5-Trifluoro-2-(4-iodo-2-methyl-phenylaminoVbenzoic acid pentafluorophenyl ester MP: 108.5-110.6 °C; 1H-NMR (400 MHz, CDC13) δ 8.35 (s, 1H), 7.89 (ddd,
J=10.4, 8.0, 2.2 Hz, 1H), 7.53 (s, 1H), 7.44 (dd, J=8.2, 1.9 Hz, 1H), 6.64 (dd, J=8.2, 5.5 Hz, 1H), 2.27 (s, 3H); 19F-NMR (376 MHz, CDC13) δ -137.25 (d, J=16.8 Hz, IF), -144.18 (dd, J=21.4, 10.7 Hz, IF), -145.55 (td, J=21.4, 7.6 Hz, IF), -152.31 (d, J=18.3 Hz, 2F), -156.60 (t, J=21.4 Hz, IF), -161.62 (t, J=18.3 Hz, 2F). Anal. Calcd/found for C20H8NO2F8I: C, 41.91/41.52; H, 1.41/1.32; N,
2.44/2.36; F, 26.52/26.34; I, 22.14/22.19.
Figure imgf000095_0002
PREPARATION 30 2-(2-Chloro-4-iodo-phenylamino -3.4.5-trifluoro-benzoic acid pentafluorophenyl ester MP: 98.2-99.2 °C; ^NMR (400 MHz, CDCI3) δ 8.50 (s, 1H), 7.93 (ddd, J=10.1, 8.0, 2.2 Hz, 1 H), 7.70 (d, J=1.7 Hz, 1H), 7.48 (dd, J=8.7, 1.7 Hz, 1H), 6.62 (t, J=7.6 Hz, 1H); 19F-NMR (376 MHz, CDCI3) δ -134.42 (d, J=18.3 Hz, IF), - 141.59 (dd, J=21.4, 9.2 Hz, IF), -145.26 (td, J=21.4, 7.6 Hz, IF), -152.26 (d,
J=18.3 Hz, 2F), -156.46 (t, J=21.4 Hz, IF), -161.53 (t, J=18.3 Hz, 2F). Anal. Calcd/found for C19H5NO2F8ClI: C, 38.45/38.39; H, 0.85/0.91; N, 2.36/2.32; Cl, 5.97/6.32; F, 25.60/25.68; I, 21.38/21.32.
Figure imgf000096_0001
PREPARATION 31 5 -Chloro-2-(2-chloro-4-iodo-phenylamino)-3.4-difluoro-benzoic acid pentafluorophenyl ester 1H-NMR (400 MHz, CDC13) δ 8.74 (s, 1 H), 8.15 (dd, J = 7.3, 2.0 Hz, 1 H), 7.71 (d, J = 2.0 Hz, 1 H), 7.49 (dd, J = 8.4, 2.0 Hz, 1 H), 6.68 (dd, J - 8.4, 7.1 Hz, 1 H); MS (APCI-) = 607.8.
Figure imgf000096_0002
PREPARATION 32 5-Bromo-2-(2-chloro-4-iodo-phenylamino -3.4-difluoro-benzoic acid pentafluorophenyl ester Yield, 1.99 g (61%); mp. 112-114 °C; 1H-NMR (400 MHz, CDC13) δ 8.75 (s, IH),
8.28 (dd, J=7.0, 2.2 Hz, IH), 7.50 (dd, J = 8.4, 1.9 Hz, IH), 7.713 (d, J=1.9 Hz, IH), 6.68 (dd, J=8.4, 7.0 Hz, IH); 19F-NMR (376 MHz, CDC13) δ -116.43 (dd, J=19.8, 6.1 Hz, IF), -135.59 (dd, J=18.3, 6.1 Hz, IF), -152.2 (d, J=16.8 Hz, 2F), - 156.47 (t, J=21.4 Hz, IF), -161.53 (t, J=18.3 Hz, 2F). Anal. Calcd/found for C19H5NO2F7BrClI: C, 34.87/34.72; H, 0.77/0.65; N, 2.14/2.07; F, 20.32/20.68; Cl,
5.42/6.06; Br, 12.21/11.67; I, 19.39/19.75.
Figure imgf000097_0001
PREPARATION 33
2-(2-Chloro-4-iodo-phenylaminoV3.4-difluoro-benzoic acid pentafluorophenyl ester Yield, 2.15g (75%); mp. 108.5-110.0 °C; 1H-NMR (400 MHz, CDC13) δ 8.77 (br s
, IH), 8.07 (br s, 1 H), 7.69 (br s, IH), 7.48 (br d, J=7.0 Hz, IH), 6.91 (br d, J=7.2 Hz, IH), 6.67 (br s., IH); 19F-NMR (376 MHz, CDC13) δ -123.74 (s, IF), -139.17 (d, J=16.8 Hz, IF), -152.35 (d, J=21.4 Hz, 2F), -156.96 (t, J=21.4 Hz, IF), -161.81 (t, J=21.4 Hz, 2F). Anal. Calcd/found for C19H6NO2F7ClI: C, 39.65/39.32; H, 1.05/0.91; N, 2.43/2.35; F, 23.10/22.85; Cl, 6.16/6.92; I, 22.05/22.50.
Figure imgf000097_0002
PREPARATION 34 3.4.5-Trifluoro-2-(2-fluoro-4-iodo-phenylaminoVbenzoic acid pentafluorophenyl ester 1H NMR (400 MHz, CDCI3) δ 8.40 (s, IH), 7.85-7.91 (m, IH), 7.35-7.43 (m, 2H), 6.67-6.73 (m, IH); ); MS (APCI')=575.9.
Figure imgf000097_0003
PREPARATION 35
5-Bromo-4-fluoro-2-(4-iodo-2-methylphenylamino -benzoic acid pentafluorophenyl ester 1H-NMR (400 MHz, acetone-d6) δ 9.04 (br. s., IH), 8.44 (d, IH, J=7.81 Hz), 7.74 (d, IH, J=1.22 Hz), 7.64 (dd, IH, J=8.31, 1,96 Hz), 7.19 (d, IH, 8.3 Hz), 6.67 (d, IH, J=11.48 Hz), 2.22 (s, 3H). 19F-NMR (376 MHz, acetone-d6) δ -97.1 (t), - 155.0 (t), -160.2 (t), -165.1 (t). MS (APCI-) 415.8 m/z, 429.9 m/z, 447.9 m/z, 615.8 m/z.
Figure imgf000098_0001
PREPARATION 36 3 ■4-Difluoro-2-r2-fluoro-4-iodo-phenylamino -benzoic acid pentafluorophenyl ester
1HNMR (400 MHz, CDCh) δ 8.67 (s, 1 H), 8.04 (ddd, J = 9.3, 5.6, 2.2 Hz, 1 H), 7.42 9dd, J = 10.0, 1.9 Hz, 1 H), 7.38 (d, J = 8.8 Hz, 1 H), 6.84 (td, J = 9.1, 6.8 Hz, 1 H), 6.77 (td, J = 8.5, 5.1 Hz, 1 H); 19F NMR (376 MHz, CDC13) δ -124.3, - 125.1, -143.5, -152.6, -157.3, -162.1; MS (APCI-) = 557.9.
Figure imgf000098_0002
PREPARATION 37 5-Bromo-3.4-difluoro-2-(2-fluoro-4-iodo-phenylaminoVbenzoic acid pentafluorophenyl ester 1H NMR (400 MHz, acetone-d6) δ 8.60 (s, 1 H), 8.39 (ddd, J = 7.1, 2.3, 0.7 Hz, 1
H),7.58 (dd, J = 10.5, 1.7 Hz, 1 H), 7.49 (dt, J = 7.5, 1.5 Hz, 1 H), 7.06 (td, J = 8.5, 4.4 Hz, 1 H); 19F NMR (376 MHz, acetone-d6) δ -120.5, -127.1, -141.5, - 154.7, -159.8, -164.8; MS (APCI-) = 635.8, 637.8.
Figure imgf000099_0001
PREPARATION 38 5-Chloro-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid pentafluorophenyl ester 1H NMR (400 MHz, CDC13) δ 8.62 (s, 1 H), 8.10 (dd, J = 7.5, 2.3 Hz, 1 H), 7.44 (dd, J = 10.0, 1.7 Hz, I H), 7.41 (dd, J = 8.4 , 1.1 Hz, 1 H), 6.76 (td, J = 8.3, 4.6 Hz, 1 H); 19F NMR (376 MHz, CDCI3) δ -124.6, -124.9, -140.3, -152.5, -156.8, 161.9; MS (APCI-) = 591.8, 593.8.
Figure imgf000099_0002
PREPARATION 39
4.5 -Difluoro-2-(2-fluoro-4-iodo-phenylaminoVbenzoic acid pentafluorophenyl ester
1H-NMR (400 MHz, acetone-d6) δ 8.99 (br. s.), 8.17 (dd, IH, J=10.99, 8.79 Hz), 7.69 (dd, IH, J=10.0, 1.95 Hz), 7.63 (m, IH), 7.38 (t, IH, J-8.55 Hz), 7.04 (qd,
IH, J=6.84, 1.47 Hz). 19F-NMR (376 MHz, acetone-d6) δ -123.0 (t), -125.7 (p), -
150.8 (m), -155.1 (d), -160.1 (t), -165.0 (t). MS (APCI-) 355.9 m/z, 391.9 m/z,
558.0 m z. Anal. Calcd for C14Hi0F2INO2: C, 40.81; H, 1.08; N, 2.50. Found: C,
40.92; H, 1.00; K 2.32.
Figure imgf000099_0003
PREPARATION 40
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino -benzoic acid pentafluorophenyl ester 1H-NMR (400 MHz, acetone-d6) δ 9.11 (br. s.), 8.2 (dd, IH, J=11.24, 8.79 Hz), 7.9 (d, IH, J=1.95 Hz), 7.73 (dd, IH, J=8.55, 2.2 Hz), 7.45 (d, IH, J=8.55 Hz), 7.17 (dd, IH, J=13.18, 6.83 Hz). 19F-NMR (376 MHz, acetone-d6) δ -96.8, -122.4, -155.0, -160.0, -165.0. MS (APCI-) 415.8 m/z (d), 453.8 m/z (d), 617.8 m/z (d). Anal. Calcd for Ci3H7BrF2LNO2: C, 34.39; H, 0.98; N, 2.26. Found: C, 36.61; H, 0.99; N, 2.09.
Figure imgf000100_0001
PREPARATION 41 2-(2-Chloro-4-iodo-phenylamino)-4.5-difluoro-benzoic acid pentafluorophenyl ester 1H-NMR (400 MHz, acetone-d6) δ 9.11 (br. s.), 8.2 (dd, IH, J=11.24, 8.79 Hz), 7.9 (d, IH, 1.95 Hz), 7.73 (dd, IH, J=8.55, 2.2 Hz), 7.45 (d, IH, J=8.55 Hz), 7.17 (dd, IH, J=13.18, 6.83 Hz). 19F-NMR (376 MHz, acetone-d6) δ -125.5 (p), -150.1 (m), -155.1 (d), -160.0 (t), -164.9 (t). MS (APCI-) 355.9 m/z, 389.9 m/z, 407.9 m/z, 573.9 m/z.
Figure imgf000100_0002
PREPARATION 42 4,5-Difluόro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid pentafluorophenyl ester 1H-NMR (400 MHz, acetone-d6) δ 8.92 (br. s.), 8.14 (dd, IH, J=11.23, 8.79 Hz),
7.75 (d, IH, J=1.46 Hz), 7.64 (dd, IH, J=8.31, 2.2 Hz), 7.2 (d, IH J=8.31 Hz),
6.76 (dd, IH, J=13.19, 6.84 Hz), 2.24 (s, 3H). 19F-NMR (376 MHz, acetone-d6) δ -125.78 (p), -152.41 (m), -155.1 (d), -160.2 (t), -165.0 (t). MS (APCI-): 355.9 m/z, 369.9 m/z, 386.9 m/z (d), 554.0 m/z.
Figure imgf000101_0001
PREPARATION 43 2-(4-Bromo-2-fluoro-phenylaminoV3.4-difluoro-benzoic acid pentafluorophenyl ester m.p. 100.9-101.5 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1 H), 8.07 (ddd, J = 9.3, 5.9, 2.0 Hz, 1 H), 7.54 (dd, J = 11.0, 2.2 Hz, 1 H), 7.35-7.22 (cm, 2 H), 7.04 (td, J = 8.9, 2.0 Hz, 1 H); 19F-NMR (376 MHz, DMSO-d6) δ -125.8 (t, J = 10.1 Hz); -126.7 (m), -145.3 (d, J = 20.2 Hz), -153.3 (d, J = 20.2 Hz), -157.8 (t, J = 22.7 Hz), -162.9 (t, J = 21.5 Hz); MS (APCI-) = 510.0/512.0.
Figure imgf000101_0002
PREPARATION 44 2-(4-Chloro-2-fluoro-phenylamino)-3.4-difluoro-benzoic acid pentafluorophenyl ester m.p. 99.0-99.4 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.59 (s, 1 H), 8.07 (ddd, J = 9.0, 5.8, 2.0 Hz, 1 H), 7.45 (dd, J = 11.2, 2.2 Hz, 1 H), 7.30 (dt, J = 7.3, 9.2 Hz, 1 H), 7.19-7.08 (m, 2 H) ; 19F NMR (376 MHz, DMSO-d6) δ -125.6 (t, J = 10.1 Hz), -126.7 (m, 1 H), -145.6 (d, J = 15.2 Hz), -153.3 (d, J = 20.2 Hz); -157.7 (t, J - 22.8 Hz), -162.8 (t, J = 20.2 Hz); MS (APCI-) = 466.0.
Figure imgf000101_0003
PREPARATION 45 2-(2,4-Difluoro-phenylamino)-3.4-difluoro-benzoic acid pentafluorophenyl ester 1H NMR (400 MHz, DMSO-dg) δ 8.58 (s, 1 H), 8.07 (ddd, J = 9.0, 5.9, 2.0 Hz, 1 H), 7.34-7.12 (cm, 3 H), 7.01 (m, 1 H); 19F NMR (376 MHz, DMSO-d6) δ -116.9 (s), -122.6 (t, J = 10.1 Hz), -126.7 (m), -147.9 (d, J = 20.2 Hz), -153.5 (d, J = 20.2 Hz), -157.7 (t, J = 22.8 Hz), -162.8 (t, J = 20.2 Hz); MS (APCI-) = 450.0.
Figure imgf000102_0001
PREPARATION 46 5-Chloro-2-(2.4-difluoro-phenylamino)-3.4-difluoro-benzoic acid pentafluorophenyl ester m.p. 92.5-93.2 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1 H), 8.21 (dd, J = 7.7, 2.1 Hz, 1 H), 7.34-7.24 (m, 2 H), 7.02 (m, 1 H); 19F NMR (376 MHz, DMSO- dβ) δ -116.7(m), -122.4 (m), -128.1 (dd, J = 20.2, 7.6 Hz), -143.4 (d, J = 17.7 Hz), -153.2 (d, J = 20.2 Hz), -157.4 (t, J = 22.7 Hz), -162.8 (t, J = 20.2 Hz); MS (APCI- ) = 483.9.
PREPARATION 47 O - 2-Vinyloxy-ethyl)-hvdroxylamine Part A: Synthesis of 2-(2-Vinyloxy-ethoxy)-isoindole-l,3-dione Ethylene glycol vinyl ether (9.88 g, 112 mmol), triphenylphosphine (29.4 g, 112 mmol), and N-hydroxyphthalimide (18.22 g, 111.7 mmol) were combined in 300 mL of anhydrous tetrahydrofuran and cooled to 0 °C (ice bath). Diethylazodicarboxylate (18.0 mL, 114 mmol) was added dropwise over 15 min and the resultant reaction mixture was allowed to warm to ambient temperature over 18 h. The reaction mixture was concentrated to a paste and the solids were filtered and washed with chloroform. The filtrate was further concentrated and filtered again, washing the solids with chloroform. The remaining chloroform solution was concentrated to an oil. The oil was dissolved in absolute ethanol (75 mL). Scratching with a glass rod induced crystallization. The crystals were collected and recrystallized from hot ethanol to afford colorless needles of 2-(2- vinyloxy-ethoxy)-isoindole-l,3-dione (13.8 g, 53% yield): 1H NMR (400 MHz, CDC13) δ 7.85 (m, 2 H), 7.75 (m, 2 H), 6.46 (dd, J = 14.3, 6.7 Hz, 1 H), 4.45 (m, 2 H), 4.16 (dd, J = 14.4, 2.2 Hz), 4.02 (m 3 H). Part B: Synthesis of O -(2-Vinyloxy-ethyl)-hydroxylamine
2-(2-vinyloxy-ethoxy)-isoindole-l,3-dione (13.8 g, 59.2 mmol) was dissolved in dichloromethane (45 mL). Methylhydrazine (3.2 mL, 60 mmol) was added dropwise and the resultant solution was stirred 30 min at ambient temperature. The resultant suspension was diluted with diethyl ether (150 mL) and was filtered. The filtrate was concentrated in vacuo. The residual oil was distilled (bp 60-65 °C
@ 20 mm Hg) to afford the amine as a colorless liquid (4.6 g, 75% yield): 1H NMR (400 MHz, CDCI3) δ 6.49 (dd, J = 14.3, 6.7 Hz, 1 H), 5.59 (br s, J = 2 H), 4.19 (dd, J = 14.3, 2.2 Hz, 1 H), 4.01 (dd, J = 6.8, 2.2 Hz, 1 H), 3.90-3.83 (m, 4 H); 13C NMR (100 MHz, CDCI3) δ 151.7, 86.8, 73.7, 66.0.
Preparations 48-51 were prepared by the general procedure of preparation 47, part A.
PREPARATION 48
O-(2-Methoxy-ethyl -hydroxylamine 1H NMR (400 MHz, CDC13) δ 5.21 (br s, 2 H), 3.82 (m, 2 H), 3.54 (m, 2 H), 3.37 (s, 3 H).
HO' "o .NH,
PREPARATION 49 3-Aminooxy-2.2-dimethyl-propan-l-ol BP 148 °C @ 20 mm Hg; 1H NMR (400 MHz, CDC13) δ 3.50 (s, 2H), 3.37 (s, 2H), 0.86 (s, 6H).
,NH, n— ' PREPARATION 50 O-(2.2-Dimethyl-["1.31dioxolan-4-ylmethyl)-hydroxylamine 1HNMR (400MHz; CDC13) δ 5.50 (bs, 1 H), 4.32 (m, 1 H), 4.04 (t, J = 6.81 Hz, 1 H), 3.72 (m, 2 H), 3.67 (m, 1 H), 1.41 (s, 3 H), 1.34 (s, 3 H); MS(APCI+)=148.
PREPARATION 51 O-[2-(2-Methoxy-ethoxy)-ethyl]-hydroxylamine BP 95-100 °C @ 20 mm Hg; 1H NMR (400 MHz, DMSO-d6) δ 5.96 (br s, 2 H), 3.62 (t, J = 4.3 Hz, 2 Hz), 3.55-3.47 (m, 4 H), 3.42 (m, 2 H) 3.24 (s, 3 H); MS
(APCI+) = 136.1.
H0, ^ , ,NH,
PREPARATION 52 2-Aminooxy-ethanol
2-Aminooxy-ethanol was prepared by the literature procedure: Dhanak, D.; Reese, C. B. J. Chem. Soc, Perkin Trans. 1 1987, 2829.
H0^0,NH2
PREPARATION 53 2-Aminooxy-propan-l-ol
2-Aminooxy-propan-l-ol was prepared according to the literature procedure (Cannon, J. G; Mulligan, P. J.; Garst, J. E.; Long, J. P.; Heintz, S. J. Med. Chem. 1973, 16, 287). 1H NMR (400 MHz, CDC13) δ 5.41 (br s, 2 H), 3.77 (m, 1 H), 3.58 (dd, J = 11.7, 2.8 Hz, 1 H), 3.52 (dd, J = 11.7, 6.9 Hz, 1 H), 1.02 (d, J = 6.4 Hz, 3 H).
HO^-θ'NH>
PREPARATION 54 3 - Aminooxy-propan- 1 -ol 3-Aminooxy-propan-l-ol was prepared by the literature procedure (Ludwig, B. J.;
Reisner, D. B.; Meyer, M.; Powell, L. S.; Simet, L.; Stiefel, F. J. J. Med Chem. 1970, 13, 60). 1HNMR (400 MHz, CDC13) δ 3.84 (t, J = 5.8 Hz, 2 H), 3,74 (t, J = 5.8 Hz, 2 H), 1.85 (quintet, J = 5.8 Hz, 2 H).
Figure imgf000105_0001
PREPARATION 55
O-(2.2-Dimethyl-[1.3]dioxolan-4-ylethyl)-hydroxylamine To a vigorously stircing suspension of 1,2,4-butanetriol (5.8g, 54.6 mmol) in dichloromethane (20 mL) was added 2,2-dimethoxypropane (6.8 mL, 54.6 mmol) and catalytic -toluenesulfonic acid. After 5 minutes, the solution became homogenous and was allowed to stir for an additional 30 minutes. The reaction mixture was then concentrated in vacuo to afford (2,2-Dimethyl-[l,3]dioxolan-4- yl)-ethanol (7.72g, 96.7%). To a stirring solution of (2,2-Dimethyl-[l,3]dioxolan- 4-yl)-ethanol (6.95g, 47.5 mmol), triphenylphosphine (12.5g, 47.5 mmol) andN- hydroxyphthalimide in freshly distilled tetrahydrofuran (200 mL) at 0 °C was slowly added (over 20 minutes) diethylazodicarboxylate. The dark red solution was allowed to stir for 2 hours at 0 °C and then allowed to warm to room temperature while stirring for 17 hours. The yellow solution was concentrated in vacuo and dissolved in chloroform (lOOmL). The solids were filtered and filtrate concentrated. This filtration was repeated twice. The remaining yellow oil was purified on silica gel eluting with hexanes-ethyl acetate (4:1) to afford 2-[2-(2,2-
Dimethyl-[l,3]dioxolan-4-yl)-ethoxy]-isoindole-l,3-dione (8.1g, 58.7%). To a stirring solution of 2-[2-(2,2-Dimethyl-[l,3]dioxolan-4-yl)-ethoxy]-isoindole-l, 3~ dione (0.86g, 2.95 mmol) in dichloromethane (lOmL) at 0 °C was added methylhydrazine (0.16 mL, 2.95 mmol). The resultant solution was allowed to warm to room temperature and stirred for 3 days. The resulting suspension was diluted with diethyl ether (20 mL) and filtered. The filtrate concentrated in vacuo to afford 0-(2,2-dimethyl-[l,3]dioxolan-4-ylethyl)-hydroxylamine (0.36g, 75.3%): 1HNMR (400MHz; CDCI3) δ 4.18 (quint, IH, J=5.9), 4.07 (dd, IH, J=5.9, 7.8), 3.86 (t, 2H, J=6.2), 3.56 (t, IH, J=7.6), 1.89 (m, 2H), 1.36 (s, 3H), 1.20 (s, 3H); MS(APCI+)=162.
Figure imgf000106_0001
PREPARATION 56 1 - Aminooxy-3 -morpholin-4-yl-propan-2-ol Step A. Synthesis of 2-(2-hydroxy-3-morpholin-4-yl-propoxy)-isoindole-l,3- dione: Triethylamine (15.0 mL, 108 mmol) was added to a solution ofN- hydroxyphthalimide (17.1 g, 105 mmol) and 4-Oxiranylmethyl-morpholine (14.3 g, 100 mmol) in anhydrous dimethylformamide (200 mL). The resultant deep red- colored reaction mixture was heated to 85 °C for 18 h. After removal ofthe solvent in vacuo, the residue was diluted with ethyl acetate (200 mL) and washed with water (3 x 100 mL) and brine (2 x 75 mL). The organics were dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was chromatographed on silica gel (chloroform-methanol, 19:1) to afford 2-(2- Hydroxy-3-morpholin-4-yl-propoxy)-isoindole-l,3-dione (7.96 g, 25% yield): JH NMR (400 MHz, CDC13) δ 7.84 (m, 2 H), 7.77 (m, 2 H), 4.26 (dd, J = 10.8, 3.4 Hz, 1 H), 4.18-4.10 (m, 2 H), 3.72 (m, 4 H), 2.70-2.47 (m, 6 H); MS (APCI+) =
307.2.
Step B. Synthesis of 1 -aminooxy-3 -morpholin-4-yl-propan-2-ol: A solution of 2- (2-hydroxy-3-morpholin-4-yl-propoxy)-isoindole-l,3-dione (7.96 g, 26.0 mmol) in dichloromethane (50 mL) was chilled to 0 °C and treated with methylhydrazine (1.45 mL, 27.3 mmol). The reaction mixture was stirred 5 min at 0 °C and 2 h at ambient temperature. Ether (200 mL) was added, the heterogenous solution was filtered, and the collected precipitate was washed with ether (300 mL). The ethereal solutions were concentrated in vacuo, and the residue was chromatographed on silica gel. Elution with chloroform-methanol (4: 1) afforded 1 -aminooxy-3 -morpholin-4-yl-propan-2-ol (3.21 g, 70% yield) as a colorless solid. Recrystallization (ether-dichloromethane) afforded colorless needles: mp 83-85 °C; 1HNMR (400 MHz, DMSO-d6) δ 5.96 (br s, 2 H), 4.56 (d, J = 4.4 Hz, 1 H), 3.81 (m, 1 H), 3.53 (apparent t, J = 4.6 Hz, 4 H), 3.50-3.38 (m, 2 H), 2.41-2.30 (m, 4 H), 2.29-2.17 (m, 2 H). Anal. Calcd/found for C7H16N2O3: C, 47.71/47.54; H, 9.15/9.23; N, 15.90/15.65. Preparations 57-62 were prepared by the general procedure of Preparation 56.
Figure imgf000107_0001
PREPARATION 57
1 -Aminooxy-3 -phenoxy-propan-2-ol m.p. 67.5 °C; 1H MR (400 MHz, DMSO-de) δ 7.27 (m, 2 H), 6.91 (m, 3 H), 6.06 (s, 2 H), 5.07 (d, J = 3.7 Hz, 1 H), 4.02 (m, 1 H), 3.92 (dd, J = 10.0, 4.3 Hz, 1 H), 3.84 (dd, J = 10.0, 6.1 Hz, 1 H), 3.59 (m, 2 H); MS (APCI+) = 183.0.
HO„ ^0,NH2
PREPARATION 58
1 - Aminooxy-butan-2-ol 1HNMR (400 MHz, CDC13) δ 5.49 (br s, 2 H), 3.78 (m, 1 H), 3.65 (dd, J = 11.2, 2.4 Hz, 1 H), 3.54-3.45 (m, 2 H), 1.42 (m, 2 H), 0.91 (t, J = 7.6 hz, 3 H); MS (APCI+) = 105.9.
HO, ,-NH,
PREPARATION 59 l-Aminooxy-propan-2-ol BP 85-87 °C @ 20 mm Hg; 1H NMR (400 MHz, DMSO-d6) δ 5.96 (br s, 2H), 4.58 (d, J = 3.9 Hz, 1 H), 3.80 (m, 1 H), 3.41-3.28 (m, 2 H), 0.99 (d, J = 6.4 Hz, 3
EL).
HO.,^,0,NH2
J7C<
PREPARATION 60 1 -Aminooxy-2-methyl-propan-2-ol
1H NMR (400 MHz, CDC13) δ 4.84 (br s, 2 H), 3.50 (s, 2 H), 1.15 (s, 6 H).
\^^\ /^ ,NH, O ^γ o 2
OH PREPARATION 61 1 -Aminooxy-3-methoxy-propan-2-ol 1H MR (400 MHz; DMSO-d6) δ 5.95 (2H, br, NH2), 4.76 (IH, br, -OH), 3.72- 3.78(1H, m), 3.36-3.46 (2H, m), 3.19-3.26 (2H, m), 3.19 (3H, s); MS (APCI+) = 121.9.
Figure imgf000108_0001
PREPARATION 62 l-Aminooxy-4.4.4-trifluoro-butan-2-ol 1H NMR (400 MHz; CDC13) δ 5.40 (2H, br, NH2), 3.60-4.10 (3H, m); MS
(APCI+) = 145.9.
Figure imgf000108_0002
PREPARATION 63 trarø-(2-Aminooxymethyl-cyclopropyl)-methanol
Step A: To a suspension of lithium aluminum hydride (7.6 g, 0.3 mol) in tetrahydrofuran (150ml) at 0 °C was added diethyl trans-1,2- cyclopropanedicarboxylate (18.6 g, O.lmol) dropwise over a period of 15 minutes. The resultant reaction mixture was removed from the cooling bath and heated at reflux for 20 h. The reaction mixture was cooled to 0°C and quenched cautiously with water (7.7 mL), 10% aqueous sodium hydroxide (7.7 mL), and water (23 mL). The resultant solids were filtered and the filtrate was dried over sodium sulfate and concentrated under reduced pressure. The residual oil was distilled under reduced pressure to afford trans 2-hydroxymethyl-cyclopropyl)-methanol (7.5 g, 73% yield) as a colorless liquid: b.p. 142-144 °C @ 20 mm Hg.
Step B: A solution of trans 2-hydroxymethyl-cyclopropyl)-methanol (7.5g, 73 mmol), triphenylphosphine (19.3 g, 73 mmol), N-hydroxyphthalimide (73 mmol) in anhydrous tetrahydrofuran (200 mL) was chilled to 0°C and treated with diethyl azodicarboxylate. The resulting mixture was allowed to warm naturally to room temperature and stirred overnight. The reaction mixture was concentrated to about 1/8 volume and filtered. The filtered precipitate was washed with ether and the combined washings and filtrate were concentrated in vacuo. The crude product was dissolved in dichloromethane. Methylhydrazine (73 mmol) was added and the reaction mixture was stirred overnight at ambient temperature. The resultant precipitate was removed by filtration. Concentration ofthe filtrate afforded additional precipitate which was also removed by filtration. The final filtrate was concentrated and distilled under reduced pressure to afford trans-(2- aminooxymethyl-cyclopropyl)-methanol (3.84 g, 45% yield) as a colorless oil: bp 183 °C @ 20 mm Hg; 1HNMR (400 MHz; CDC13) δ 3.80 (br, NH2), 3.50-3.70 (2H, m), 3.30-3.42 (2H, m), 0.95-1.15 (2H, m), 0.40-0.60 (2H m); MS (APCI+) =
117.9
HO O
PREPARATION 64 ( 1 -Aminooxymethyl-cyclopropylVmethanol
Step A: Diethyl 1,1-cyclopropanedicarboxylate (25 g, 0.13 mol) was added dropwise over 1 h to a stirring suspension of lithium aluminum hydride in tetrahydrofuran (150 mL) at 0°C. After addition was complete, the reaction mixture was heated at reflux for additional 18 h. The mixture was cooled to 0 °C and sequentially treated with water (lOg), then 10% aqueous sodium hydroxide
(lOg) and water (30g). The mixture was filtered, and the filtrate was dried over potassium carbonate and concentrated under reduced pressure. Distillation provided (l-hydroxymethyl-cyclopropyl)-methanol (8.8 g, 66% yield) as a colorless viscous oil: 1HNMR (400 MHz; CDCI3) δ 3.57 (4H, s), 3.26 (2H, s), 0.48 (4H, s).
Step B: (1 -Hydroxy methyl-cyclopropyl)-methanol (4.08g, 0.04mol), N- hydroxyphthalimide (6.53g, 0.04 mol) and triphenylphosphine (10.50g, 0.04mol) were combined in anhydrous tetrahydrofuran (100 mL)and stirred at 0°C for 1.5 hours. Diethyl azodicarboxylate (6.97g, 0.04mol) was added at 0°C and the reaction mixture was stirred at room temperature overnight. Repeated concentration ofthe reaction mixture from chloroform and filtration ofthe resulting precipitate (triphenylphosphine oxide) afforded the crude product which was further purified by silica gel chromatography. Elution with hexane/ethyl acetate (3 :2) provided 2-( 1 -Hydroxymethyl-cyclopropylmethoxy)-isoindole- 1,3- dione (5.63 g, 57% yield) as a white solid: 1H NMR (400 MHz; CDC13) δ 7.82- 7.85 (2H, m), 7.74-7.78 (2H, m), 4.19 (2H, s), 3.72 (2H, s), 0.63 (4H, s)
Step C: To a stirring solution of 2-(l'-Hydroxymethyl-cyclopropylmethoxy)- isoindole-l,3-dione (5.63 g, 22.8 mmol) in dichloromethane (60ml) at 0°C was added methylhydrazine (1.1 g, 23.8). The reaction mixture was stirred at room temperature overnight, filtered and concentrated under reduced pressure. Distillation afforded pure l-Aminooxymethyl-cyclopropyl)-methanol (2.9 g, 71% yield) as a colorless oil: bp 140 °C @ 20 mm Hg; 1H NMR (400 MHz; CDC13) δ 4.00 (br s, NH2), 3.61 (2H, s), 3.43 (2H, s), 0.49 (4H, s); MS (APCI+) = 117.9.
1 /
O ^" O 2
PREPARATION 65
O- [3 -(tert-Butyl-dimethyl- silanyloxyV propyll -hy droxylamine Step A: Diisopropylethylamine (43 mL, 246 mmol) was added to a stirring solution of N-hydroxphthalimide (20.6g, 123 mmol) in dimethylformamide (95 mL). After 5 minutes, 3-bromopropanol (11.5 mL, 127 mmol) was added and the reaction mixture was heated to 80 °C for 18 h. The cooled solution was diluted with ethyl acetate (700 mL) and was washed with water (4 x 500 mL) and saturated brine (2 x 500 mL), dried over sodium sulfate and concentrated to an oil that solidified on standing to afford 2-(3-hydroxy-propoxy)-isoindole-l,3-dione (17.5 g, 65% yield) as a tan-colored solid: 1H NMR (400 MHz, CDCI3) δ 7.81 (m, 2H), 7.74 (m, 2H), 4.36 (t, 2H, J=5.6 Hz), 3.92 (t, 2H, J=5.9 Hz), 1.98
(quintet, 2H, J=5.9 Hz).
Step B: To a solution of 2-(3-hydroxy-propoxy)-isoindole-l,3-dione (17.5 g, 79.1 mmol) and imidazole (5.92 g, 86.1 mmol) in dichloromethane (200 mL) was added tert-butyldimethylsilyl chloride (13.2 g, 86.1 mmol). After 30 min, the reaction was transferred to a separatory funnel and shaken with dilute aqueous hydrochloric acid (400 mL). The organic layer was washed with saturated aqueous sodium bicarbonate, dried over magnesium sulfate and concentrated in vacuo to afford 2-[3-(tert-Butyl-dimethyl-silanyloxy)-propoxy]-isoindole-l,3- dione (26.3 g, 99% yield) as a viscous liquid: 1H NMR (400 MHz, CDC13) δ 7.76 (m, 2H), 7.67 (m, 2H), 4.25 (t, 2H, J=5.9 Hz), 3.77 (t, 2H, J=6.0 Hz), 1.91 (quintet, 2H, J=6.1 Hz), 0.82 (s, 9H), 0.00 (s, 6H).
Step C: A solution of 2-[3-(tert-butyl-dimethyl-silanyloxy)-propoxy]-isoindole- 1,3-dione (26.3 g, 78.3 mmol) in dichloromethane (120 mL) was cooled to 0 °C and treated with methylhydrazine (16.1 g, 78.3 mmol). The reaction mixture was stirred for 30 min at 0 °C and filtered. The filtrate was concentrated under reduced pressure, redissolved in ether, and refrigerated (4 °C) overnight. The resultant crytalline material was removed by filtration and the filtrate was concentrated under reduced pressure to afford O-[3-(tert-butyl-dimethyl- silanyloxy)-propyl]-hydroxylamine (15.95 g, 99% yield) as a colorless oil: H NMR (400 MHz, CDC13) δ 4.69 (br s, 2 H), 3.74 (t, J = 6.3 Hz, 2 H), 3.67 (t, J = 6.3 Hz, 2 H), 1.78 (quintet, J = 6.3 Hz, 2 H), 0.88 (s, 9 H), 0.00 (s, 6 H); MS
(APCI+) = 206.1. Anal. Calcd./Found for C9H23NO2Si: C, 52.64/52.22; H, 11.29/10.94; N, 6.82/6.46.
Figure imgf000111_0001
PREPARATION 66
O-[4-(tert-butyl-diphenyl-silanyloxy -butyl]-hydroxylamine Step A: To a solution of 1,4-butanediol (5g, 55 mol) in dichlormethane (lOmL) containing diisopropylethylamine (lOmL) was added tert- butylchlorodiphenylsilane (5 mL, 18 mmol) dropwise under N2 atmosphere at 18°C over 2 h. The resultant solution was stirred at room temperature for 4 hours and concentrated under reduced pressure. Purification by column chromatography with hexane/ethyl acetate (1/1) gave 4-(tert-butyl-diphenyl-silanyloxy)-butan-l-ol (10.2 g, 85% yield) as colorless oil: 1H NMR (400 MHz, CDCI3) δ 7.62-7.71 (4H, m); 7.32-7.43 (6H, m), 3.63-3.69 (4H, m), 1.83 (IH, br s), 1.59-1.71 (4H, m), 1.03 (9H, s). Step B: 4-(tert-Butyl-diphenyl-silanyloxy)-butan-l-ol (10.0 g , 30.5 mmol), triphenylphosphine (8.0 g, 30 mmol), and N-hydroxyphthalimide (4.97g, 30.5 mmol) were combined in anhydrous tetrahydrofuran (200 ml) att 0 °C and the resultant solution was stirred at 0°C for 1 hour. Diethyl azodicarboxylate (5.3 lg, 30.5 mmol) was added at 0°C, and the reaction mixture was allowed to gradually warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in chloroform. Precipitation ensued, and the white solid was removed by filtration. The filtrate was concentrated and purified with column chromatography (hexane/ethyl acetate(3/l)) to afford 2-[4-(tert-butyl-diphenyl-silanyloxy)-butoxy]-isoindole-l,3- dione (11.06g, 77% yield) as colorless crystals: 1H NMR (400 MHz, DMSO-d6) δ 7.84 (4H, s), 7.59 (4H, dd, J=7.6, 1.0 Hz), 7.39-7.43 (6H, m), 4.13 (2H, t, J = 6.4 Hz), 3.68 (2H t, J = 5.8 Hz),1.67-1.78 (4H, m), 0.95 (9H, s). Step C: A solution of 2-[4-(tert-butyl-diphenyl-silanyloxy)-butoxy]-isoindole-l,3- dione (11. l g, 23.4 mmol) in dichloromethane ( 100ml) was treated with methylhydrazine. The reaction mixture was stirred overnight and was filtered. The filtrate was concentrated and purified by column chromatography [hexane/ethyl acetate (3.5/1)] to afford O-[4-(tert-butyl-diphenyl-silanyloxy)- butyl]-hydroxylamine (7.2 g, 90% yield) as a colorless oil: 1H NMR (400 MHz, CDC13) δ 7.62-7.66(4H, m), 7.33-7.42 (6H, m), 3.64-3.68 (4H), 1.54-1.70 (4H, m),
1.02 (9H, s); MS (APCI+) =344.2.
Figure imgf000112_0001
PREPARATION 67 2-Aminooxy-2-methyl-propan- 1 -ol
Step A: To a stirring solution of t-butyl-N-hydroxycarbamate (2.38g, 17.87 mmol) in absolute ethanol (50 mL) is added potassium hydroxide (1.2g, 21.45 mmol) and ethyl-2-bromoisobutyrate (3.15 mL, 21.45 mmol). The reaction mixture was heated at reflux for 17 hours. The solids were filtered off and filtrate concentrated. The afforded residue was partitioned between diethyl ether and water. The aqueous layers were extracted twice with ether. The organic layers were collected and dried over Na2SO4, filtered and concentrated in vacuo, affording 2-Boc-aminooxy-2-methyl-propionic acid ethyl ester as a clear oil (4.2g, 95%): 1HNMR (400 MHz;CDCl3) δ 7.34 (bs, IH), 4.16 (q, 2H, J=13.9,6.6), 1.45 (s, 6H), 1.42 (s, 9H), 1.16 (t, 3H, J=7.1); MS (APCI-)=246.0. Step B: 2-Boc-aminooxy-2-methyl-propionic acid ethyl ester (2.54g, 10.27 mmol) was dissolved in freshly distilled THF (100 mL), cooled to 0°C and charged with 2.0 M lithium borohydride solution (10.3 mL, 20.54 mmol) in THF. The ice bath was removed and reaction was heated to reflux. After 17 hours, the reaction was cooled to 0°C and quenched with methanol and concentrated in vacuo. The afforded residue was partitioned between ethyl acetate and 1M sodium hydroxide solution. The organic layers were washed twice with 1M sodium hydroxide solution, twice with saturated sodium chloride solution, collected and dried over Na2SO4, filtered and concentrated in vacuo, affording 2- Boc-aminooxy-2-methyl-propan-l-ol (1.50g, 71%) as a white solid: 1H NMR (400 MHz;CDCl3) δ 6.84 (bs, IH), 3.37 (s, 2H), 1.45 (s, 9H), 1.18 (s, 6H); MS (APCI 204.0.
STEP C: 2-Boc-aminooxy-2-methyl-propan-l-ol (0.21g, 1.02 mmol) was dissolved in methanol (5 mL) and charged with anhydrous hydrogen chloride gas for 1 minute. After stircing for 1 hour , the reaction mixture was concentrated in vacuo and to the resulting residue was added diethylether, affording white solids. The solids were washed several times with diethylether and dried in vacuo to afford 2-aminooxy-2-methyl-propan-l-ol as the hydrogen chloride salt (0.091g, 63%). 1HNMR (400MHz;CDCl3) δ 3.61 (s, 2H), 1.16 (s, 6H); MS (APCI+)=105.9.
NH, o-7 PREPARATION 68
O-(2.2-Dimethyl-π.3]dioxan-5-yl)-hydroxylamine
Step A: 2,2-Dimethyl-[l,3]dioxan-5-ol was prepared as described previously (Forbes, D.C. et. al.; Synthesis; 1998, 6, 879-882). 1H NMR (400MHz;DMSO-d6) δ 4.91 (d, 1H, J=5.1), 3.70-3.75 (m, 2H), 3.41-3.46 (m, 3H), 1.30 (s, 3H), 1.24 (s, 3H); MS (APCI+)=132.9.
Step B: To a stircing solution of 2,2-dimethyl-[l,31dioxan-5-ol (1.50g, 11.35 mmol), N-hydroxyphthalimide (1.85g, 11.35 mmol) and triphenylphosphine (2.98g, 11.35 mmol) in anhydrous tetrahydrofuran (30 mL) at 0°C was added diethyl azodicarboxylate (2.3 mL, 14.75 mmol). The resultant solution was allowed to warm to room temperature. After stircing for 3 hours, the mixture was concentrated in vacuo and charged with chloroform affording white solids. The solids were filtered off and filtrate was collected and concentrated. The residue was purified via silica column chromatography (4: 1 hexanes/ethyl acetate) affording 2-(2,2-dimethyl-[l,3]dioxan-5-yloxy)-isoindole-l,3-dione as clear crystals (1.74g, 55% over 2 steps): 1H NMR (400MHz;DMSO-d6) δ 7.83 (s, 4H), 4.11-4.12 (m, IH), 4.04-4.09 (m, 2H), 3.92-3.96 (m, 2H), 1.32 (s, 3H), 1.25 (s, 3H); MS (APCI+)=278.0. Step C: To a stircing solution of 2-(2,2-dimethyl-[l,3]dioxan-5-yloxy)-isoindole-
1,3-dione (l-72g, 6.20mmol) in dichloromethane (15 mL) at 0°C under nitrogen was added methylhydrazine (0.36 mL, 6.82 mmol) and allowed to warm to room temperature. After stirring for two hours the reaction mixture was concentrated in vacuo and charged with diethylether. The solids were filtered off and the filtrate was collected and concentrated to afford O-(2,2-dimethyl-[l,3]dioxan-5-yl)- hydroxylamine as a yellow oil (0.97g, 100%). 1H NMR (400MHz;DMSO-d6) δ 5.98 (bs, 2H), 3.84-3.87 (m, 2H), 3.66-3.68 (m, 2H), 3.30-3.35 (m, IH), 1.29 (s, 3H), 1.22 (s, 3H); MS (APCI+)=147.9.
^O^.NH. o- - PREPARATION 69
O-(2.2.5.5-Tetramethyl-|"l,3]dioxolan-4-ylmethyl)-hvdroxylamine Step A: To a stirring solution of N-hydroxyphthalimide (Aldrich, 1.63g, 10.0 mmol) in anhydrous ethanol (50 mL) was added 1 -bromo-3 -methyl-but-2-ene (Aldrich, 1.4 mL, 12.0 mmol) and potassium hydroxide (0.67g, 12.0 mmol). After the reaction was allowed to stir at 50 °C for 4 hours, it was concentrated in vacuo and then dissolved in ethyl acetate and partitioned with water. The organic layer was washed twice with water, twice with saturated sodium chloride solution, collected and dried over Na2SO4, filtered and concentrated in vacuo, affording a white solid. The collected solid was purified via silica column in 10% methanol in dichloromethane to afford 2-(3-methyl-but-2-enyloxy)-isoindole-l,3-dione
(0.53 g, 23%): 1H NMR (400MHz;DMSO-d6) δ 7.81 (s, 4H), 5.38 (t, IH, J=1.5), 4.57 (d, 2H, J=7.6). 1.67 (s, 3H), 1.62 (s, 3H); MS (APCI+)=232.0 Step B: 2-(3-Methyl-but-2-enyloxy)-isoindole-l,3-dione was dissolved in a t- butanol/THF/H2O solution (10mL/3mL/lmL) and charged withN- methylmorpholine N-oxide ( 0.085g, 0.73 mmol) and a catalytic amount of potassium osmate dihydrate. After stirring for 17 hours the reaction was diluted with a saturated solution of sodium metabisulfate and partitioned with ethyl acetate. The organic layer was washed twice with saturated solution of sodium metabisulfate, twice with saturated sodium chloride solution, collected and dried over Na2SO4, filtered and concentrated in vacuo affording 2-(2,3-dihydroxy-3- methyl-butoxy)-isoindole-l,3-dione as a clear oil, which was charged with dichloromethane (10 mL), 2,2-dimethoxypropane (0.12 mL, 0.75 mmol) and a catalytic amount of -toluenesulfonic acid. After stircing for 17 hours, the reaction was concentrated in vacuo, and partitioned between ethyl acetate and water. The organic layer was washed twice with water, once with saturated sodium chloride solution, collected and dried over Na2SO4, filtered and concentrated in vacuo, affording 2-(2,2,5,5-tetramethyl-[l,3]dioxolan-4- ylmethoxy)-isoindole-l,3-dione as a light brown solid (0.158g, 77.1%): 1HNMR (400 MHz;DMSO-d6) δ 7.82 s, (4H), 4.12-4.26 (m, 2H), 4.04-4.07 (m, IH), 1.22 (s, 9H), 1.17 (s, 3H), 0.97 s(3H).
Step C : 2-(2, 2, 5, 5 -tetramethyl- [1,3] dioxolan-4-ylmethoxy)-isoindole- 1 , 3 -dione (0.158g, 0.52 mmol) was dissolved in dichloromethane (3 mL), cooled to 0 °C, and charged with methylhydrazine (30μL, 0.57 mmol). The ice bath was removed and the reaction was allowed to stir at ambient temperature for 1 hour. The reaction mixture was diluted with diethylether and the solids were filtered off and filtrate concentrated in vacuo to afford O-(2,2,5,5-tetramethyl-[l,3]dioxolan-4- ylmethyl)-hydroxylamine as a yellow oil (0.042g, 46%). 1H NMR (400 MHz;DMSO-d6) δ 6.06 (bs, 2H), 3.84-3.87 (m, IH), 3.50-3.59 (m, 2H), 1.26 (s, 3H), 1.19 (s, 3H), 1.16 (s, 3H), 0.94 (s, 3H); MS (APCI+)=176.9.
Figure imgf000116_0001
PREPARATION 70 rS)-(+ -(2.2-Dimethyl-[1.3]dioxolan-4-vn-methanol
Step A: To a stirring suspension of D-Mannitol (1.82 g, 10.0 mmol) in tetrahydrofuran (21 mL) and dimethylformamide (9 mL) was added p- toluenesulfonic acid monohydrate (0.02 g, O.lmmol,) at ambient temperature, followed by 2,2-dimethoxypropane (2.8 ml, 0.023 mole). The reaction mixture was stirced for 18 h at room temperature, then additional 2,2-dimethoxypropane
(0.3 ml, 2.4 mmol) was added. The suspension was heated to 40-45 C, and stirred for 2 hrs. Sodium bicarbonate (1.8 g, 0.016 mol) was added to neutralize the acid and the mixture was stirced for 30 minutes. The excess Na2CO3 was filtered and washed with tetrahydrofuran (5ml). The filtrate was concentrated. To the remaining light yellow oil was added toluene (15mL) and the mixture was stirred at 3-5 °C until a light-yellow gelatinous solid formed. The solid was filtered and washed with hexane (2 x 5mL). The product was dried in a vacuum oven for 18 h to give l,2:5,6-Di-O-isopropylidene-D-mannitol (1.24 g, 47.3%) as an off-white solid, mp 110-113 °C. Step B: To a solution of l,2:5,6-di-O-isopropylidene-D-mannitol (50 g, 0.191 mol) in water (700 mL), was added solid sodium bicarbonate (20 g). The resultant solution was stirced until all the solid dissolved, and then cooled in an ice-water bath. Solid sodium periodate (81.5 g, 0.381 mol) was slowly added to the solution portionwise. Gas evolution observed. The white mixture was stirced at ambient temperature for 2 hrs. Solid sodium chloride (30 g) was added, and the mixture was stirred for 15 min. The white solid was filtered. The filtrate was cooled in an ice-water bath. Solid sodium borohydride was added slowly. Gas bubble evolved. The mixture was warmed to ambient temperature, and stirced overnight. The milky mixture turned to a clear solution. The aqueous solution was extracted with dichloromethane (3 X). The organic solution was washed with brine, and dried over magnesium sulfate. The solvent was removed in vacuo to give (S)-(+)- (2,2-Dimethyl-[l,3]dioxolan-4-yl)-methanol as a colorless oil, which was dried under high vacuum at ambient temperature overnight, 34.82 g (60%); MS (APCI+) = 133 (M++1).
X° TOH
PREPARATION 71 t7 -(+ -(2.2-Dimethyl- 1.31dioxolan-4-yl)-methanol
Step A: To a solution of L-ascorbic acid (83.9 g, 0.477 mole) in water (600 mL) was added Pd/C (10%, 8.3 g). The mixture was subjected to hydrogenation in a Parr hydrogenator at 48 psi, 18 °C for 62 hrs. The reaction mixture was filtered and the filtrate was concentrated in vacuo to afford L-gulonic γ-lactone (81.0 g, 96%) as an off-white solid, after drying at 50 °C in a vacuum oven for 18 hrs: m.p.
182-184 °C.
Step B: L-Gulonic γ-lactone (25.0 g, 140.3 mmol) was dissolved in mixture of tetrahydrofuran (140 mL) and dimethylformamide (200 mL). ^-Toluenesulfonic acid monohydrate (2.67 g, 14.0 mmol) was added and the reaction mixture was cooled to 0 - 5 °C in an ice- water bath. 2,2-dimethoxypropane (22.4 mL, 182.4 mmol) was added dropwise and the reaction mixture was stirced at ambient temperature for 18 hours. The mixture was neutralized with solid sodium carbonate (24.0 g), and stirred for 1 hour. The solid was filtered and washed with tetrahydrofuran. The THF was removed under vacuo, and DMF by distillation under high vacuum. The resulting orange solid was triturated with toluene (300 mL), filtered, washed with toluene (20 mL), and dried in a vacuum oven at 40 °C for 3 days, to yield 5,6-Isopropylidene-L-gulonic Acid γ-lactone (28.9 g, 94%) as a pale orange solid: mp 155-158 °C; MS(APCI+) = 219.0 (V +1).
Step C: To a stircing suspension of 5,6-O-isopropylidene-L-gulono-l,4-lactone (15.16 g, 69.5 mmol) in water (0.3 L) was added solid sodium periodate in small portions at 3-5°C. The pH ofthe mixture was adjusted to 5.5 with IN aqueous sodium hydroxide. The suspension was stirred for 2 hrs at ambient temperature, then saturated with sodium chloride (20.0 g) and filtered. To the filtrate, at 3-5°C, was added sodium borohydride (10.5 g, 0.278 mol) in small portions. The reaction mixture was stirred for 18 h at ambient temperature. Acetone (100 mL) was added to destroy the excess of sodium borohydride, and the stircing was continued for 30 minutes. The acetone was removed under reduced pressure and the aqueous residue was extracted with dichloromethane (3 x 300 mL) and EtOAc (3 x 300 mL). The combined organic layers were dried over magnesium sulfate, filtered, and evaporated to give (R)-(+)-(2,2-Dimethyl-[l,3]dioxolan-4-yl)-methanol (5.07g, 55.7%) as a colorless clear liquid: MS(APCI+) = 132.9 (M'+l).
° R ° S PREPARATION 72
Preparation of t7 )-O-(2.2-dimethyl-[1.3]dioxolan-4-ylmethyl -hydroxylamine and
^S')-O-(2.2-dimethyl- L3]dioxolan-4-ylmethyl)-hydroxylamine fK O-(2,2-dimethyl-[l,3]dioxolan-4-ylmethyl)-hydroxylamine and (S)-0-(2,2- dimethyl-[l,3]dioxolan-4-ylmethyl)-hydroxylamine were prepared from (S)-(+)- (2,2-dimethyl-[l,3]dioxolan-4-yl)-methanol and (R)-(-) -(2,2-dimethyl-
[l,3]dioxolan-4-yl)-methanol respectively by the following procedure: Step A: A 3-L round-bottomed flask equipped with mechanical stirrer and additional funnel was charged with N-hydroxyphthalimide (68.0 g, 0.416 mol) and tetrahydrofuran (1.2 L) under nitrogen atmosphere. To this solution was added triphenylphosphine (109.2 g, 0.416 mol) and (R)- or f>(2,2-dimethyl-
[l,3]dioxolan-4-yl)-methanol (55.0 g, 0.416 mol). The mixture was cooled to 3- 5°C and diethyl azodicarboxylate (85.2 mL, 0.541 mol) was added dropwise, while keeping the inner temperature below 15 °C. The reaction mixture was warmed to ambient temperature, and stirred for 18 hrs. The tetrahydrofuran was evaporated under reduced pressure. To the remaining orange solid was added dichloromethane (0.5 L) and the mixture was stirced for lh. The white solid (Ph3PO) was filtered and washed with dichloromethane (0.1 L). The solvent was removed and ethanol (0.5 L) was added to the resulting solid. The mixture was stirced for 2 h at 3-5 l°C. The white solid was filtered, washed with a small amount of cold EtOH and dried in vacuum oven at 40 °C to give (S)~ or (R)-2-
(2,2-Dimethyl-[l,3]dioxolan-4-ylmethoxy)-isoindole-l,3-dione (112.5 g, 97%) as a white solid: 1H ΝMR (CDC13): δ 1.33 (s, 3H), 1.99 (s, 3H), 3.96 (m, IH), 4.15 (m, 2H), 4.30 (m, IH), 4.48 (m, IH), 7.59 (m, 2H), 7.84 (m, 2H); MS (APCI+) = 278 (N +1).
Step B: To a stirring solution of (S)- or (R)-2-(2,2-Dimethyl-[l,3]dioxolan-4- ylmethoxy)-isoindole-l,3-dione (74.9 g, 0.27 mol) in dichloromethane (480 mL) at 3-5°C was added methylhydrazine (15.8 mL, 0.29 mole) dropwise. The color of the suspension turned from yellow to white. The cooling bath was removed and the mixture was stirced for 2 hrs at ambient temperature. The resulting suspension was concentrated on a rotary evaporator. To the white solid was added ether (0.5 L) and the resulting mixture was stirced for 1.5 h at ambient temperature. The white precipitate was filtered and washed with ether (0.2L). The filtrate was concentrated on rotary evaporator to give (SJ- or (7?)-O-(2,2-dimethyl- [l,3]dioxolan-4-ylmethyl)-hydroxylamine (39.0 g, 98.3 %): 1H NMR (CDC13): δ 1.35 (s, 3H), 1.42 (s, 3H), 3.73 (m, 3H), 4.05 (m, IH), 4.33 (m, IH), 5.39 (m, 2H); MS (APCI+) = 148.1 ( ÷M-l)
Figure imgf000119_0001
PREPARATION 73 O-(2-Phenylamino-ethyl)-hydroxylamine; hydrochloride O-(2-Phenylamino-ethyl)-hydroxylamine was prepared from 2-Phenylamino- ethanol by the general procedure of Preparation 48 and was isolated as the hydrochloride salt by precipitation from etheral hydrogen chloride. 1H NMR (DMSO-d6): δ 7.12 (t, J = 7.7 Hz, 2 H), 6.72-6.61 (m, 3 H), 4.16 (t, J = 5.4 Hz, 2 H), 3.35 (t, J = 5.4 Hz, 2 H); MS (APCI+) = 153.1 (M^+l).
^N^0'NH2
PREPARATION 74 (2-Aminooxy-ethyl -methyl-carbamic acid tert-butyl ester Step A: (2-Hydroxy-ethyl)-methyl-carbamic acid tert-butyl ester was prepared as previously described: Mewshaw, R. E.; et. al. J.MedChem. 1999, 42, 2007. Step B: Diethylazodicarboxylate was added dropwise over 45 min to a stircing solution of (2-hydroxy-ethyl)-methyl-carbamic acid tert-butyl ester (7.10 g, 40.5 mmol), N-hydroxyphthalimide (7.17 g, 44.0 mmol) and triphenylphosphine (11.5 g, 43.8 mmol) in tetrahydrofuran (150 mL). The resultant reaction mixture was stirced 22 h at ambient temperature and was concentrated in vacuo to a thick oil.
Chloroform (200 mL) was added and the resultant solution was chilled to affect crystallization of diethyl 1,2-hydrazaine dicarboxylate. The precipitate was filtered and the filtrate was concentrated and further diluted with hexanes. A single crystal of triphenylphosphine oxide was added. The resultant crystals of triphenylpho shine oxide were removed by filtration and the filtrate was concentrated in vacuo and chromatographed on silica gel to afford [2-(l,3-dioxo- l,3-dihydro-isoindol-2-yloxy)-ethyl]-methyl-carbamic acid tert-butyl ester (12.8 g, 98% yield) as a colorless oil: 1H NMR (400 MHz, DMSO-d6) δ 7.86 (bs, 4 H), 8.55 (bs, H), 4.24 (t, J =5.5 Hz, 2H), 3.50 brt, J = 5.4 Hz, 2H), 2.92 and 2.88 (br s, 3 H), 1.39 and 1.36 (br s, 9 H).
Step C: A solution of [2-(l,3-dioxo-l,3-dihydro-isoindol-2-yloxy)-ethyl]-methyl- carbamic acid tert-butyl ester (4.50 g, 14.0 mmol) in dichloromethane (40 mL) was treated with methylhydrazine (0.78 mL, 14.7 mmol) and the reaction mixture was stirred 6 h at ambient temperature. Diethyl ether (80 mL) was added and the heterogeneous solution was allowed to stand overnight. The precipitate was removed by filtration and was washed with ether (80 mL). The filtrate was further concentrated and the resultant precipitate was filtered and the second filtrate concentrated to afford (2-Aminooxy-ethyl)-methyl-carbamic acid tert-butyl ester (2.83 g) as a viscous oil: !H NMR (400 MHz, CDC13) δ 3.73 (t, J = 5.2 Hz, 2 H), 5.45 (br s, NH2), 3.46 and 3.42 (br s, 2 H), 2.86 br s, 3 H), 1.25 (br s, 9 H); MS
(APCI+) = 191.1.
Figure imgf000121_0001
EXAMPLE l 3.4.5-Trifluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide Step A: To a solution comprised of 2-(4-iodo-2-methyl-phenylamino)-3,4,5- trifluoro-benzoic acid (3.60 g, 8.84 mmol), O-(2-vinyloxyethyl)hydroxylamine (1.09 g, 10.5 mol) and diisopropylethylamine (2.80 mL, 16.0 mmol) in dichloromethane (50 mL) was added benzotriazole-1-yl-oxy-tris-pyrrolidino- phosphonium-hexafluorophosphate (5.26 g, 10.1 mmol). The resultant solution was stirred 90 min at ambient temperature. The reaction mixture was diluted with ether (100 mL) and washed with water (3 x 50 mL) and saturated brine (50 mL). The organics were dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography to afford 2-(4-iodo- 2-methyl-phenylamino)-3,4,5-trifluoro-Ν-(2-vinyloxyethoxy) benzamide (3.17 g, 73 %) as a pale-yellow foam.
Step B : A solution of 2-(4-iodo-2-methyl-phenylamino)-3 ,4,5-trifluoro-N-(2- vinyloxyethoxy)-benzamide (3.00 g, 6.09 mmol) in ethanol (80 mL) was treated with 1 M aqueous hydrochloric acid (16 mL, 16 mol). The resultant solution was stirred for 2.5 h at ambient temperature. Water (50 mL) was added and the slurry was filtered. The solids were washed with ethanol-water (1:1, 150 mL) and recrystallized from methanol-acetone to afford N-(2-hydroxyethoxy)-2-(4-iodo-2- methyl-phenylamino)-3,4,5-trifluoro- benzamide (2.12 g, 75%): m.p. 205-207 °C (dec); 1H NMR (400 MHz, DMSO-d6) δ 11.85 (br s, 1 H), 8.13 (s, 1 H), 7.54 (dd, J = 8.9, 8.7 Hz, 1 H), 7.47 (d, J = 1.0 Hz, 1 H), 7.32 9d, J = 8.5 Hz, 1 H), 6.41 (dd, J = 8.1, 5.0 Hz, 1 H), 4.69 (br s, 1 H), 3.79 (br s, 2 H), 3.52 (br s, 2 H), 2.20 (s, 3
H); MS (APCI+) = 467.1; MS (APCI-) = 465.1; Anal. Calcd/found for dsH^sIN^: C, 41.22/41.28; H, 3.03/2.91; N, 6.01/5.79.
Examples 2-11 were prepared by the general procedure of Example 1.
Figure imgf000122_0001
EXAMPLE 2
3.4-Difluoro-N-(2-hydroxy-ethoxy -2-(4-iodo-2-methyl-phenylamino)-benzamide MP 181-183 °C; 1HΝMR (400 MHz, DMSO-d6) δ 11.87 (s, 1 H), 8.50 (s, 1 H), 7.49 (s, 1 H), 7.40 (dd, 7.3, 6.6 Hz, 1 H), 7.35 (dd, J = 8.3, 1.7 Hz, 1 H), 7.16 (dt, J =7.3, 9.3 Hz, 1 H), 6.46 (dd, J = 8.5, 5.6 Hz, 1 H), 4.70 (br s, 1 H), 3.81 (br s, 2 H), 3.54 (br s, 2 H), 2.21 (s, 3 H); MS (APCI+) = 449.1; MS (APCI-) = 447.1;
Anal. Calcd/found for CieHisFzI Λ: C, 42.88/42.94; H, 3.37/3.39; N, 6.25/6.05.
Figure imgf000122_0002
EXAMPLE 3 2-(2-Chloro-4-iodo-phenylamino)-3.4-difluoro-N-(2-hydroxy-ethoxy)-benzamide
Method A: By the general procedure of Example 1: m.p. 173-175 °C; 1HΝMR (400 MHz, DMSO-de) δ 11.93 (br s, 1 H), 8.85 (br s, 1 H), 7.76 (d, J = 1.7 Hz, 1 H), 7.48 (dd, J = 8.6, 1.7 Hz, 1 H), 7.44 (dd, J = 8.5, 6.2 Hz, 1 H), 7.25 (dt, J = 8.5, 9.3 Hz, IH), 6.58 (dd, J = 8.5, 6.4 Hz, 1 H), 4.70 (br s, 1 H), 3.86 (br s, 2 H), 3.56 (br d, J = 3.9 Hz, 2 H); MS (APCI+) = 469.0; MS (APCI-) = 467.0; Anal.
Calcd/found for Cι5Hι2ClF2rN2O3: C, 38.45/38.60; H, 2.58/2.53; N, 5.98/5.91; F, 8.11/8.08; I, 27.08/27.43.
Method B : To a solution of 2-(2-chloro-4-iodo-phenylamino)-3 ,4-difluoro- benzoic acid pentafluorophenyl ester (10. Og, 17.4 mmol) in anhydrous dimethylformamide (36 mL) was added 2-(aminooxy)-ethanol (1.6 g, 20.8 mmol) and N,N-diisopropylethylamine (6.0 mL, 34.8 mmol). The resultant solution was stirred at ambient temperature for 16 h. The reaction mixture was concentrated to 20% volume then diluted with ethyl acetate (360 mL). The resultant solution was washed with water (6 x 60 mL) and brine (2 x 60 mL). The organics were dried over anhydrous magnesium sulfate and concentrated under reduced pressure to afford a white solid that was purified on silica gel. Elution with ethyl acetate- methanol (9:1) afforded 2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2- hydroxy-ethoxy)-benzamide (7.31 g, 90%) as a white solid. Recrystallization from methanol afforded analytically pure material, identical in all respects to the material prepared by method A.
Figure imgf000123_0001
EXAMPLE 4
2-(2-Chloro-4-iodo-phenylamino -4-fluoro-N-(2-hydroxy-ethoxy -benzamide
1HNMR (400 MHz, DMSO-ds) δ 11.88 (br s, 1 H), 9.81 (s, 1 H), 7.85 (d, J = 2.0
Hz, 1 H), 7.64 (m, 1 H), 7.60 (dd, J = 8.5, 1.9 Hz, 1 H), 7.31 (d, J = 8.3 Hz, 1 H), 7.00 (dd, J = 11.7, 2.5 Hz, 1 H), 6.75 (td, J = 8.5, 2.5 Hz, 1 H), 4.73 br s, 1 H),
3.90 (t, J = 4.6 Hz, 2 H), 3.60 (br t, J = 4.2 Hz, 2 H); MS (APCI+) = 451.0; MS
(APCI-) = 449.0; Anal. Calcd/found for C15H13CIF1L 2O3: C, 39.98/40.07; H,
2.91/2.83; N, 6.22/6.11.
Figure imgf000123_0002
EXAMPLE 5
4-Fluoro-N-(2-hydroxy-ethoxyV2-(4-iodo-2-methyl-phenylamino)-benzamide
1HNMR (400 MHz, CDCI3) δ 9.16 (br s, 1 H), 8.67 (s, 1 H), 7.60 (d, J = 1.7 Hz, 1
H), 7.51 (dd, J = 8.4, 1.7 Hz, 1 H), 7.37 (dd, J = 7.8, 6.6 Hz, 1 H), 7.02 (d, 8.3 Hz, 1 H), 6.59 (dd, J = 12.2, 2.4 Hz, 1 H), 6.41 (m, 1 H), 4.08 (t, J = 4.2 Hz, 2 H), 3.80
(t, J = 4.2 Hz, 2 H), 2.22(s, 3 H); MS (APCI+) = 431.0; MS (APCI-) = 429.0. EXAMPLE 6
2-(2-Chloro-4-iodo-phenylamino -3.4.5-trifluoro-N-(2-hydroxy-ethoxy)- benzamide Yield: 96%; m.p. 183-184.5 °C; 1H-NMR (400 MHz; DMSO-d6) δ 8.46 (s, IH), 7.73 (d, IH, J=1.7 Hz), 7.58 (m, IH), 7.44 (dd, IH, J=8.5, 2.0 Hz), 6.54 (dd, IH,
J=8.5, 5.4 Hz), 4.70 (broad s, IH), 3.84 (m, 2H), 3.54 (s, 2H); 19F-NMR (376 MHz; DMSO-de) δ -137.03 (d, IF, J=20.2 Hz), -141.04 (s, IF), -154.73 (s, IF); MS (APCI+) 486.9 (M+1, 100); MS (APCT) 484.9 (M-l, 50), 424.9 (100); IR (KBr) 3337 (O-H stretch), 1652 (C=O stretch), 1502 cm"1. Anal. Calcd./found for C15H11ClF3LN2O3: C, 37.02/37.16; H, 2.28/2.29; N, 5.76/5.49.
EXAMPLE 7 5-Chloro-3.4-difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-phenylaminoVbenzamide Yield: 21%; m.p. 174-176 °C; 1H-NMR (400 MHz; DMSO-d6) δ 11.72 (s, IH), 8.47 (s, IH), 7.53 (d, IH, J=7.1 Hz), AB[7.43 (d, 2H, J=8.3 Hz), 6.63 (d, 2H,
J=7.6 Hz)], 4.67 (s, IH), 3.74 (s, 2H), 3.49 (s, 2H); 19F-NMR (376 MHz; DMSO- d6) δ -134.59 (s, IF), -139.07 (d, IF, J=17.7 Hz); MS (APCI+)469.0 (M+1, 100); MS (APCT) 467.0 (M-l, 40), 406.9 (100); LR (KBr) 1636 cm-1 (C=O stretch). Anal. Calcd./found for
Figure imgf000124_0001
C, 38.45/38.61; H, 2.58/2.43; N, . 5.98/5.94.
EXAMPLE S 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-berιzamide Yield: 96%; m.p. 117-119 °C; 1H-NMR (400 MHz; DMSO-d6) δ 11.83 (s, IH), 9.62 (s, IH), 7.69 (d, IH, J=10.5 Hz), 7.60 (m, IH), 7.49 (d, IH, J=8.6 Hz), 7.27
(m, IH), 6.84 (d, IH, J=11.2 Hz), 6.70 (m, IH), 4.73 (broad s, IH), 3.90 (m, 2H), 3.60 (m, 2H); 19F-NMR (376 MHz; DMSO-d6) δ -106.74 (s, IF), -124.58 (s, IF); MS (APCI+) 435.0 (M+1, 100); MS (APCT)433.0 (M-l, 82), 373.0 (100); IR (KBr) 1638 (C=O stretch), 1597 cm"1. Anal. Calcd./found for Ci5H13F2rN2O3: C, 41.49/41.52; H, 3.02/2.97; N, 6.45/6.18. EXAMPLE 9 3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy -benzamide Method A: By the general procedure of example 32. Yield: 54%; m.p. 155-156 °C; 1H-NMR (400 MHz; DMSO-d6) δ 11.83 (s, IH), 8.69 (s, IH), 7.56 (dd, IH, J=11.0, 1.5 Hz), 7.36 (m, 2H), 7.19 (m, IH), 6.65 (m, IH), 3.82 (s, 2H), 3.55 (s,
2H); 19F-NMR (376 MHz; DMSO-d6) δ -128.18 (s, IF), -133.11 (s, IF), -144.16 (s, IF); MS (APCI+) 453.0 (M+1, 100); MS (APCT) 451.0 (M-l, 100); IR (KBr) 3349 (O-H stretch), 1641 (C=O stretch), 1610 cm"1. Anal.Calcd./found for C15Hi2F3rN2θ3: C, 39.84/39.99; H, 2.67/2.81; N, 6.20/6.20.
EXAMPLE 10 5-Chloro-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy - benzamide Yield: 96%; m.p. 180-180.5 °C; 1H-NMR (400 MHz; DMSO-d6) δ 11.89 (s, IH), 8.68 (s, IH), 7.59 (m, 2H), 7.34 (d, IH, J=8.8 Hz), 6.72 (m, IH), 4.70 (broad s,
IH), 3.82 (m, 2H), 3.55 (s, 2H); 19F-NMR (376 MHz; DMSO-d6) δ -127.72 (s, IF), -134.13 (s, IF), -140.35 (d, IF, J=17.7 Hz); MS (APCI+) 487.0 (M+1, 100); MS (APCT) 484.9 (M-l, 63), 424.9 (100); JR (KBr) 3333 (O-H stretch), 1643 (C=O stretch), 1609, 1490 cm"1. Anal.Calcd./found for C15HπClF3iN2θ3: C, 37.02/37.30; H, 2.28/2.23; N, 5.76/5.69.
EXAMPLE 11 5-Bromo-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide Yield: 100%; m.p. 189-190 °C; 1H-NMR (400 MHz; DMSO-d6) δ 11.89 (s, IH),
8.70 (s, IH), 7.69 (d, IH, J=6.1 Hz), 7.57 (d, IH, J=10.7 Hz), 7.34 (d, IH, J=7.8 Hz), 6.73 (m, IH), 4.70 (broad s, IH), 3.81 (s, 2H), 3.54 (s, 2H); 19F-NMR (376 MHz; DMSO-de) δ -126.43 (s, IF), -127.65 (s, IF), -140.20 (d, IF, J=17.7 Hz); MS (APCI+) 533.0 (95), 531.0 (M+1, 100); MS (APCT) 531.0 (40), 529.0 (M-l, 42), 470.9 (95), 468.9 (100); IR (KBr) 3341 (O-H stretch), 1647 (C=O stretch),
1606, 1509, 1484 cm"1. Anal.Calcd./found for C15H1ιBrF3IN2θ3: C, 33.93/33.89; H, 2.09/2.02; N, 5.27/5.13. EXAMPLE 12 4,5-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide To a solution of 4,5-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid pentafluorophenyl ester (2.96 g, 0.533 mmol) in dimethylformamide at rt was added diisopropylethylamine (0.184 mL, 1.1 mmol). After the reaction stirced overnight, the reaction mixture was concentrated to about half volume. The solution was diluted with ether (30 mL) then washed with water (4 x 10 mL) and brine (10 mL). The ether layer was dried over magnesium sulfate and the resultant mixture was filtered. The filtrate solvent was removed in vacuo to obtain an oily solid. The oily solid was purified by flash chromatography (35 g silica gel), eluting with a gradient of ethyl acetate in hexanes. The solvent was removed in vacuo to obtain a solid which was dried on a vacuum pump overnight. Recrystalization from hexanes-acetone afforded 4,5-difluoro-N-(2-hydroxy- ethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide as a solid (0.107g, 45 % yield): m.p. 151.2-152.5 C; 1H-NMR (400 MHz, (CD3)2CO) δ 9.22 (br. S, IH), 7.63 (m, 2H), 7.53 (dd, IH, J=8.3, 1.95 Hz), 7.14 (d, IH, J=8.3 Hz), 6.41 (m, IH), 4.03 (t, 2H, J=4.4 Hz), 3.69 (t, 2Η, J=4.88 Hz), 2.23 (s, 3H); 19F-NMR (376 MHz, (CD3)2CO) δ -132.75, -152.61; MS 478.9 m/z (APCI+); 476.9 m/z (APCI-). Anal. Calcd. for C16H15F2IN2O3: C, 42.88; H, 3.39; N, 6.25. Found: C, 42.79; H, 3.19;
N, 6.02.
Examples 13 to 20 were prepared by the general procedure of Example 12.
EXAMPLE 13
5-Bromo-3.4-difluoro-N-(2-hydroxy-ethoxy -2-(4-iodo-2-methyl-phenylamino)- benzamide m.p. 208.2-209.6 C; 1H-NMR (400 MHz, (CD3)2CO) δ 8.62 (br. S, IH), 7.79 (dd, IH, J=7.08, 1.47 Hz), 7.55 (s, IH), 7.42 (d, IH, J=8.79 Hz), 6.65 (dd, IH, J=8.30, 5.86 Hz), 4.02 (t, 2H, J=4.64 Hz), 3.67 (t, 2H,
J=4.64 Hz), 2.32 (s, 3H); 19F-NMR (376 MHz, (CD3)2CO) δ -126.85, -139.3 (d, J=15.16 Hz). Anal. Calcd. for Ci6H14BrF2iN2O3: C, 36.46; H, 2.68; N, 5.31; F, 7.21; Br, 15.16; I, 24.08. Found: C, 36.67; H, 2.62; N, 5.23; F, 7.23; Br, 15.32; I, 23.3.
EXAMPLE 14 5-Bromo-2-f2-chloro-4-iodo-phenylaminoV3,4-difluoro-N-(2-hydroxy-ethoxyV benzamide m.p. 190.2-200.2 C; 1H-NMR (400 MHz, (CD3)2CO) δ 11.11 (br s, IH), 8.92 (br. s., IH), 7.84 (dd, IH, J=6.84, 2.2 Hz), 7.76 (d, IH, J=1.95 Hz), 7.54 (dd, IH, J=8.54, 6.59 Hz), 6.77 (dd, IH, J=8.54, 6.59 Hz), 4.40 (t, 2H, J=4.39 Hz), 3.69 (t, 2H, J=4.89 Hz). 19F-NMR (376 MHz, (CD3)2CO) δ -126.16, -137.47 (d, J=17.69
Hz); MS 546.9 m/z, 548.9 m/z (AP+); 544.9 m z, 546.9 m/z (AP-). Anal. Calcd. for
Figure imgf000127_0001
C, 32.91; H, 2.03; N, 5.12; F, 6.94; Br, 14.58; I, 23.18. Found: C, 32.94; H, 1.95; H, 5.30; F, 6.87; Br, 14.79; I, 22.91.
EXAMPLE 15
5-Chloro-3.4-difluoro-N-(2-hydroxy-ethoxy -2-(4-iodo-2-methyl-phenylamino)- benzamide m.p. 199.1-200.8 C; 1H-NMR (400 MHz, (CD3)2CO) δ 8.57 (br. S, IH), 7.68 (dd, IH, J=7.32, 2.2 Hz), 7.55 (s, IH), 7.41 (dd, IH, J=8.3, 1.71 Hz), 6.64 (dd, IH, J=8.3, 5.86), 4.02 (t, 2H, J=4.63 Hz), 3.67 (t, 2H, J=4.88 Hz), 2.32 (s, 3H). 19F-
NMR (376 MHz, (CD3)2CO) δ -134.75, -139.56 (t, J=15.17 Hz); MS 483.0 m/z (AP+); 481.0 m/z (AP-). Anal. Calcd. for C16Hι4CιF2iN2O3: C, 39.82; H, 2.92; N, 5.8; F, 7.87; Cl, 7.35; I, 26.29. Found: C, 39.91; H, 2.92; N, 6.0; F, 7.91; Cl, 7.39; I, 27.06.
EXAMPLE 16 5-Bromo-4-fluoro-N-(2-hvdroxy-ethoxy -2-(4-iodo-2-methyl-phenylamino)- benzamide m.p. 154.4-156.4; 1H-NMR (400 MHz, (CD3)2CO) δ 9.42 (br. s, IH), 7.86 (d, IH, J=7.57 Hz), 7.66 (d, IH, J=1.46 Hz), 7.56 (dd, IH, J=8.3, 2.2 Hz), 7.16 (d, IH,
J=8.55 Hz), 6.8 (dd, IH, J=l 1.72, 6.59 Hz), 4.04 (t, 2H, J=7.9, 4.4 Hz), 3.69 (t, 2 H, J=6.84, 4.64 Hz), 2.23 (s, 3H). 19F-NMR (376 MHz, (CD3)2CO) δ -103.3; MS 508.9 m/z, 510.9 m/z (AP+); 506.9 m/z, 508.9 m/z (AP-). Anal. Calcd. for C16H15BrFrN2O3: C, 37.75; H, 2.97; N, 5.50. Found: C, 37.68; H, 2.7; N, 5.31.
EXAMPLE 17 2-(2-Chloro-4-iodo-phenylamino -4.5-difluoro-N-(2-hydroxy-ethoxy)-benzamide
1H-NMR (400 MHz, (CD3)2CO) δ 11.01 (br. s, IH), 9.53 (br. s, IH), 7.79 (br. s, IH), 7.67 (br. s, IH), 7.59 (br. d, IH, J=7.82 Hz), 7.32 (d, IH, J=8.55 Hz), 7.26 (br. s, IH), 4.03 (br. s, 2H), 3.7 (br. s, 2H); 19F-NMR (376 MHz, (CD3)2CO) δ - 132.54, -149.93; MS 469.0 (AP+); 467.0 (AP-).
EXAMPLE 18 4.5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-benzamide m.p. 189.6-190.6 C; 1H-NMR (400 MHz, (CD3)2CO) δ 11.00 (br s, IH), 9.39 (br. s, IH), 7.65 (dd, IH, J=11.23, 8.79 Hz), 7.59 (dd, IH, J=10.26, 1.96 Hz), 7.51 (m, IH), 7.31 (t, IH, J=8.8 Hz), 7.13 (m, IH), 4.02 (t, 2 , J=4.64 Hz), 3.69 (t, 2H,
J=4.89 Hz); 19F-NMR (376 MHz, (CD3)2CO) δ -125.9 (d, J=50.55 Hz), -132.74, - 151.05; MS 453.0 m/z (AP+); 451.0 m/z (AP-). Anal. Calcd. for Cι5H12F3lN2O3: C, 39.84; H, 2.67; N, 6.20. Found: C, 40.22; H, 2.62; N, 6.03.
EXAMPLE 19
5-Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hvdroxy-ethoxy)- benzamide m.p. 173-175 C; 1H-NMR (400 MHz, (CD3)2CO) δ 9.59 (br. s.), 7.89 (d, IH, J=7.57 Hz), 7.62 (dd, IH, J=10.26, 1.95 Hz), 7.55 (m, IH), 7.34 (t, IH, J=8.64 Hz), 7.03 (d, Hi J=l 1.48 Hz), 4.04 (d, 2H J=4.39 Hz), 3.70 (d, 2H, J=4.64 Hz);
19F-NMR (376 MHz, (CD3)2CO) δ -103.07, -124.7 (d, J=53.1 Hz); MS 512.8 m/z, 514.8 m/z (AP+); 510.9 m/z, 512.9 m/z (AP-). Anal. Calcd. for C15H12BrF2lN2θ3-0.17 CA02 -0.13 C6H14: C, 36.66; H, 2.84 N, 5.19. Found: C, 36.65; H, 2.57; N, 5.16. EXAMPLE 20
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hvdroxy-ethoxy)- benzamide m.p =178-181°C; 1NMR (400MHz; DMSO-d6) δ 12.00 (s, IH), 8.80 (s, IH), 7.76 (s, IH), 7.66 (d, IH, J=7.1), 7.47 (d, IH, J=8.5), 6.66 (t, IH, J=7.6), 4.70 (bs, IH),
3.85 (m, 2H), 3.56 (m, 2H); MS(APCI+)=502.9/504.9. Anal. calcd/found for
Figure imgf000129_0001
C 35.81/35.69, H 2.20/2.25, N 5.57/5.22, F 7.55/7.72.
Examples 21-24 and 26-27 were prepared by the general method of Example 38.
EXAMPLE 21 3.4.5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)- N-(2-hvdroxy-ethoxyV benzamide m.p.=185-187°C; 1H NMR (400 MHz, DMSO-d6) δ 11.79 (s, IH), 8.32 (s, IH), 7.53 (m, 2H), 7.30 (d, IH, J=8.5), 6.60-6.55 (m,lH), 4.69 (bs, IH), 3.80 (bs, 2H),
3.50 (bs, 2H); MS(APCI+)=471.0. Anal. calcd/found for dsHπFJN^: C, 38.32/38.38; H, 2.36/2.15; N, 5.96/5.76; F, 16.16/15.87.
EXAMPLE 22 2-(4-Bromo-2-fluoro-phenylamino)-3.4-difluoro-N-(2-hydroxy-ethoxy)- benzamide m.p. 146.1-146.4 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.82 (IH, s), 8.71 (IH, s), 7.47 (IH dd, J=l l.lHz, 2.1Hz), 7.30-7.40 (IH, m), 7.15-7.20 (2H, m), 6.76- 6.81 (IH, m), 4.69 (IH, br s), 3.80 (2H, t, J<4.0Hz), 3.52 (2H, t, J<4.0Hz). Anal. Calcd/Found for C15H12F3BrN2O3: C, 44.47/44.58; H, 2.99/2.88; N, 6.91/6.72; F,
14.07/14.01; Br, 19.72/19.60.
EXAMPLE 23 2-(4-Bromo-2-fluoro-phenylamino)-4.5-difluoro-N-f2-hydroxy-ethoxy)- benzamide m.p. 190.8-192.5 °C; 1H MR (400 MHz, Acetone-d6) δ 9.40 (br s, 1 H), 7.67 (IH, dd, J=l 1.48Hz, 8.79 Hz), 7.48 (2H, m), 7.37 (IH, m), 7.12 (IH, m), 4.05 (2H, t, J=4.64 Hz), 3.71 (2H, t, J=4.64 Hz). Anal Calcd/Found Cι5Hi2BrF3 2θ3: C, 44.47/45.55; H, 2.99/2.98; N, 6.91/6.29.
EXAMPLE 24 2-(4-Chloro-2-fluoro-phenylamino)-3.4-difluoro-N-(2-hydroxy-ethoxy)- benzamide m.p. 142.1-142.5 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.83 (IH, s), 8.72 (IHs), 7.36-7.39 (2H, m), 7.16 (IH, dd, J=16.5Hz, 9.4Hz), 7.07 (IH, dd, J=8.5Hz, 1.3 Hz), 6.82-6.88 (IH, m), 4.69 (IH, br s), 3.80 (2H, t, J=4.6Hz), 3.52 (2H, t, J=4.6Hz). Anal Calcd/Found for C15H12ClF3N2O3: C, 49.95/50.18; H, 3.35/3.21;
N, 7.77/7.70; F, 15.80/15.70; Cl 9.83/9.94.
EXAMPLE 25 3.4-Difluoro-2-(2-fluoro-phenylamino)-N-(2-hydroxy-ethoxyVbenzamide Prepared from 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- ethoxy)-b enzamide by the general method of Example 86. m.p. 129.6-130.4 °C; 1H NMR (400 MHz, DMSO-ds) δ 11.85 (IH, s), 8.72 (IH, s), 7.36-7.39 (IH, m), 6.82-7.18 (5H, m), 4.69 (IH, br s), 3.82 (2H, t, J=4.7Hz), 3.53 (2H, t, J=4.7Hz). Anal Calcd/Found for sH^^Os: C, 55.22/55.16; H, 4.02/3.97; N, 8.59/8.51; F, 17.47/17.15.
EXAMPLE 26 5-Chloro-2-(2,4-difluoro-phenylamino)-3.4-difluoro-N -(2-hydroxy-ethoxy - benzamide m.p. 161.6-162.4 °C; 1HNMR (400 MHz, DMSO-d6) δ 11.89 (IH, s), 8.69 (IH, s), 7.56 (IH, dd, J=7.5Hz, 1.9Hz), 7.21-7.27 (IH, m), 6.94-7.06 (IH, m), 6.89- 6.92 (IH, m), 4.69 (IH, br s), 3.81 (2H t, J=4.6 Hz), 3.53 (2H, t, J=4.6Hz). Anal Calcd/Found for C15HuClF4N2O3: C, 47.57/47.74; H, 2.93/2.83; N, 7.40/7.31; F, 20.07/19.76; Cl, 9.36/9.39.
EXAMPLE 27 2-(2.4-Difluoro-pnenylamino)-3,4-difluoro-N- 2-hydroxy-ethoxy)-benzamide m.p.141.1-141.6 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.84 (IH, s), 8.73 (IH s); 7.34-7.37 (IH, m), 7.11-7.27 (IH, m), 7.04-7.09 (IH, m), 6.89-6.99 (2H, m), 4.70 (IH, br s), 3.82 (2H, t, J=4.9 Hz), 3.53 (2H, t, J=4.8Hz). Anal Calcd/Found for Cι5H12F4N2θ3: C, 52.33/52.34; H, 3.51/3.39; N 8.14/8.01; F, 22.07/21.93.
EXAMPLE 28 4-Fluoro-N-(3-hydroxy-propoxy -2-(4-iodo-2-methyl-phenylamino -benzamide Step A: To a mixture of 4-fluoro-2-(4-iodo-2-methyl-phenylamino) benzoic acid (3.32g, 8.95 mmol) in dichloromethane at ambient temperature was added diisopropylethylamine (2.82 mL, 16.2 mmol). To the resultant solution was added
O-[3-(tert-butyl-dimethyl-silanyloxy)-propyl]-hydroxylamine (2.19g, 10.65 mmol) and PyBOP. After 1.5 h of stirring, the solution was diluted with ether (100 mL) and was washed with water (3x50 mL) and brine (50 mL), dried over magnesium sulfate and filtered, and concentrated in vacuo to obtain a gum. Chromatographed the gum using a gradient of 100% hexanes to 30% ethyl acetate in hexanes over 45 min. The solvent ofthe combined fractions was removed in vacuo to obtain a yellow gum. The gum was dried on a vacuum pump for c. a. 18h which afforded N-[3-(tert -Butyl-dimethyl-silanyloxy)-propoxy]-4-fluoro-2- (4-iodo-2-methyl-phenylamino)-benzamide as a solid. (4.06g, 81% yield). 1H- NMR (400 MHz, CDC13) δ 9.3 (br. s., IH), 9.0 (br. s., IH), 7.58 (s, IH), 7.49 (dd,
IH, J=8.3, 1.95Hz)), 7.36 (br. t, 1H,=5.71 Hz), 7.05 (d, IH, J=8.3 Hz), 6.65 (dd, IH, J=11.96, 2.44 Hz), 6.4 (br. t, J=7.1 Hz), 4.14 (t, 2Η, J=5.61 Hz), 3.812 (t, 2H, J=5.62 Hz), 2.28 (s, 3H), 1.94 (p, 2H, J=5.86 Hz), 0.9 (s, 9H), 0.08 (s, 6H). 19F- NMR (376 MHz, CDCI3) δ -105.25. MS (AP+) 559.2 m/z, (AP-) 557.1 m/z. Step B: To a solution of N-[3-(tert -Butyl-dimethyl-silanyloxy)-propoxy]-4- fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide (4.0g, 7.27 mmol) in methanol (5 mL) at ambient temperature was added 5 M H2SO4 in methanol (0.073 mL, 0.364 mmol). After lh of stirring, to the reaction was added additional 5 M H2SO4 in methanol (0.035 mL, 0.182 mmol). After 2h of stirring, the reaction was adjusted to pH 7 using saturated NaHCO3 (aq) (c. a. 1.5 mL), followed by addition of water (35 mL). The aqueous layer was extracted with ethyl acetate (1x20 mL, 2x10 mL). The extracts were combined, washed with brine, and dried over magnesium sulfate. The resultant mixture was filtered, and the filtrate solvent was removed in vacuo to obtain an oil that was dried on a vacuum pump over the weekend. The oil was purified by flash chromatography, eluted with a gradient of 100% hexanes to 100% ethyl acetate in 50 min. The solvent was removed in vacuo of combined fractions to obtain a solid which was dried on a vacuum pump for c. a. 6 h. Recrystahzed solid in a mixture of hexanes and ethyl acetate to afford 4-fluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide as a solid (2.4g, 74% yield): m.p. 120.8-122.4 C; 1H- NMR (400 MHz, (CD3)2CO) δ 10.91 (br s, 1 H), 9.59 (br. S, IH), 9.68 (m, 2H), 7.57 (d, IH τ=8.54 Hz), 7.18 (d, IH, J=8.34 Hz), 6.72 (m, IH); 6.53 (m, IH);
4.12 (t, 2H, J=6.11 Hz), 3.71 (t, 2H, J=5.86 Hz), 2.26 (s, 3H), 1.86 (m, 2H); 19F- NMR (376 MHz, (CD3)2CO) δ -108.14; MS 445.1 m/z (AP+), 443.1 m/z (AP-). Anal. Calcd. for C17Hι8FLN2O3: C, 45.96; H, 4.08; N, 6.31; F, 4.28; I, 28.57. Found: C, 45.78; H, 3.88; N, 6.14; F, 4.30; I, 28.27.
Examples 29-33 were prepared by the general procedure of example 28.
EXAMPLE 29 5-Chloro-3.4-difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide m.p. 155.2-156.6 C; 1H-NMR (400 MHz, (CD3)2CO) δ 10.98 (br s, IH), 8.70 (br.
S, IH), 7.66 (dd, IH, J=7.33, 1.95 Hz), 7.55 (s, IH), 7.42 (dd, IH J=8.54, 1.95 Hz), 6.64 (dd, IH J=8.55, 6.11 Hz), 4.08 (t, 2H, J=6.11 Hz), 3.67 (t, 2H, J=6.10 Hz), 2.32 (s, 3H), 1.83 (m, 2H); 19F-NMR (376 MHz, (CD3)2CO) δ -135.0, - 139.63 (d, J=17.67 Hz); MS 497.1 m/z (AP+); 495.1 m/z (AP-). Anal. Calcd. for C17H16ClF2iN2O3: C, 41.11; H, 3.25; N, 5.64; F, 7.65; Cl, 7.14; I, 25.55. Found:
C, 41.09; H, 3.07; N, 5.46; F, 7.63; Cl, 7.24; I, 25.57.
EXAMPLE 30 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-propoxy)-benzamide m.p. 158.8-160.8 C; 1H-NMR (400 MHz, (CD3)2CO) δ 10.90 (br s, IH), 9.93 (br.
S, IH), 7.84 (d, IH, J=1.95 Hz), 7.72. (dd, IH, J=8.55, 1.96 Hz), 7.65 (dd, IH, J=8.55, 1.96 Hz), 7.39 (d, IH, J=8.54 Hz), 7.05 (dd, IH, J=11.72, 2.44 Hz), 6.67 (td, IH, J=8.55, 2.69Hz), 4.13 (t, 2H, J=6.34 Hz), 3.71 (t, 2H, J=6.10 Hz), 1.86 (m, 2H). 19F-NMR (376 MHz, (CD3)2CO) δ -108.0; . MS 465.1 m/z (AP+), 463.1 m/z (AP-). Anal. Calcd. for Cι6H15ClFLN2O3: C, 41.36; H, 3.25; N, 6.03; F, 4.09; Cl, 7.63; I, 27.31. Found: C, 41.41; H, 3.13; N, 5.84; F, 4.10; Cl, 7.62; I, 27.41
EXAMPLE 31 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3.4-difluoro- N-(3-hydroxy- propoxyVbenzamide m.p. 120-121°C; 1NMR (400MHz;DMSO-d6) δ 11.90 (bs, IH), 8.91 (bs, IH),
7.76 (bs, 2H), 7.47 (d, IH, J=8.1), 6.67 (m, IH), 4.48 (bs, IH), 3.89 (bs, 2H), 3.47 (bs, 2H), 1.73 (m, 2H); MS(APCI+)=560.8/562.8. Anal. calcd/found for C16Hι3BrClF2lN2O3: C 34.22/34.45, H 2.33/2.36, N 4.99/4.91, F 6.77/6.72.
EXAMPLE 32
3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino -N-(3-hydroxy-propoxy)- benzamide m.p. 151.8-152.4 °C; 1HNMR (400 MHz, DMSO-d6) δ 11.74 (IH, s), 8.71 (IH s), 7.56 (IH d, J=11.0Hz), 7.20-7.30 (2H m), 7.16-7.22 (IH, m), 6.62-6.68 (IH, m), 4.46 (IH, br s), 3.83 (2H, t, J=5.6Hz), 3.46 (2H, t, J=4.6Hz), 1.67-1.70 (2H, m). Anal. Calcd/Found for
Figure imgf000133_0001
C,41.22/41.27; H, 3.03/2.87; N, 6.01/5.92; F, 12.23/11.97; I, 27.22/27.44.
EXAMPLE 33 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(4-hydroxy-butoxy)-benzamide m.p. 131.4-131.9 °C; JH NMR (400 MHz, DMSO-d6) δ 11.71 (IH, s), 8.68 (IH, s), 7.54 (IH, d, J=11.0Hz), 7.20-7.36 (2H, m), 7.14-7.18 (IH, m), 6.60-6.66 (IH, m), 4.38 (IH, br s), 3.74 (2H, t, J=6.1Hz), 3.36 (2H, t, J=4.2Hz), 1.41-1.55 (4H m). Anal. Calcd/Found for CπHiβFsINaOg: C, 42.52/42.91; H, 3.36/3.27; N, 5.83/5.58; F, 11.87/11.61; I, 26.43/26.67. EXAMPLE 34
5-Chloro-2-(2-chloro-4-iodo-phenylamino -N-(2.3-dihydroxy-propoxy -3.4- difluoro-benzamide Step A: To a stircing solution of 5-chloro-2-(2-chloro-4-iodo-phenylamino)-3,4- difluoro-benzoic acid pentafluorophenyl ester (5.80 g, 9.51 mmol) is freshly distilled tetrahydrofuran (40 mL) was added O-(2,2-dimethyl-[l,3]dioxolan-4- ylmethyl)-hydroxylamine (1.54g, 10.5 mmol) and diisopropylethylamine (1.8 mL, 10.5 mmol). After 20 hours, the mixture was partitioned between ethyl acetate and water. The organic layer was washed twice with water and twice with saturated brine solution. The organic layer was collected, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by crystallization in ethyl acetate/hexanes affording 5-chloro-2-(2-chloro-4-iodo-phenylamino)- N- (2,2-dimethyl-[l,3]dioxolan-4-ylmethoxy)-3,4-difluoro-benzamide as a white solid (3.7 g, 67.9%): 1HΝMR (400 MHz;CDCl3) δ 9.82 (bs, IH), 8.10 (bs, IH), 7.68 (s, IH), 7.47 (bs, IH), 7.40-7.43 (m, IH), 6.44-6.47 (m, IH), 4.40 (bs, IH),
3.97-4.20 (m, 3H), 3.77 (t, IH, J=8.0), 1.44 (s, 3H), 1.37 (s, 3H); MS (APCI+) = 573.0/575.0.
Step B: To a stircing solution of 5-chloro-2-(2-chloro-4-iodo-phenylamino)- N- (2,2-dimethyl-[l,3]dioxolan-4-ylmethoxy)-3,4-difluoro-benzamide (3.7g, 6.45 mmol) in methanol (20 mL) and water (2 mL) was added ?-toluenesulfonic acid
(0.12g, 0.65 mmol). After 20 hours the reaction was concentrated in vacuo. The afforded residue was partitioned between ethyl acetate and water. The organic layer was washed twice with saturated aHCO3 solution and twice with saturated brine solution. The organic layers were collected, dried over Na2SO , filtered and concentrated in vacuo. The residue was purified by crystallization with methanol/water and the solids were dried in a vacuum oven at 40°C to afford 5- chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-3,4-difluoro- benzamide: m.p.=152-154°C; !NMR (400 MHz, DMSO-de) δ 12.03 (s, IH), 8.83 (s, IH), 7.76 (s, IH), 7.66 (d, IH, J=6.8), 7.47 (d, IH J=8.5), 6.68 (t, IH, J=6.6), 4.83 (bs, IH), 4.60 (bs, IH), 3.89-3.92 (m, IH), 3.68-3.76 (m, 2H), 3.30 (2H, partially hidden by HDO); MS(APCI+)=533.0/535.0; Anal. calcd/found for Cι6H13Cl2F2IN2O4: C, 36.05/36.23; H, 2.46/2.40; N, 5.25/5.03; F, 7.13/7.14. Examples 35-37 were prepared by the general procedure described in example 34.
EXAMPLE 35 5-Chloro-N-(2.3-dihydroxy-propoxy -3.4-difluoro-2-(4-iodo-2-methyl- phenylaminoVbenzamide m.p.=67-69°C; 1HΝMR (400 MHz, CDC13) δ 7.51 (s, IH), 7.46 (d, Hi J=6.3), 7.38 (d, IH, J=8.5), 6.44 (dd, IH, J=8.3, 4.9), 3.94-3.98 (m, 2H), 3.89 (m, IH), 3.74 (A of abx, IH, J=11.7, 3.9), 3.61 (B of abx, IH, J=11.5, 4.9), 2.30 (s, 3H); MS(APCI+)=513.0/515.0. Anal. calcd/found for C17H1eClF2lN2O4: C,
39.83/39.90; H, 3.15/3.23; N, 5.46/5.03; F, 7.41/7.20.
EXAMPLE 36 5 -Chloro-N-(3.4-dihydroxy-butoxy)-3.4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide m.p.=135-138°C ; 1HΝMR (400 MHz, DMSO-de) δ 11.86 (bs, IH), 8.55 (bs, IH), 7.85 (s, IH), 7.60 (d, IH, J=7.1), 7.51 (s, IH), 7.35 (d, Hi J=8.5), 6.53 (dd, IH, J=8.3,5.4), 4.51-4.52 (m, 2H), 3.86-3.88 (m, 2H), 3.53 (bs, IH), 3.23-3.28 (cm, IH), 2.20 (s, 3H), 1.73-1.77 (cm, IH), 1.45-1.48 (cm, IH); MS(APCI+)=527.0. Anal.calcd/found for C18Hi8ClF2rN2O4: C, 41.05/41.12; H, 3.44/3.41; N,
5.32/5.13; F, 7.21/6.83.
EXAMPLE 37 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(3.4-dihydroxy-butoxy)-3.4- difluoro-benzamide m.p.=146-148°C ; 1H NMR (400 MHz, DMSO-d6) δ 11.92 (s, IH), 8.84 (s, IH), 7.76 (s, IH), 7.65 (d, IH, J=7.1), 7.47 (d, IH, J=8.8), 6.67 (dd, IH, J=8.3,6.3), 4.54-4.50 (m, 2H), 3.93 (t, 2H, J=6.3), 3.54 (t, IH, J=4.2), 3.28-3.20 (m, 2H), 1.76 (cm, IH), 1.52-1.47 (cm, 1H); MS (APCI+)=547.0/549.0. Anal.calcd/found for C17H15Cl2F2IN2O4: C, 37.32/37.26; H, 2.76/2.62; N, 5.12/4.99; F, 6.94/7.07. EXAMPLE 38
N-(2.2-Dimethyl-[ 1.3 ]dioxolan-4-ylmethoxyV3.4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide To a stircing solution of 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid (4.52g, 11.5 mmol) in freshly distilled tetrahydrofuran (20 mL) at -15°C was added diphenylphosphinic chloride (2.85 mL, 14.95 mmol). The resultant reaction mixture was stirced for 30 minutes at -15°C. N-Methylmorpholine (1.26 mL, 11.5 mmol) was added and stircing was continued for 90 minutes at -15°C. The reaction was then charged with O-(2,2-dimethyl-[l,3]dioxolan-4-ylmethyl)- hydroxylamine (2.03g, 13.8 mmol) and allowed to stir at -15°C for 30 minutes.
N-methylmorpholine (1.9 mL, 17.25 mmol) was added and the reaction was allowed to warm to room temperature. After 17 hours, the mixture was diluted with ethyl acetate and partitioned twice with saturated ΝaHCθ3 solution, then twice with water, and twice with saturated brine solution. Organic layers were collected, dried over sodium sulfate, filtered and concentrated in vacuo. The afforded residue was purified by silica column chromatography in 3 : 1 hexanes/ethyl acetate. The corresponding fractions were collected, dried in vacuo, and crystallized from ethyl acetate/hexanes affording N-(2,2-dimethyl- [l,3]dioxolan-4-ylmethoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide (A.12g, 68.6%) as light brown solid: m.p.=l 14-115°C; 1ΝMR (400
MHz, DMSO-de) δ 11.89 (s, IH), 8.62 (s, IH), 7.53-7.55 (m, IH), 7.31-7.37 (m, 2H), 7.17 (dd, IH, J=16.9, 9.3), 6.60-6.65 (m, IH), 4.22 (t, Hi J=6.1), 3.96 (t, IH, J=8.3), 3.76-3.77 (m, 2H), 3.63 (t, IH, J=4.9), 1.26 (s, 3H), 1.21 (s, 3H); MS(APCI+)=522.9; Anal.calcd/found for C19Hi8F3rN2O4: C, 43.70/43.88; H, 3.47/3.43; N, 5.36/5.20; F, 10.91/10.87.
EXAMPLE 39 N-(2.3-Dihvdroxy-propoxy)-3.4-difluoro-2-(2-fluoro-4-iodo-phenylaminoV benzamide (Form II of Compound A) To a stirring solution ofN-(2,2-dimethyl-[l,3]dioxolan-4-ylmethoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide (3.03g, 5.81 mmol) in methanol (30 mL) and water (3 mL) at ambient temperature was added -toluene sulfonic acid (O. l lg, 0.581 mmol). After 18 hours another O.l lg of added p- toluene sulfonic acid and 2 mL of water was added. After an additional 24 hours the reaction mixture was concentrated in vacuo. The residue was partitioned between ethyl acetate and water. The organic layer was washed twice with saturated NaHCO3 solution and twice with saturated brine solution. The organic layers were collected, dried over Na2SO4, filtered and concentrated in vacuo affording a light brown solid, which was crystallized from ethyl acetate/hexanes to afford N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide as a white solid. m.ρ.=135.5-137.3°C ; NMR (400MHz, DMSO-d6) δ 11.87 (s, IH), 8.69 (s, IH), 7.54 (dd, IH, J=10.9, 1.5), 7.32-7.38 (m, 2H), 7.17
(dd, IH, J=16.8, 9.0), 6.61-6.66 (cm, IH), 4.82 (bs, IH), 4.58 (bs, IH), 3.84-3.85 (m, IH), 3.71-3.64 (cm, 2H), 3.33 (2H, partially hidden by HDO); MS(APCI+)=483.0; Anal.calcd/found for C1eH14F3LN2θ4: C, 39.85/40.12; H, 2.93/2.84; N, 5.81/5.65; F, 11.82/11.47. Alternatively, the crude white solid of N-(2,3-Dihydroxy-propoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide was suspended in heptane - CH2C12 (1 : 1). The ratio was 6 mL ofthe solvent per gram of solid. The suspension was stirred at ambient temperature for 30 min. The solid was filtered, and dried at a vacuum oven (20 mmHg), 45 °C for 18 hrs, to give white crystals, mp l31 - 132 °C.
EXAMPLE 39A N-f2.3-Dihydroxy-propoxyV3.4-difluoro-2-f2-fluoro-4-iodo-phenylamino)- benzamide (Form I of Compound A)
To a stirring solution of N-(2,2-dimethyl-[l,3]dioxolan-4-ylmethoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide (0.907g, 1.74 mmol) in methanol (10 mL) and wafer (1 mL) at ambient temperature was added jt?-toluene sulfonic acid (0.032g, 0.17 mmol). After stircing for 18 hours the reaction mixture was concentrated in vacuo and the affording residue was partitioned between ethyl acetate and water. The organic layers were washed twice with water and once with saturated brine solution. Organic layers were collected, dried over Νa2SO4, filtered and concentrated in vacuo affording a light brown solid, which was dissolved in ethanol and precipitated with water to afford N-(2,3-dihydroxy- propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide as a white solid (0.387g). m.p.=83-85°C; 1ΝMR (400MHz, DMSO-de) 11.87 (s, IH), 8.69 (s, IH), 7.56 (d, IH, J=l 1.0), 7.33-7.39 (m, 2H), 7.19 (dd, IH, J=16.6, 9.0), 6.62-6.68
(cm, IH), 4.82 (d, IH, J=4.2), 4.58 (t, IH, J=5.5), 3.84-3.87 (m, IH), 3.66-3.72 (m, 2H), 3.3 (2H, partially hidden by HDO); MS(APCI+)=483.0; Anal.calcd/found for
Figure imgf000138_0001
H2O: C, 39.41/39.02; H, 3.02/2.93; N, 5.75, 5.81; F, 11.69/11.68. Alternatively, the crude solid N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide was dissolved in minimum amount of boiling ethanol (95%). Water was added to this boiling solvent until slightly cloudy. The mixture was cooled to ambient temperature and then at 0 °C for 18 hrs. Solid formed was filtered and dried at a vacuum oven (20 mmHg), 45 °C for 18 hrs, mp 81 - 84 °C.
Furthermore, the crude solid iV-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide was dissolved in minimum amount of boiling ethyl acetate, and heptane was added to this solution until slight cloudy. The mixture was cooled to ambient temperature and then at 0 °C for 18 hrs. Solid formed was filtered and dried at a vacuum oven (20 mmHg), 45 °C for 18 hrs, mp
86 °C.
The compounds of examples 40-48 were prepared by the procedures described in Examples 38 and 39.
EXAMPLE 40 5-Bromo-N-(2,3-dihydroxy-propoxy)-3.4-difluoro-2-(2-fluoro-4-iodo- phenylaminoVbenzamide m.p.=172-174°C ; 1H NMR (400MHz, DMSO-de) δ 11.92 (s, IH), 8.69 (s, IH),
7.67 (d, IH, J=6.8), 7.56 (d, IH, J=10.7), 7.34 (d, IH J=8.3), 6.73 (cm, IH), 4.81 (m, IH), 4.58-4.57 (m, IH), 3.86-3.84 (m, IH), 3.70-3.67 (m, 2H), 3.30 (2H, partially under HDO); MS(APCI+)=561.0. Anal.calcd/found for C16Hi3BrF3rN2O4: C, 34.25/34.27; H, 2.34/2.22; N, 4.99/4.75.
EXAMPLE 41 5-Chloro-N-(2.3-dihydroxy-propoxy -3.4-difluoro-2-(2-fluoro-4-iodo- phenylaminoVbenzamide m.p.=152-155°C ; 1HΝMR (400 MHz, DMSO-d6) δ 11.91 (s, IH), 8.66 (s, IH), 7.58-7.55 ( , 2H), 7.34 (d, IH, J=8.1 Hz), 6.72 (cm, IH), 4.81 (d, Hi J=4.1 Hz), 4.58 (t, Hi J=5.9 Hz), 3.87-3.84 (m, IH), 3.70-3.68 (m, 2H), 3.33 (2H, partially under HDO); MS(APCI+)=517.0. Anal.calcd/found for C1eH13ClF3rN2O4: C
37.20/36.88, H 2.54/2.43, N 5.42/5.14, F 11.03/11.70.
EXAMPLE 42 N-(2.3-Dihydroxy-propoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylaminoV benzamide m.p.= 173-175°C ; 1HNMR (400 MHz, DMSO-de) δ 11.86 (s, IH), 9.59 (s, IH), 7.69 (d, IH, J=10.3), 7.58 (t, IH, J=7.8), 7.49 (d, IH, J=8.5), 7.27 (t, IH, J=8.5), 6.82 (d, Hi J=11.5), 6.69 (t, IH, J=7.8), 3.94-3.92 (m, IH), 3.78-3.71 (m, 2H), 3.4 (2H under HDO); MS(APCI+)=465.0.
EXAMPLE 43 N-(2.3-Dihydroxy-propoxy)-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide m.p.=157-160°C; 1HNMR (400 MHz, DMSO-de) δ 11.82 (s, IH), 8.32 (s, IH), 7.53-7.48 (m, 2H), 7.29 (d, IH) J=8.3), 6.58-6.55 (m, IH), 4.80 (d, IH, J=3.0),
4.57 (t, Hi J=5.9), 3.83-3.81 (m, IH), 3.67-3.65 (m, 2H), 3.30 (2H, under HDO); MS(APCI+)=500.9. Anal.calcd/found for C16H13F4ιN2O4: C, 38.42/38.48; H, 2.62/2.54; N, 5.60/5.55; F, 15.19/14.96.
EXAMPLE 44
2-(4-Bromo-2-fluoro-phenylamino)-N-(2.3-dihydroxy-propoxy -3.4-difluoro- benzamide Prepared in the manner of N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide (Example 39): m.p. 110-117 °C (dec). Anal. Calcd Found for C1eH14BrF3BrN2θ4: C, 44.16/43.86; H, 3.24/2.97; N, 6.44/6.13; F, 13.10/12.76; Br, 18.36/18.64.
EXAMPLE 45 2-(4-Chloro-2-fluoro-phenylamino -N-(2.3-dihydroxy-propoxy -3.4-difluoro- benzamide m.p. 114.0-114.9 °C; 1HNMR (400 MHz, DMSO-de) δ 11.87 (IH, s), 8.74 (IH, s), 7.38 (IH, dd, J=11.3Hz, 2.3Hz), 7.36 (IH, m), 7.07-7.20 (2H, m), 6.84-6.90
(IH, m), 4.83 (IH, br s), 4.59 (IH br s), 3.84-3.87 (IH, m), 3.65-3.72 (2H, m), 3.20-3.40 (2H m). Anal Calcd/Found for C16H14F3ClN2O4: C, 49.18/49.09; H, 3.61/3.56; N, 7.07/7.03; F, 14.59/14.45; Cl, 9.07/9.16.
EXAMPLE 46
N-(2.2-Dimethyl- 1.3]dioxan-5-yloxyV3.4-difluoro-2-(2-fluoro-4-iodo- phenylaminoVbenzamide m.p.=154-155°C; 1H NMR (400 MHz, DMSO-d6) δ 11.93 (s, IH), 8.64 (s, IH), 7.55 (dd, IH, J=10.7, 1.7), 7.40 (t, IH, J=7.1), 7.33 (d, IH, J=8.3), 7.21-7.14 (m, IH), 6.69-6.65 (m, IH), 3.95 (A of AB, 2H, J=10.7), 3.80 (B of AB, 2H, J=12.2),
3.65 (bs, IH), 1.33 (s, 3H), 1.25 (s, 3H); MS (APCI+)=523.1; Anal.calc/found for Cι9H18F3ιN2O4: C, 43.70/43.76; H, 3.47/3.44; N, 5.36/5.21; F, 10.91/10.73.
EXAMPLE 47 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylaminoV N-(2-hydroxy- 1 -hydroxymethyl- ethoxyVb enzamide m.p. 111-114°C; 1H MR (400 MHz, DMSO-d6) δ 11.82 (bs, IH), 8.64 ( bs, IH), 7.55 (dd, IH, J=10.7, 1.9), 7.40 (t, IH, J=7.3), 7.34-7.31 (m, IH), 7.20 (dd, IH, J=16.6,9.3), 6.65-6.60 (m, IH), 4.64 (bs, 2H), 3.75-3.72 (m, IH), 3.48-3.44 (m, 4H); MS (APCI+)=482.9; Anal.calc/found for
Figure imgf000140_0001
C,
39.85/39.93; H, 2.93/2.93; N, 5.81/5.51; F, 11.82/11.72. EXAMPLE 48 5-Chloro-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- N-(2-hydroxy- 1 - hydroxymethyl-ethoxyVbenzamide m.p. 173-175°C; 1H MR (400 MHz, DMSO-de) δ 11.87 (s, IH), 8.56 (s, IH), 7.61 (d, IH, J-6.3), 7.55 (d, IH, J=9.3), 7.32 (d, IH, J=9.5), 6.69 (m, IH), 4.61 (m,
2H), 3.73 (m, IH), 3.48 (m, 4H); MS(APCI+)=516.9/518.9.
EXAMPLE 49 N- [(R)-2, 3 -Dihy droxy-propoxy] -3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide (Form I of Compound B)
Step A: To a solution of 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid (39.3 g, 100.0 mmol) in dry tetrahydrofuran (500 mL, 0.2 M), under nitrogen atmosphere, was added (R -O-(2,2-dimethyl-[l,3]dioxolan-4-ylmethyl)- hydroxylamine (14.7 g, 100.0 mmol), followed by N-methylmorpholine (27.5 mL, 0.25 mole). The orange-colored solution was cooled with an ice-water bath.
Diphenylphosphinic chloride (22.9 mL, 0.12 mole) was added dropwise. Some solid formed. The mixture was warmed to ambient temperature and stirred for 18 hrs. Water was added to quench the reaction and the tetrahydrofuran was evaporated in vacuo. The remaining oil was dissolved in ethyl acetate (500 mL), washed with a mixture of saturated brine and saturated sodium bicarbonate (1:1) two times. The ethyl acetate was removed and the crude oily solid was purified by flash chromatography (silica gel, hexane-acetone 12 : 1) to give Ν-((R)-2,2- Dimethyl- [1,3] dioxolan-4-ylmethoxy)-3 ,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide as an off-white solid after drying in a vacuum oven at 40 °C for 20 hrs: 41.7 g (79.8%), m.p. 124-125 °C. The impure fractions were combined and purified by a second column chromatography using the same condition to give a 2nd batch of 6.4 g (12.3%), mp 124-125 °C, total yield 48.1 g (92.1%). 1HNMR (d6-DMSO): δ 11.9 (s, br, IH), 8.7 (s, br, IH), 7.6 (d, IH, J=10.99 Hz), 7.4 (m, 2H), 7.2 (m, IH), 6.7 (m, IH), 4.2 (m, IH), 4,0 (t, IH, Jl=8.3 Hz, J2=6.8 Hz), 3.8 (m, 2H), 3.7 (m, IH), 1.3 (s, 3H), 1.2 (s, 3H); 19F
NMR (d6-DMSO): δ -128.0, -133.1, -144.3; MS: 523 (M++l). Step B: N-((R)-2,2-Dimethyl-[l,3]dioxolan-4-ylmethoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide (22.3 g, 42.7 mmol) was suspended in methanol (223 mL, lOmL/g), and a solution of ρTsOHH2O (4.1 g, 21.35 mmol) in water (22.3 mL) was added. The mixture was stirced at ambient temperature for 18 hrs, during which all solids dissolved to give a colorless, clear solution.
The solution was concentrated and extracted with ethyl acetate (2 x 300 mL). The organic solution was washed with sodium bicarbonate, dried over MgSO4. After filtration, the filtrate was concentrated, and co-evaporated with heptane to give a foaming solid. To this solid was added hexane-CH2Cl2 (1 : 1, 100 mL) and the mixture was stirred for 30 min. A white solid formed, which was filtered, washed with hexane. The solid was recrystallized from hexane-AcOEt to give N-((R)-2,3- dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide as white crystals, 13.57 g (65.9%), after drying at 60 °C vacuum oven for 3 days. A second crop of 5.05 g was obtained from the mother liquor, after recrystallization from the same solvent system. The total yield was 18.62 g (90.4%): m.p. 89-90
°C (Form II of Compound B). The combined crystals were ground with a set of mortar and pestle to fine powder, and dried at 60 °C in a vacuum oven for 3 days: m.p. 117-118 °C (Form I of Compound B); [α]= -2.05° (c=1.12, methanol); Analysis: Calcd. For: CιeH14F3lιN2O4: C, 39.85; H, 2.93; N, 5.81; F, 11.82, I, 26.32. Found: C, 39.95; H, 2.76; N, 5.72; F, 11.71; I, 26.53. 1NMR (400MHz,
DMSO-de) δ 11.87 (s, IH), 8.69 (s, IH), 7.54 (dd, IH, J=10.9, 1.5), 7.32-7.38 (m, 2H), 7.17 (dd, IH, J=16.8, 9.0), 6.61-6.66 (cm, IH), 4.82 (bs, IH), 4.58 (bs, IH), 3.84-3.85 (m, IH), 3.71-3.64 (cm, 2H), 3.33 (2H, partially hidden by HDO).
EXAMPLE 49A
N-[(R)-2.3-Dihvdroxy-propoxyl-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide (Form II of Compound B) Step A: To a solution of 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid (2.25 g, 5.10 mmol) in dry tetrahydrofuran under nitrogen atmosphere, at - 15C was added diphenylphosphinic chloride (1.26 mL, 6.63 mole) dropwise.
After stirring 20 min., Ν-methyl morpholine (0.70 mL, 6.375 mmol) was added and the reaction stirced an additional 20 min. (7? -O-(2,2-dimethyl-[l,3]dioxolan- 4-ylmethyl)-hydroxylamine (0.748 g, 5.1 mmol) was added and the reaction stirced for 1 hour, at which point N-methylmorpholine (0.7 mL, 6.37 mmol) was added. The mixture was warmed to ambient temperature and stirred for 12 h. The reaction was concentrated in vacuo and then diluted with EtOAc. The organic layer was washed with sat'd ΝaHCθ3 (2x), brine (lx), dried over Na2SO4, filtered and concentrated. The crude product was purified on SiO2 using 4: 1 hexane/EtOAc as elutant to provide 1.82g (68%) of a brownish red solid. Step B : N-((R)-2,2-Dimethyl-[ 1 , 3 ]dioxolan-4-ylmethoxy)-3 ,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide (0.210 g, 0.40 mmol) was suspended in 10:1 methanol/H2O and pTsOHH2O (0.008 g, 0.04 mmol) was added. The mixture was stirred at ambient temperature for 18 hrs, during which all solids dissolved to give a colorless, clear solution. The solution was diluted with EtOAc. The organic solution was washed with sodium bicarbonate (2x), brine (lx) and dried over Na2SO4. After filtration, the filtrate was concentrated, and recrystallized from EtOAc and heptane. This solid was washed with heptane-
CH C12 (1 : land dried in vacuo at 60C to give N-((R)-2,3-Dihydroxy-propoxy)- 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide as a white solid, (0.136g, 70%). Product shrinks at 90.8C, melts at 115-117C. Analysis shows C 40.92, H 3.16, N 5.41, F 11.30, 123.92 (6.75% EtOAc, 0.96 % heptane).
EXAMPLE 50
N-[(S -2.3-Dihydroxy-propoxy]-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide (Form I of Compound O
Prepared from (SJ-O-(2,2-dimethyl-[l,3]dioxolan-4-ylmethyl)-hydroxylamine and 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid by the procedure described above for N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide: m.p. 116-118 °C (Form II of Compound C); and m.p. 116-118 °C (Form I of Compound C); [α]= +1.77° (c=1.13, methanol). Analysis: Calcd. For:
Figure imgf000143_0001
C, 39.85; H, 2.93; Ν, 5.81; F, 11.82, 1, 26.32. Found: C, 40.01; H, 2.73; Ν, 5.84; F, 11.45; I, 26.42. EXAMPLE 50A
N-[(S -2.3-Dihydroxy-propoxy]-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide (Form II of Compound C)
Prepared from (S -O-(2,2-dimethyl-[l,3]dioxolan-4-ylmethyl)-hydroxylamine and 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid by the alternative procedure described above for N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide: m.p. 118-119 °C.
EXAMPLE 51 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-[(R -2.3-dihydroxy-propoxy]-3.4- difluoro-benzamide Prepared from (R -O-(2,2-dimethyl-[l,3]dioxolan-4-ylmethyl)-hydroxylamine and 5-chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid by the procedure described for N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide: m.p. 155-156 °C; [ ]= -5.1° (c=3.5 mg/mL, ethanol); XΝMR (400 MHz, DMSO-de) δ 12.03 (s, IH), 8.83 (s, IH), 7.76 (s, IH), 7.66 (d, IH J=6.8 Hz), 7.47 (d, IH, J=8.5 Hz), 6.68 (t, IH, J=6.6 Hz), 4.83 (bs, IH), 4.60 (bs, IH), 3.89-3.92 (m, IH), 3.68-3.76 (m, 2H), 3.30 (2H, partially hidden by HDO); MS (APCI+)=533.0/535.Q; Anal.calcd/found for C16H13Cl2F2IN2O4: C, 36.05/36.04; H, 2.46/2.25; N, 5.25/5.10; F, 7.13/7.18; Cl,
13.30, 13.50; I, 23.80, 24.02.
EXAMPLE 52 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-[(S -2.3-dihydroxy-propoxy]-3.4- difluoro-benzamide
Step A: A IL single necked round-bottomed flask equipped with a magnetic stircer was charged with a solution of 5-chloro-2-(2-chloro-4-iodo-phenylamino)- 3, 4-difluoro-benzoic acid (59.6 g, 135 mmol) in dry tetrahydrofuran (300 mL). The solution was cooled to 0 °C in an ice-acetone bath. To this solution was added diisopropylethylamine (34.8 g, 270 mmol), (o O-(2,2-dimethyl-
[l,3]dioxolan-4-ylmethyl)-hydroxylamine (29.7 g, 202 mmol), 1- hydroxybenzotriazole (30.93 g, 202 mmol), and benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (89.32g, 202 mmol). After 30 minutes, the cooling bath was removed, and the reaction was stirred at ambient temperature for 18 hrs. The solvent was evaporated in vacuo, and the residue was dissolved in diethyl ether. The organic solution was washed with 10% aqueous sodium hydroxide (3 x 500 mL) and brine, and dried (MgSO4).
The solution was concentrated to afford 5-chloro-2-(2-chloro-4-iodo- phenylamino)-N-((S)-2,2-dimethyl-[l,3]dioxolan-4-ylmethoxy)-3,4-difluoro- benzamide (69.9 g) as a pale yellow solid that was used directly in the next hydrolysis reaction. Step B: A 3L single necked round bottomed flask equipped with a magnetic stircer was charged with a solution of 5-chloro-2-(2-chloro-4-iodo-phenylamino)- N-((S)-2,2-dimethyl-[l,3]dioxolan-4-ylmethoxy)-3,4-difluoro-benzamide (69.9 g, 122 mmol) in tetrahydrofuran (1.5 L). Aqueous IN hydrochloric acid (500 mL) solution was added and the reaction mixture was stirced at ambient temperature for 18 hrs. The reaction mixture was concentrated and extracted with ethyl acetate (3 x 800 mL). The organic extracts were washed with saturated aqueous sodium bicarbonate (500 ml) and brine (500 ml), and dried (MgSO4). The crude pale yellow solid was recrystallized from ethyl acetate/hexane and dried at 70 °C in vacuum oven to afford 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-((S)-2,3- dihydroxy-propoxy)-3,4-difluoro-benzamide (35 g, 54%) as pale yellow crystals: m.p. 153-154 °C; [α]= +3.36° (c=1.04, methanol); 1H NMR (d6-DMSO) δ 12.02 (s, IH), 8.85 (s, IH), 7.74 (s, IH), 7.64 (d, IH), 7.45 (d, IH), 6.66 (t, IH), 4.82 (s, IH), 4.58 (s, IH), 3.88 (m, 2H), 3.74 (m, 3H); 19F NMR (d6-DMSO) δ -133.21 (s, IF), -137.18 (s, IF); MS (m/z): 534 (68), 532 (100), 483 (28), 481 (41), 440 (51). Anal.calcd/found for
Figure imgf000145_0001
C, 36.05/36.36; H, 2.46/2.38; N,
5.25/5.30; F, 7.13/7.15; Cl, 13.30/13.76; I, 23.80/23.83.
EXAMPLE 53 5-Chloro-N-r(2(R).3-dihvdroxy-propoxy1-3.4-difluoro-2-(2-fluoro-4-iodo- phenylaminoVbenzamide
Prepared from from (R O-(2,2-dimethyl-[l,3]dioxolan-4-ylmethyl)- hydroxylamine and 5-dhloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzoic acid by the procedure described above for N-[(R)-2,3-dihydroxy- propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide: m.p. 142-143 °C. 1HΝMR (400 MHz, DMSO-dg) δ 11.91 (s, IH), 8.66 (s, IH), 7.58-7.55 (m, 2H), 7.34 (d, IH, J=8.1 Hz), 6.72 (cm, IH), 4.81 (d, IH, J=4.1 Hz), 4.58 (t, IH, J=5.9 Hz), 3.87-3.84 (m, IH), 3.70-3.68 (m, 2H), 3.33 (2H, partially under HDO).
EXAMPLE 54 5-Chloro-N-[(2(S).3-dihydroxy-propoxy1-3.4-difluoro-2-(2-fluoro-4-iodo- phenylaminoVbenzamide Prepared from from (S^-O-(2,2-dimethyl-[l,3]dioxolan-4-ylmethyl)- hydroxylamine and 5-dhloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- benzoic acid by the procedure described above for N-[(R)-2,3-dihydroxy- propoxy]-3 ,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide: m.p. 157- 158 °C; [α]= +5.29° (c=1.02, methanol); 1HΝMR (400 MHz, DMSO-de) δ 11.91 (s, IH), 8.66 (s, IH), 7.58-7.55 (m, 2H), 7.34 (d, Hi J=8.1 Hz), 6.72 (cm, IH),
4.81 (d, IH τ=4.1 Hz), 4.58 (t, IH, J=5.9 Hz), 3.87-3.84 (m, IH), 3.70-3.68 (m, 2H), 3.33 (2H, partially under HDO). Anal.calcd/found for
Figure imgf000146_0001
C, 37.20/37.47; H, 2.54/2.57; N 5.42/5.32; F, 11.03/11.09; Cl, 6.86/6.87; I, 24.56/24.80.
EXAMPLE 55 2-(4-Bromo-2-fluoro-phenylamino)-N-((R)-2.3-dihydroxy-propoxy)-3.4-difluoro- benzamide Prepared in the manner of N-[2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide (Example 39) with the following exception:
Organics were dried over sodium sulfate and concentrated to afford a white foam. This was heated to 100 °C under vacuum (0.5mm) for 1 hr to afford a glass: m.p. 52 °C (shrink), 70 °C melt; [α] = -4.4 °(c = 6.8, ethanol); 1H MR (400 MHz, CD3OD) δ 7.40 [cm, IH]; 7.29 [dd, J = 11.0, 2.2 Hz, IH]; 7.16 [d, J = 8.5 Hz, IH]; 6.98 [dd, J = 16.4, 9 Hz, IH]; 6.73 [cm, IH]; 3.94 [cm, IH]; 3.83 [m, 2H];
3.55 [m, 2BTJ. Anal. Calcd/Found for C16Hι4BrF3BrN2O4: C, 44.16/43.77; H, 3.24/3.36; N, 6.44/6.09; F, 13.10/12.64; Br, 18.36/18.24. The compounds of examples 56-61 were prepared by the general procedure of example 1.
EXAMPLE 56
2-(2-Chloro-4-iodo-phenylaminoV3.4-difluoro-N-(2-vinyloxy-ethoxy)- benzamide Yield: 55%; m.p. 141.5-143.0 °C; 1H NMR (400 MHz, DMSO-de) δ 12.01 (s, 1 H), 8.84 (s, 1 H), 7.77 (d, J = 1.7 Hz, 1 H), 7.51-7.42 (m, 2 H), 7.27 (ddd, J = 9.0, 8.8, 7.8 Hz, I H), 6.59 (dd, J = 8.6, 6.4 Hz, 1 H), 6.49 (dd, J = 14.2, 6.6 Hz, 1 H),
4.19 (d, J = 14.1 Hz, 1 H), 4.06 (br s, 2 H), 3.98 (d, J = 6.6 Hz, 1 H), 3.87 (br s, 2 H); 19F NMR (376 MHz, DMSO-d6) δ -132.4, -141.4; MS (APCI+) = 495.1; MS (APCI-) = 493.0. Anal. Calcd/found for Cι7Hι4ClF2N2O3 with 0.08 moles residual C6H14: C, 41.86/41.90; H, 3.04/2.91; N, 5.59/5.72.
EXAMPLE 57 2-(2-Chloro-4-iodo-phenylamino -3.4.5-trifluoro-N-(2-vinyloxy-ethoxy)- benzamide Yield: 25%; m.p. 115-116 °C; 1H-NMR (400 MHz; DMSO-d6) δ 11.96 (s, IH), 8.42 (s, IH), 7.73 (d, IH, J=1.7 Hz), 7.59 (m, IH), 7.44 (dd, IH, J=8.6, 1.7 Hz),
6.54 (m, IH), 6.47 (dd, Hi J=14.2, 6.6 Hz), 4.15 (d, IH, J=14.2 Hz), 4.02 (s, 2H), 3.96 (dd, Hi J=6.9, 1.7 Hz), 3.83 (s, 2H); 19F-NMR (376 MHz; DMSO-d6) δ - 137.08 (d, IF, J=20.2 Hz), -140.97 (s, IF), -154.65 (s, IF); MS (APCI+) 513.0 (M+1, 100); MS (APCT) 511.0 (M-l, 65), 424.9 (100); LR (KBr) 1647 (C=O stretch), 1621, 1488 cm"1. Anal. Calcd./found for C17H13ClF3iN2θ3: C,
39.83/40.04; H, 2.56/2.54; N, 5.46/5.32.
EXAMPLE 58 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino -N-(2-vinyloxy-ethoxy -benzamide Yield: 44%; m.p. 103.5-104 °C; 1H-NMR (400 MHz; DMSO-de) δ 11.90 (s, IH),
9.62 (s, IH), 7.69 (dd, IH, J=10.5, 2.0 Hz), 7.60 (m, IH), 7.49 (d, IH, J=8.3 Hz), 7.27 (m, IH), 6.84 (d, IH J=H.7 Hz), 6.70 (m, IH), 6.52 (dd, IH, J=14.4, 6.8 Hz), 4.20 (dd, IH 1=14.4, 2.0 Hz), 4.09 (m, 2H), 3.98 (dd, IH, J=6.8, 1.7 Hz), 3.90 (m, 2H); 19F-NMR (376 MHz; DMSO-dg) δ -106.73 (s, IF), -124.58 (s, IF); MS (APCT1) 461.0 (M+1, 100); MS (APCT) 459.0 (M-l, 100); LR (KBr) 1641 (C=O stretch), 1602 cm'1. Anal.Calcd./found for C17H15F2iN2θ3: C, 44.37/44.42; H, 3.29/3.28; N, 6.09/5.89.
EXAMPLE 59 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylaminoVN-(2-vinyloxy-ethoxy - benzamide 1H-NMR (400 MHz; DMSO-de) δ l 1.89 (s, 1 H), 8.67 (s, 1 H), 7.57 (dd, 11.0,
1.7 Hz, 1 H), 7.41-7.32 (m, 2 H), 7.20 (m, 1 H), 6.66 (m, 1 H), 6.46 (dd, J= 14.2,
6.8 Hz, 1 H), 4.17 (dd, J = 14.2, 1.5 Hz, 1 H), 4.00 (br s, 2 H), 3.97 (dd, J = 6.7, 1.8 Hz, 1 H), 3.84 (br s, 2 H); 19F-NMR (376 MHz; DMSO-de) δ.-128.1(s, 1 F), - 133.1 (s, 1 F), -144.3 (d, 17.7 Hz, 1 F). Anal.Calcd./found for C17H14F3ιN2θ3: C, 42.70/42.30; H, 2.95/2.92; N, 5.86/5.52.
EXAMPLE 60 5-Chloro-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-vinyloxy-ethoxy)- benzamide Yield: 34%; m.p. 119-120 °C; 1H-NMR (400 MHz; DMSO-de) δ 11.96 (s, IH),
8.64 (s, IH), 7.59 (m, 2H), 7.35 (d, IH τ=8.3 Hz), 6.71 (m, IH), 6.48 (dd, IH, J=14.4, 6.8 Hz), 4.17 (d, Hi J=14.2 Hz), 3.98 (m, 3H), 3.84 (m, 2H); 19F-NMR (376 MHz; DMSO-de) δ -127.60 (s, IF), -134.09 (d, IF, J=15.2 Hz), -140.45 (d, IF, J=17.7 Hz); MS (APCT) 511.0 (M-l, 100); IR (KBr) 1646 (C=O stretch), 1608 cm"1. Anal.Calcd./found for C17H13ClF3LN2O3: C, 39.83/39.78; H, 2.56/2.57;
N, 5.46/5.36.
EXAMPLE 61 5-Bromo-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-vinyloxy-ethoxy)- benzamide Yield: 39%; m.p. 128-130 °C; 1H-NMR (400 MHz; DMSO-d6) δ 11.95 (s, IH), .
8.67 (s, IH), 7.69 (d, IH, J=6.4 Hz), 7.57 (dd, Hi J=10.7, 1.7 Hz), 7.35 (d, IH, J=8.1 Hz), 6.72 (m, IH), 6.48 (dd, IH, J=14.4, 6.6 Hz), 4.17 (d, IH, J=14.2 Hz), 3.98 (m, 3H), 3.83 (s, 2H); 19F-NMR (376 MHz; DMSO-de) δ -126.37 (s, IF), - 127.54 (s, IF), -140.31 (d, IF, J=17.7 Hz); MS (APCI+) 558.9 (100), 556.9 (M+1, 98); MS (APCT) 556.9 (31), 554.9 (M-l, 32), 468.9 (100); IR (KBr) 1644 (C=O stretch), 1607, 1515, 1490 cm"1. Anal.Calcd./found for C7H13BrF3LN2O3: C, 36.65/36.71; H, 2.35/2.23; N, 5.03/4.97.
The compounds of Examples 62-64 were prepared by the general procedure of example 12.
EXAMPLE 62
5-Bromo-2-(2-chloro-4-iodo-phenylamino -3.4-difluoro-N-(2-hydroxy- 1.1- dimethyl-ethoxyVbenzamide m.p.=179-181°C ; 1H ΝMR (400 MHz;DMSO-d6) δ 11.36 (s, IH), 8.48 (s, IH), 7.76 (d, Hi J=6.8), 7.72 (s, IH), 7.43 (d, IH, J=8.5), 6.59 (m, IH), 4.55 (t, IH, J=6.4), 3.20 (d, 2H, J=5.9), 1.09 (s, 6H); MS (APCI+) = 574.9/576.9.
Anal.calcd/found for C17H15BrClF2ιΝ2O3: C 35.48/35.56, H 2.63/2.53, N 4.87/4.71, F 6.60/6.68.
EXAMPLE 63 3.4-Difluoro-N-(2-rιvdroxy- 1.1 -dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylaminoVbenzamide m.p.=175-176°C ; 1H ΝMR (400MHz;DMSO-d6) δ 11.29 (s, IH), 8.15 (s, IH), 7.46 (s, IH), 7.41 (m, IH), 7.32 (d, IH, J=8.3), 7.32 (q, IH, J=16.4,8.8), 6.38 (m, IH), 4.59 (bs, IH), 3.15 (d, 2H, J=4.9), 2.17 (s, 3H), 1.08 (s, 6H); MS(APCI+)=477.0. Anal.calcd/found for C18H19F2lΝ2O3 (0.05eq CH2C12): C
45.12/44.73, H 4.01/3.96, N 5.83/5.54, F 7.91/7.71.
EXAMPLE 64 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hvdroxy-2-methyl- propoxyVbenzamide
Yield: 17%; m.p. 140-153 °C; 1H-NMR (400 MHz; DMSO-de) δ 11.94 (s, IH), 8.82 (s, IH), 7.76 (d, IH, J=1.5 Hz), 7.48 (dd, IH, J=8.5, 2.0 Hz), 7.42 (m, IH), 7.25 (m, IH), 6.57 (m, IH), 4.58 (s, IH), 3.63 (s, 2H), 1.12 (s, 6H); 19F-NMR (376 MHz; DMSO-de) δ -132.53 (s, IF), -141.45 (d, IF); MS (APCI+) 496.9 (M+1, 100); MS (APCT) 495.0 (M-l, 48), 406.9 (100); IR (KBr) 1637 cm"1 (C=O stretch). . Anal.Calcd./found for Ci7Hi6ClF2IN2O3 with 0.03 mole residual acetone: C, 41.18/41.57; H, 3.27/3.14; N, 5.62/5.31.
The compounds of examples 65-76 were prepared by the general procedure of example 38.
EXAMPLE 65
3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino - N-(2-hydroxy- 1.1 -dimethyl- ethoxyVb enzamide m.p.=182-183°C; 1HΝMR (400 MHz, DMSO-de) δ 11.25 (s, IH), 8.38 (s, IH), 7.54 (d, IH, J=11.0), 7.39 (m, IH), 7.31 (d, IH, J=8.1), 7.24 (dd, Hi J=16.9, 9.5), 6.59-6.56 (m, IH), 4.58, (m, IH), 3.16 (d, 2H J=6.3), 1.08 (s, 6H);
MS(APCI+)=481.0. Anal.calcd/found for Cι7Hi6F3rN2O3 (+0.47 C HgOz): C, 43.47/43.86; H, 3.82/3.40; N, 5.37/5.60.
EXAMPLE 66 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino - N-(2-hydroxy-l,l- dimethyl-ethoxyVbenzamide m.p.=178-180°C; 1HΝMR (400 MHz, DMSO-d6) δ 11.31 (s, IH), 8.41 (s, IH), 7.64 (d, IH, J=7.1), 7.56 (d, IH, J=11.0), 7.33 (d, IH, J=8.3), 6.69-6.65 (m, IH), 4.57 (t, Hi J=6.1), 3.19 (d, 2H, J=6.6), 1.10 (s, 6H); MS(APCI+) = 514.9/516.9. Anal.calcd/found for
Figure imgf000150_0001
C, 39.67/39.99; H, 2.94/2.74; N,
5.44/5.31; F, 11.07/ 11.05.
EXAMPLE 67 3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl-propoxy)- benzamide m.p. 156.7-156.9 °C; 1H NMR (400 MHz, DMSO-de) δ 11.85 (lH, s), 8.70 (IH, s), 7.55 (Hi dd, J=10.8Hz, 1.9Hz), 7.33-7.37 (2H, m), 7.17 (IH, dd, J=16.7Hz, 9.4Hz), 6.62-6.67 (IH, m), 4.57 (IH, br s), 3.58 (2H, s), 1.09 (6H, s). Anal. Calcd/Found for Cι7H1eF3lN2O3: C, 42.52/42.48; H, 3.36/3.21; N, 5.83/5.67; F, 11.87/11.51; 1, 26.43/26.38.
EXAMPLE 68
3.4-Difluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylaminoVbenzamide m.p. 136.2-136.5 °C; 1H NMR (400 MHz, DMSO-de) δ 11.90 (IH, s), 8.49 (IH, s), 7.50 (IH, d, J=1.7Hz), 7.34-7.41(2H, m), 7.14 (IH, dd, J=16.6Hz, 9.3Hz), 6.45 (IH, dd, J=8.4Hz, 5.6Hz), 4.97 (IH, s), 3.69-3.79 (3H, m), 3.25-3.31 (2H, m),
3.21 (3H, s), 2.21 (3H). Anal. Calcd/Found for C18H19F2rN2O4: C,43.92/44.14; H3.89/3.88; N,5.69/5.59; F, 7.72/7.79; I, 25.78/25.89.
EXAMPLE 69 5-Bromo-2-(2-chloro-4-iodo-phenylamino -3.4-difluoro-N-(2-hydroxy-3- methoxy-propoxyVbenzamide m.p. 139.5-140.1°C; 1H NMR (400 MHz, DMSO-de) δ 12.03 (IH, s), 8.83 (IH, s), 7.50-7.76 (2H, m), 7.47 (IH, dd, J=8.6Hz, 1.5Hz), 6.65-6.69(lH,m), 4.98 (IH, s), 3.70-3.90 (3H, m), 3.31 (2H, m), 3.22 (3H, s). Anal. Calcd/Found for C17Hι5BrClF2rN2O4: C,34.52/34.92; H,2.56/2.54; N,
4.74/4.67; F, 6.42/6.48; I, 21.45/21.12.
EXAMPLE 70 3.4-Difluoro-N-( 1 -hydroxymethyl-cyclopropylmethoxy -2-(4-iodo-2-methyl- phenylaminoVbenzamide m.p. 165.4-165.6°C; 1H MR (400 MHz, DMSO-de) δ 11.74 (IH, s), 8.49 (IH, s), 7.47 (IH, d, J=1.5Hz), 7.31-7.36 (2H, m), 7.11 (IH, dd, J=16.5Hz, 9.4Hz), 6.43 (IH, dd, J=8.3Hz, 5.6Hz), 4.55 (IH, br s), 3.67 (2H, s), 3.33 (2H, s), 2.17 (3H, s), 0.36 (4H, J=4.9Hz). Anal. Calcd/Found for C19H19F2rN2O3: C,46.74/46.87; H,3.92/3.93; N, 5.74/5.99; F, 7.78/7.64; I, 25.99/25.84. EXAMPLE 71
5-Bromo-2-(2-chloro-4-iodo-phenylamino -3.4-difluoro-N-(l-hydroxymethyl- cyclopropylmethoxy -benzamide m.p. 152.6-153.9°C; 1H NMR (400 MHz, DMSO-de) δ 11.88(1H, s), 8.81 (IH, s), 7.75 (IH s), 7.69 (IH, d, J=6.6Hz), 7.45 (IH, d, J=8.5Hz), 6.63-6.67 (IH, m),
4.53 (IH, br s), 3.73 (2H, s), 3.33 (2H, s), 0.36 (4H, J=4.9Hz). Anal. Calcd/Found for C18H15BrClF2LN2O3: C:36.79/37.21; H,2.57/2.57; N,4.77/4.64; F, 6.47/6.58; I, 21.60/21.78.
EXAMPLE 72
3.4-Difluoro-2-(4-iodo-2-methyl-phenylaminoVN-(3.3.3 -trifluoro-2-hydroxy- propoxyVbenzamide m.p. 175.2-175.5 °C; 1H NMR (400 MHz, DMSO-d6) δ 12.00 (Hi s), 8.41 (IH, s), 7.47 (IH), 7.40 (IH, m), 7.33 (IH, d), 7.12 (IH dd, J=16.6Hz, 9.3Hz), 6.54 (IH, br s), 6.44 (IH, dd, J=8.3Hz, 5.3Hz), 4.24 (Him), 3.83-3.98 (2H, m), 2.18
(3H, s). Anal. Calcd/Found for C17H14F5LN2O3: C,39.56/39.87; H, 2.73/2.66; N, 5.43/5.30; F, 18.40/18.32; I, 24.58/24.63.
EXAMPLE 73 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3.4-difluoro-N-(3.3.3-trifluoro-2-
' hydroxy-propoxyVbenzamide m.p. 186.9-187.3°C; 1H NMR (400 MHz, DMSO-de) δ 12.16 (IH, s), 8.77 (IH, s), 7.80 (Hi dd, J=7.0Hz, 1.5Hz), 7.75 (IH, d, J=1.7Hz), 7.47 (IH, dd, J=8.6Hz, 1.9Hz), 6.66 (IH, dd, J=8.5Hz, 5.9Hz), 6.55 (IH, br s), 4.31 (IH m), 3.92-4.07 (2H, m). Anal. Calcd/Found for C16Hι0BrClF5lN2O3: C, 31.22/31.52;
H,l.64/1.60; N,4.55/4.46; F, 15.43/15.39; I, 20.62/20.87.
EXAMPLE 74 3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N- trans-(2-hydroxymethyl- cvclopropylmethoxy ]-benzamide m.p. 128.5-128.7 °C; 1H NMR (400 MHz, DMSO-de) δ 11.71(1H, s), 8.69 (IH, s), 7.54 (IH dd, J=10.9Hz, 1.8Hz), 7.32-7.36 (2H, m), 7.17 (IH, dd, J=16.6Hz, 9.3Hz), 6.60-6.66 (IH, m), 4.43 (IH, t, J=5.6Hz), 3.54-3.65 (2H, m), 3.14-3.34 (2H, m), 0.85-0.89 (2H, m), 0.34-0.41 (2H, m). Anal. Calcd/Found for C18HιeF3rN2O3: C,43.92/44.23 ; FL3.28/3.23 ; N, 5.69/5.54; F, 11.58/11.47; I, 25.78/25.58.
EXAMPLE 75 5-Chloro-3.4-difluoro-2-(2-fluoro-4-iodo-phenylamino -N-[trans-(2- hydroxymethyl-cvclopropylmethoxy)]-benzamide m.p. 152.5-153.1 °C; 1H NMR (400 MHz, DMSO-de) δ 11.76 (IH, s), 8.65 (IH, s), 7.56 (Hi m), 7.52-7.53 (IH, m), 7.32 (IH, d, J=8.5Hz), 6.66-6.72 (IH, m),
4.44-4.47 (IH ), 3.54-3.62 (2H, m), 3.12-3.42 (2H ), 0.81-0.89 (2H, m), 0.32- 0.40 (2H, m). Anal. Calcd/Found for C18H15ClF3rN2O3: C, 41.05/41.00; H, 2.87/2.96; N, 5.31/5.13; F, 10.82/10.48; I, 24.09/24.33.
EXAMPLE 76
N-(2.3-Dihvdroxy-3-methyl-butoxy)-3.4-difluoro-2 (2-fluoro-4-iodo- phenylamino)-benzamide m.p.=180-183°C; 1H MR (400 MHz, DMSO-d6) δ 11.85 (s, IH), 8.69 (bs, IH),
7.56 (d, Hi J=10.7), 7.40 (m, IH), 7.35 (d, IH, J=9.0), 7.20 (dd, IH J=16.6, 8.3), 6.65 (m, IH), 4.87 (bs, IH), 4.31 (s, IH), 4.07 (d, IH, J=9.8), 3.65 (t, IH, J=9.8),
3.44-3.41 (m, IH), 1.05 (s, 3H), 0.97 (s, 3H); MS(APCI+)=511.1.
Anal.calcd/found for C18H18F3LΝ2θ4 (+0.22 eq CdisO^: C, 42.82/43.20; H,
3.76/3.61; N, 5.29/5.15.
EXAMPLE 77
2-(2-Chloro-4-iodo-phenylamino -3.4-difluoro-N-(2-phenylamino-ethoxy)- benzamide The title compound was prepared in the manner described for example 1. A white solid: m.p.157.8 °C; 1H NMR (400 MHz, DMSO-de) δ 11.3 (s, IH), 7.70 (m, 2H), 7.44 (dd, J=8.6 Hz, 1.95 Hz, IH), 7.01 (t, J=8.1 Hz, 2H), 6.94 (t, J=9.2 Hz,
IH), 6.47 (m, 4H), 5.58 (brt, J=5.1 Hz, IH), 3.91 (t, J=5.6 Hz, 2H), 3.19 (q, J=5.6 Hz, 2H); 19F NMR (376 MHz, DMSO-d6) δ -139.77 (s, IF), -143.39 (d, J=20.2 Hz, IF). EXAMPLE 78 3.4-Difluoro-2-(4-iodo-2-methyI-phenylamino)-N-(2-methylamino-ethoxy - benzamide Step A: To a solution of (2-aminooxy-ethyl)-methyl-carbamic acid tert-butyl ester
(0.63 g, 3.31 mmol) and diisopropylethylamine (0.6 mL, 3.44 mmol) in dimethylformamide (10 mL) was added 3,4-Difluoro-2-(4-iodo-2-methyl- phenylamino)-benzoic acid pentafluorophenyl ester (1.66 g, 2.99 mmol). The resultant reaction mixture was stirced 5 h at ambient temperature and concentrated under reduced pressure. The residue was diluted with ether (100 mL), washed with water (2 x 25 mL) and brine (2x 25 mL), dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography. Elution with dichloromethane afforded [2-({l-[3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-phenyl]-methanoyl}-aminooxy)-ethyl]-methyl-carbamic acid tert- butyl ester (1.05 g, 62%) as a white foam: 1H NMR (400 MHz, DMSO-de) δ 11.85 and 11.80 (br s, 1 H), 8.49 (br s, 1 H), 7.50 (s, 1 H), 7.39 (m, 1 H), 7.35 (d, J = 8.3 Hz, 1 H), 7.14 (m, 1 H), 6.46 (dd, J = 7.8, 5.9 Hz, 1 H), 3.85 (br s, 2 H), 3.35 (br s, 2 H), 2.79 (br s, 3 H), 2.21 (s, 3 H), 1.36 and 1.33 (s, 9 H); 19F NMR (376 MHz, DMSO-de) δ -132.9, -143.3 (d, J = 17.7 Hz); MS (APCI+) = 562.1. Step B: Trifluoroacetic acid (3.0 mL, 39 mmol) was added to a 0 °C solution of
[2-({l-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanoyl}- aminooxy)-ethyl]-methyl-carbamic acid tert-butyl ester (0.75 g, 1.3 mmol) in dichlormethane (12 mL). The resultant solution was stirred 2.5 h at 0 °C and diluted with ether (50 mL). Water (20 mL) was added and, with vigorous stirring, the pH ofthe aqueous layer was adjusted to pH 8 with saturated aqueous sodium bicarbonate. The heterogeneous mixture was stirced 30 min and the precipitate was removed by filtration and washed with water-ethanol (2:1) and acetone. The solid (471 mg) was dried overnight in vacuo and was further triturated with hot methanol and dried at 70 °C under reduced pressure to afford 3,4-difluoro-2-(4- iodo-2-methyl-phenylamino)-N-(2-methylamino-ethoxy)-benzamide (272 mg) as a white powder: m.p. 183-185 (dec); 1HNMR (400 MHz, DMSO-de) δ 10.33 (s, 1 H), 7.69 (t, J = 7.0 Hz, 1 H), 7.46 (d, J = 1.7 Hz, 1 H), 7.33 (dd, J = 8.6, 2.0 Hz, 1 H), 6.95 (app q, J = 9.0 Hz, 1 H), 6.40 (t, J = 7.8 Hz, 1 H), 3.87 (br t, J = 4.4 Hz, 2 H), 2.82 (br s, 2 H), 2.47 (s, 3 H), 2.24 (s, 3 H); 19F NMR (376 MHz, DMSO-de) δ -137.7 (d, J = 7.6 Hz), -143.3 (d, J = 20.2 Hz). Anal Calcd./Found for Cι7Hι8F2LN3O2+0.07 GJHJOO: C, 44.50/44.61; H, 4.01/3.97; N, 9.01/8.72.
EXAMPLE 79 3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methylamino-ethoxy - benzamide. hydrochloride salt Step A: A solution of 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid (3.11 g, 7.91 mmol) in tetrahydrofuran (20 mL) was cooled with a -40 °C bath and treated with N-methylmorpholine (0.87 mL, 7.9 mmol). Diphenylphosphinic chloride (2.00 mL, 10.5 mmol) was added dropwise over 5 min and the reaction mixture was stirced for 90 min, during which time the temperature ofthe cooling bath slowly warmed to 0 °C. The reaction mixture was again cooled to -40 °C and (2-aminooxy-ethyl)-methyl-carbamic acid tert-butyl ester (2.00 g, 10.5 mmol) was added as a solution in tetrahydrofuran (6 mL). After an additional 10 min, N- methylmorpholine (1.33 mL, 12.1 mmol) was added. The temperature ofthe cooling bath was allowed to warm to ambient temperature over 4 h and the reaction mixture was further stirced overnight. The reaction was diluted with ethyl acetate (40 mL) and washed with saturated aqueous ammonium chloride (2 x
10 mL). The organics were dried over magnesium sulfate, concentrated and purified by silica gel chromatography. Elution with 35% ethyl acetate-hexanes afforded [2-({ 1 -[3 ,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]- methanoyl}-aminooxy)-ethyl]-methyl-carbamic acid tert-butyl ester (3.28 g, 73% yield) as an off-white foam: 1H NMR (400 MHz, DMSO-d6) δ 11.84 and 11.75
(br s, 1 H total), 8.66 (br s, 1 H), 7.54 (dd, J = 10.9, 1.6 Hz, 1 H), 7.36 (br t, J = 8.8 Hz, 1 H), 7.33 (br d, J = 8.8 Hz), 7.20 (m, 1 H), 6.64 (m, 1 H), 3.85 (t, J = 5.2 Hz, 2 H), 3.34 (br s, 2 H), 2.81 and 2.79 (br s, 3 H total), 1.34 and 1.32 (s, 9 H total); 19F NMR (376 MHz, DMSO-d6) δ -128.0 (d, J = 32.9 Hz), -133.0, -144.2 (d, J = 17.7 Hz); MS (APCI-) = 564.1.
Step B: [2-({ l-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylammo)-phenyl]- methanoyl}-aminooxy)-ethyl]-methyl-carbamic acid tert-butyl ester (3.28 g5 5.80 mmol) was dissolved in ethereal hydrogen chloride solution (20 mL, 1.0 M in diethyl ether). The resultant solution was stirced at ambient temperature for 48 h, during which precipitation of a white solid ensued. Hexanes (20 mL) was added and the reaction mixture was stirred vigorously for an additional 20 min. The reaction mixture was filtered, and the filter cake was broken up with a spatuala.
The solid was washed with hexanes (50 mL) and ether (20 mL) and was dried in vacuo to afford a free-flowing, tan-colored powder (2.46 g, 85% yield). Recrystallization from acetonitrile afforded colorless needles: m.p. 173-176 °C; 1H NMR (400 MHz, DMSO-dg) δ 12.27 (s, 1 H), 8.76 (br s, 2 H), 8.64 (s, 1 H), 7.55 (dd, J = 11.0, 1.9 Hz, 1 H), 7.47 (dd, J = 7.1, 6.3 Hz, 1 H), 7.33 (d, J = 8.3
Hz, 1 H), 7.23 (dt, J = 7.6, 9.2 Hz, 1 H), 6.64 (td, J = 8.8, 4.2 Hz, 1 H), 4.05 (t, 4.9 Hz, 2 H), 3.11 (br s, 2 H), 2.56 (t, J = 4.6 Hz, 3 H); 19F NMR (376 MHz, DMSO- de) δ -128.2 (t, J = 10.1 Hz), -132.5 (d, J = 20.2 Hz), -144.0 (d, 20.2 Hz). Anal Calcd./Found for
Figure imgf000156_0001
C, 38.31/38.20; H, 3.21/3.10; N, 8.38/8.34; F, 11.36/11.21; Cl, 7.07/7.05.
EXAMPLE 80 3.4-Difluoro-2-(4-iodo-2-methyl-phenylamino -N-[2-(2.2.2-trifluoro-ethylamino - ethoxy]-benzamide; hydrochloride Step A: Diethylazodicarboxylate (3.60 mL, 22.9 mmol) was added dropwise over 30 min to a solution comprised of O-[2-(2,2,2-trifluoro-ethylamino)-ethyl]- hydroxylamine (3.19 g, 22.3 mmol, prepared as inJ. Am. Chem. Soc. 1979, 101, 4300), triphenylphosphine (6.05 g, 23.1 mmol), and N-hydroxyphthalimide (3.65 g, 22.4 mmol). The resultant reaction mixture was stirced at ambient temperature. After 20 h, the reaction mixture was concentrated and the residue was dissolved in
60 mL of warm chloroform. Upon cooling, crystallization of diethyl 1,2- hydrazaine dicarboxylate ensued. The precipitate was filtered and the filtrate was concentrated and further diluted with ether. A single crystal of triphenylphosphine oxide was added, initiating copious precipitation. The resultant precipitate was removed by filtration and the filtrate was concentrated in vacuo and chromatographed on silica gel. Elution with hexanes-ethyl acetate (2:1) afforded 2-[2-(2,2,2-trifluoro-ethylamino)-ethoxy]-isoindole-l,3-dione (4.05 g, 63% yield) as a colorless oil: 1H NMR (400 MHz, CDC13) δ 7.84-7.73 (m, 4H), 4.30 (t, J=4.8 Hz, 2H), 3.26 (q, J=9.5 Hz, 2H), 3.00 (t, J=4.9 Hz, 2H), 2.33 (br s, IH); MS (APCI+) = 289.0.
Step B: Dichloromethane (5 mL) was added to 2-[2-(2,2,2-trifluoro-ethylamino)- ethoxy]-isoindole-l,3-dione (0.46 g, 1.6 mmol) and the resultant solution was cooled to 0 °C. Methylhydrazine (0.086 mL, 1.62 mmol) was added and the resultant solution was stirced at ambient temperature for 1 h. Ether (20 mL) was added and the precipitate was filtered and the filtrate was concentrated in vacuo. Dimethylformamide (5 mL) was added and the resultant solution was treated sequentially with 3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid pentafluorophenyl ester (0.847 g, 1.51 mmol) and diisopropylethylamine (0.60 mL, 3.4 mmol). The resultant reaction mixture was stirced overnight, diluted with ethyl acetate and washed with water (4x) and saturated brine, dried over magnesium sulfate and concentrated in vacuo. Purification by silica gel chromatography (hexanes-ethyl acetate, 1:1) afforded 3,4-difluoro-2-(4-iodo-2- methyl-phenylamino)-N- [2-(2, 2,2-trifluoro-ethylamino)-ethoxy] -b enzamide (0.70 g, 83% yield) as a waxy foam: 1H NMR (400 MHz, Acetone-de) δ 10.98 (br s, IH), 8.69 (br s, IH), 7.52 (br s, 2H), 7.39 (dd, J=8.6 Hz, 2.0 Hz, IH), 7.00 (m, IH), 6.55 (dd, J=8.6 Hz, 6.4 Hz, IH), 3.27 (q, J=10.0 Hz, 2H), 2.90 (br t, J=4.9 Hz, 2H), 2.82 (br s, 2H), 2.30 (s, 3H); 19F NMR (376 MHz, Acetone-de) δ -73.1 (t,
J=10.0Hz, 3F), -133.8 (s, IF), -143.2 (s, IF); MS (APCI+) = 530.0. Step C: The hydrochloride salt was prepared by treatment of a solution of 3,4- difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2,2,2-trifluoro-ethylamino)- ethoxy]-benzamide (375 mg, 0.708 mmol) in ether (5 mL) with ethereal hydrogen chloride (2 mL, 1.0 M in ether) and precipitation by addition of hexanes (50 mL).
The resultant solid was dried in vacuo at 75 °C overnight to afford a straw-colored powder: 1H NMR (400 MHz, Acetone-de) δ 12.35 (br s, IH), 8.84 (br s, IH), 7.73 (br s, IH), 7.54 (s, IH), 7.40 (dd, J=8.4 Hz, 1.9 Hz, IH), 7.00 (apparent q, J=8.4 Hz, IH), 6.58 (dd, J=8.4 Hz, 6.40 Hz, IH), 4.43 (br s, 2H), 4.17 (br q, 2H), 3.59 (br s, 2H), 2.30 (s, 3H); 19F NMR (376 MHz, Acetone-de) δ -68.39 (s, 3F), -
133.07 (s, IF), -143.20 (s, IF). Anal Calcd./Found for C18H17F5IN3O2+0.86 HC1: C, 38.57/38.77; H, 3.21/3.04; N, 7.49/7.19; Cl, 5.44/5.66. EXAMPLE 81 2-(2-Chloro-4-iodo-phenylamino -4-fluoro-N-(2-hvdroxy-ethoxy)-N-methyl- benzamide A solution of 2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-ethoxy)- benzamide (0.460 g, 1.02 mmol) in dimethylformamide (10 mL) was sequentially treated with potassium carbonate (0.61 g, 4.4 mmol) and iodomethane (0.075 mL, 1.2 mmol). The resultant reaction mixture was stirced 1 h at ambient temperature, was diluted with excess water and was extracted with ethyl acetate. The organic extracts were washed with brine, dried over magnesium sulfate and concentrated in vacuo. Chromatography on silica gel afforded a white solid (200 mg). Further purification by chromatography on C-18 reverse phase silica gel (30% water- acetonitrile) afforded 2-(2-chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy- ethoxy)-N-methyl-benzamide (139 mg, 29% yield) as a white foam: 1HNMR (400 MHz, Acetone-de) δ 8.45 (s, 1 H), 7.79 (d, J = 2.0 Hz, 1 H), 7.69 (dd, J = 8.8,
6.6 Hz, 1 H), 7.60 (dd, J = 8.5, 2.0 Hz, 1 H), 7.28 (d, J = 8.5 Hz, 1 H), 7.09 (dd, J = 11.4, 2.3 Hz, 1 H), 6.77 (td, J = 8.6, 2.5 Hz, 1 H), 3.90 (t, J = 2 H), 3.85 (br m, OH), 3.58 (t, J = 4.5 Hz, 2 H), 3.38 (s, 3 H); 19F-NMR (376 MHz, Acetone-de) δ - 109.8 (dd, J = 10.1, 7.6 Hz); MS (APCI+) = 465.0.
EXAMPLE 82 Acetic acid 2-(f l-[3.4.5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]- methanoyll-aminooxyVethyl ester To a 0 °C solution of 3,4,5-trifluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide (0.25g, 0.536 mmol) in THF (10.72 mL) was added triethylamine (0.113 mL, 0.804 mmol). After 5 min, acetyl chloride (0.039 mL, 0.536 mmol) was added to the cold solution, which immediately produced a precipate. After stirring for 50 min between 0-5 °C, the reaction mixture was partitioned between water (20 mL) and ethyl acetate (20mL). The aqueous layer was extracted with ethyl acetate (20 mL). The organic layers were combined and dried over anhydrous magnesium sulfate. The resultant mixture was filtered and the filter cake was thoroughly rinsed with ethyl acetate. The filtrate was concentrated in vacuo to obtain a yellow oil (0.1755g). Chromatographed crude oil using a gradient of hexanes and ethyl acetate. Combined fractions and removed the solvent in vacuo to obtain a solid. The solid was recrystahzed in a mixture of hexanes/acetone to afford 0.0221g (8%) of a solid; 1H NMR (400 MHz, Acetone-de): δ 10.15 (br s, IH), 8.49 (br s, IH), 7.88 (t, J=0.9Hz, 1H),7.56
(s, IH), 7.43 (d, J=8.3Hz, IH), 6.69 (dd, J=8.55, 5.86Hz, IH), 4.53 (br s, 2H), 4.19 (br s, 2H), 2.33 (s, 3H), 1.81 (br s, 3H). 19F NMR (375 MHz, Acetone-de): δ -139.52 (br t, IF), -146.62 (br q, IF), -153.43 (br s, IF). Anal. Calcd/Found for Cι8H16F3ιN2O4: C, 42.54/40.87; H, 3.17/2.98; N, 5.51/5.17.
EXAMPLE 83 [3.4-Difluoro-2-(2-fluoro-4-iodo-ρhenylamino -phenyl]-(4-hydroxy-isoxazolidin-
2-yl)-methanone To a stircing solution of 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic • acid pentafluorophenyl ester (171 mg, 0.306 mmol) and 4- hydroxytetrahydroisoxazol-2-ium chloride (BIONET, 58 mg, 0.46 mmol) in dimethylformamide (2 mL) was added 4-methylmorpholine (0.1 mL, 0.91 mmol). The resultant reaction mixture was stirced at ambient temperature for 3 h. Ethyl acetate (50 mL) was added the mixture was washed with water (3 x 10 mL) and saturated brine solution (10 mL). The extracts were dried over magnesium sulfate and concentrated in vacuo. Chromatography (10% methanol-dichloromethane) afforded a tan-colored oil that solidified upon standing. Recrystallization from acetone-ether afforded [3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]- (4-hydroxy-isoxazolidin-2-yl)-methanone (61 mg, 43% yield) as a white powder: m.p. 122-124 °C; 1H NMR (400 MHz, Acetone-de) δ 7.97 (br s, 1 H), 7.51-7.45
(m, 2 H), 7.38 (ddd, J = 8.6, 1.7, 1.2 Hz, 1 H), 7.12 (m, 1 H), 6.68 (td, J = 8.8, 5.2 Hz, 1 H), 4.82 (m, 1 H), 4.71 (br d, J = 4.2 Hz, OH), 3.98 (dd, J = 8.8, 4.2 Hz, 1 H), 3.96-3.88 (m, 2 H), 3.75 (dd, J = 11.8, 0.9 Hz, 1 H); 19F-NMR (376 MHz, Acetone-de) δ -30.5, -135.4, -144.4. Anal Calcd/Found C16H12F3LN2O3: C, 41.40/41.52; H, 2.61/2.53; N, 6.03/6.05. EXAMPLE 84
5-Bromo-N-(2.3-dihydroxy-propoxy -3.4-difluoro-2-(2-fluoro-phenylamino)- benzamide A solution of 5-bromo-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide (0.240g, 0.429 mmol) and triethylamine (0.2g,
1.98 mmol) in tetrahydrofuran (16 mL) was hydrogenated over Raney Nickel (0.12g, pre-rinsed with tetrahydrofuran) at 10 psig at room temperature for a total of 7 hours. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The afforded residue was partitioned between ethyl acetate and water. The organics were washed twice with water, twice with saturated brine, collected, dried over sodium sulfate, filtered and concentrated in vacuo. HPLC purification was performed using a YMC 3 Ox 100mm 5u (C18) column in 0-100% acetonitrile (3.0% n-propanol)/ 100-0% water (3.0% n-proρanol)at 30 mL/min. The desired fractions were collected, concentrated and dried in a vacuum oven overnight at 50°C to afford 5-bromo-N-(2,3-dihydroxy-propoxy)-
3,4-difluoro-2-(2-fluoro-phenylamino)-benzamide as a white solid (0.054g, 30%): m.p.=143.5-144.5°C; JΝMR (400 MHz, DMSO-d6) δ 11.95 (bs, IH), 8.74 (bs, IH), 7.68 (d, IH, J=6.1 Hz), 7.17 (t, IH, J=9.8 Hz), 7.01-7.04 (m, IH), 6.94 (m, 2H), 4.81 (m, IH), 4.57 (m, IH), 3.86 (m, IH), 3.69-3.71 (m, 2H), 3.3, (2H, under HDO); MS(APCI+)=435.0/437.0.
EXAMPLE 85 N-(2.3-Dihydroxy-propoxy)-3.4-difluoro-2-(2-fluoro-phenylamino)-benzamide A solution of N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide (0.260g, 0.539 mmol) and triethylamine (2.0 mL,
14.3 mmol) in tetrahydrofuran (14 mL) was hydrogenated over Raney Nickel (0.2g wet) at 50 psig at room temperature for 20 hours. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The afforded residue was partitioned between ethyl acetate and water. The organics were washed twice with saturated sodium bicarbonate solution, twice with water, collected, dried over sodium sulfate, filtered and concentrated in vacuo. HPLC purification was performed using a YMC 30x100mm 5u (C18) column in 0-100% acetonitrile (3.0% n-ρropanol)/100-0% water (3.0% n-propanol) at 30 mL/min. The desired fractions were collected and concentrated. The afforded residue was extracted with ethyl acetate/water. Organic layers were washed with saturated NaCl solution, collected and dried in vacuo to afford N-(2,3-dihy droxy-propoxy)-3, 4- difluoro-2-(2-fluoro-phenylamino)-benzamide as a white solid (0.061g, 31%): m.p.=113-115°C; ΝMR (400 MHz;DMSO-d6) δ .11.90 (s, IH), 8.73 (s, IH), 7.37 (m, IH), 7.10-7.19 (m, 2H), 7.02 (t, IH, J=7.4 Hz), 6.84-6.93 (m, 2H), 4.82 (m, IH), 4.57-4.58 (m, IH), 3.86-3.88 (m, IH), 3.67-3.73 (m, 2H), 3.3 (2H, under HDO); MS(APCI+)=357.1; Anal.calcd/found for C16H15F3N O4: C, 53.94/53.97; H, 4.24/4.37; N, 7.86/7.83.
EXAMPLES 86-97 Examples 86 to 97 were prepared utilizing combinatorial synthetic methods, as detailed below, by the combination ofthe respective alkoxyamine and pentafluorophenyl ester, prepared as described above. General Procedure:
Step A: An array of 2-dram vials was charged with the appropriate pentafluorophenyl ester diarylamine (0.12 mmol) as a solid and diluted with 2 mL of N,N-dimethylformamide. Using a bulk dispenser, each reaction was charged with 0.2 grams of polymer-supported morpholine resin (commercially available from Novabiochem or prepared by the method of Booth and Hodges: J. Am.
Chem. Soc, 1997, 119, 4842). Solutions were prepared ofthe hydroxylamine acetonides in N, N-dimethylformamide (0.8M, 1.6mL) and dispensed (0.1 mmol, 0.2 mL) into the corresponding reaction vial. The reactions were sealed with teflon coated caps and were allowed to shake on an orbital shaker for 5 days at ambient temperature. The 14 reactions were charged with 0.2 grams of polymer- supported tris(2-aminoethyl)amine [Novabiochem; see also: Booth, R. J.; Hodges, J. C. J Am. Chem. Soc, 1997, 119, 4842.], 0.1 grams of polymer-supported methylisocyanate [Novabiochem; see also: Booth, R. j.; Hodges, j. C. J. Am. Chem. Soc, 1997, 119, 4842.], and 1 mL of dichloromethane. The reaction vessels were resealed and allowed to shake an additional 6 hours at ambient temperature. The reactions were filtered through a Specdisk 3 A filter and rinsed with 6 mL of a 10% methanol/dichloromethane solution and concentrated via a nitrogen stream.
Step B: The resulting acetonide benzamides were charged with 2 mL of methanol, 0.05 mL of deionized water, approximately 2 milligrams ofp- toluenesulfonic acid, and 0.1 grams of glycerol resin. Reactions were sealed with teflon coated caps and allowed to shake for 17 hours. The reactions were filtered through a Specdisk 3 A filter and washed with 6 mL of 50% methanol in dichloromethane and concentrated via a nitrogen stream. Purification was performed on all samples using a SQ1600 Combi-Flash column eluting with acetonitrile/water (0.05% trifluoroacetic acid). LC/MS was performed using CPI
120SE C18 column (4.6x 50 μm) eluting with acetonitrile/water (0.05% trifluoroacetic acid).
Figure imgf000163_0001
Figure imgf000164_0001
EXAMPLES 98-235
Examples 98-235 were prepared utilizing combinatorial synthetic methods, as detailed below, by the combination ofthe respective alkoxyamine and pentafluorophenyl ester, prepared as described above. General Procedure: Two- dram vials were each charged with 100-110 mg of polymer-supported morpholine (3.55 mmol N/g) employing a bulk resin dispenser. [Polymer-supported morpholinomethyl resin is commercially available (Novabiochem) or may be prepared by the method of Booth and Hodges: J Am. Chem. Soc, 1997, 119, 4842.] The appropriate vials were treated sequentially with a 0.08 M stock solution ofthe alkoxyamine in DMF (0.6 mL, 0.048 mmol) and a 0.12 M stock solution ofthe pentafluorophenyl ester in DMF (0.48 mL, 0.0576 mmol, 1.2 eq). The vials were sealed with Teflon-lined caps and agitated on an orbital shaker at ambient temperature. After 48 h, the reaction mixtures were treated with polymer-supported tris(2-aminoethyl)amine (100 mg, 4.28 mmol/g) [Novabiochem; see also: Booth, R. J.; Hodges, J. C. J. Am. Chem. Soc, 1997, 119, 4842.] and dichloromethane (1.0 mL). The vials were capped again and shaken an additional 6 h. The solids were removed by filtration though a Speckdisc 3 A filter and washed with 10% methanol-dichloromethane solution (3 x 2mL). The filtrates were concentrated under a stream of nitrogen and purified by HPLC using a SQ1600 Combiflash column eluting with acetonitrile/water (0.05% trifluoroacetic acid). LC/MS was performed using CPI 120SE C18 column (0.0046x 0.050 mm) eluting with acetonitrile/water (0.05% trifluoroacetic acid).
Example Compound Formula Exact Mass
No. (APCI+)
98 5-Bromo-2-(2-chloro-4- C1eHι3BrClF2LN2O3 561/563 (M+1) iodo-phenylamino)-3,4- difluoro-N-(3 -hydroxy- propoxy)-benzamide
99 2-(2-Chloro-4-iodo- C16Hι4ClF2IN2O3 483 (M+1) phenylamino)-3 ,4-difluoro- N-(3 -hydroxy-propoxy)- benzamide
100 3,4,5-Trifluoro-N-(3- C17Hi6F3rN2θ3 481 (M+1) hydroxy-propoxy)-2-(4- iodo-2-methyl- phenylamino)-benzamide
101 2-(2-Chloro-4-iodo- C16H13CIF3IN2O3 501 (M+1) phenylamino)-3 ,4, 5 - trifluoro-N-(3 -hydroxy- propoxy)-benzamide
102 5-Bromo-3 ,4-difluoro-N-(3 - Cι7Hι6BrF2LN2O3 541/543 (M+1) hydroxy-propoxy)-2-(4- iodo-2-methyl- phenylamino)-benzamide
103 3 ,4-Difluoro-N-(3 -hydroxy- C17H17F2LN2O3 463 (M+1) propoxy)-2-(4-iodo-2- methyl-phenylamino)- benzamide
104 2-(2-Chloro-4-iodo- CI7H16C1F2ΓN2O3 496.9 (M+1) phenylamino)-3 ,4-difluoro- N-(2-hydroxy-butoxy)- benzamide
105 2-(2-Chloro-4-iodo- C17H15ClF3iN2O3 514.9 (M+1) phenylamino)-3 ,4, 5- trifluoro-N-(2-hydroxy- butoxy)-benzamide
106 3,4,5-Trifluoro-N-(2- C18Hi8F3IN2O3 494.9 (M+1) hydroxy-butoxy)-2-(4-iodo- 2-methyl-phenylamino)- benzamide
107 5-Bromo-2-(2-chloro-4- Cι7Hι5BrClF2LN2O3 574.8/576.8 iodo-phenylamino)-3,4- (M+1) difluoro-N-(2-hydroxy- butoxy)-benzamide
108 5-Bromo-3,4-difluoro-N-(2- Cι8H18BrF2rN2O3 554.9/556.9 hydroxy-butoxy)-2-(4-iodo- (M+1) 2-methyl-phenylamino)- benzamide
109 3 ,4-Difluoro-N-(2-hydroxy- CI8H19F2ΓN2O3 476.9 (M+1) butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide
110 5-Chloro-2-(2-chloro-4- C17H15Cl2F2LN2O3 530.8 (M+1) iodo-phenylamino)-3,4- difluoro-N-(2-hydroxy- butoxy)-benzamide
111 5-Chloro-3,4-difluoro-N-(2- Cι8H18ClF2IN2O3 510.9 (M+1) hydroxy-butoxy)-2-(4-iodo- 2-methyl-phenylamino)- benzamide
112 3 ,4-Difluoro-2-(2-fluoro-4- C17Hi6F3IN2O3 481.1 (M+1) iodo-phenylamino)-N-(2- hydroxy-butoxy)-benzamide
113 5-Bromo-3,4-difluoro-2-(2- C17H15BrF3LN2O3 559.0/561.0 fluoro-4-iodo-phenylamino)- (M+1) N-(2-hydroxy-butoxy)- benzamide 5-Chloro-3 ,4-difluoro-2-(2- C17HI5CIF3ΓN2O3 515.1 (M+1) fluoro-4-iodo-phenylamino)- N-(2-hydroxy-butoxy)- benzamide
4,5-Difluoro-2-(2-fluoro-4- C17H16F3ΓN O3 481.1 (M+1) iodo-phenylamino)-N-(2- hy droxy-butoxy)-b enzamide
5-Chloro-2-(2,4-difluoro- C17 H15 Cl F4 N2 O3 407.4 (M+1) phenylamino)-3 ,4-difluoro- N-(2-hydroxy-butoxy)- benzamide
2-(2,4-Difluoro- C17 Hι6 F4 N2 O3 373.5 (M+1) phenylamino)-3,4-difluoro- N-(2-hydroxy-butoxy)- benzamide
2-(4-Bromo-2-fluoro- Cι7 H16 Br F3 N2 O3 433.3/435.3 (M+1) phenylamino)-3 ,4-difluoro- N-(2-hydroxy-butoxy)- benzamide
5-Chloro-3 ,4-difluoro-N-(2- Cι7H16ClF2ιN2O3 496.9 (M+1) hydroxy- 1 -methyl-ethoxy)- 2-(4-iodo-2-methyl- phenylamino)-benzamide
2-(2-Chloro-4-iodo- Cι6Hι4ClF2rN2θ3 482.9 (M+1) phenylamino)-3,4-difluoro- N-(2-hydroxy- 1 -methyl- ethoxy)-benzamide
2-(2-Chloro-4-iodo- C1eH13ClF3lN2θ3 500.9 (M+1) phenylamino)-3 ,4,5- trifluoro-N-(2-hydroxy- 1 - methyl-ethoxy)-benzamide
3,4,5-Trifluoro-N-(2- CπHieFgLNzOg 480.9 (M+1)
Figure imgf000169_0001
Figure imgf000170_0001
methoxy-ethoxy)-benzamide
139 5-Bromo-2-(2-chloro-4- C1eH13BrClF2IN2O3 560.8/562.8 iodo-phenylamino)-3,4- (M+1) difluoro-N-(2-methoxy- ethoxy)-benzamide
140 5 -Chloro-2-(2-chloro-4- C16Hi3Cl2F2rN2θ3 516.8 (M+1) iodo-phenylamino)-3,4- difluoro-N-(2-methoxy- ethoxy)-b enzamide
141 5-Chloro-3 ,4-difluoro-2-(4- C17H16ClF2iN2O3 496.9 (M+1) iodo-2-methyl- phenylamino)-N-(2- methoxy-ethoxy)-benzamide
142 5-Chloro-3,4-difluoro-2-(2- Ci6H13ClF3IN2O3 501.1 (M+1) fluoro-4-iodo-phenylamino)- N-(2-methoxy-ethoxy)- benzamide
143 2-(2-Chloro-4-iodo- C20H2iClF2lN3O4 568.0 (M+1) phenylamino)-3 ,4-difluoro- N-(2-hydroxy-3 -morpholin- 4-yl-propoxy)-benzamide
144 5-Bromo-2-(2-chloro-4- C2oH2oBrClF2IN3O4 645.9/647.9 (M+1) iodo-phenylamino)-3 ,4- difluoro-N-(2-hydroxy-3 - morpholin-4-yl-propoxy)- benzamide
145 2-(2-Chloro-4-iodo- C2oH20ClF3IN3θ4 585.9 (M+1) phenylamino)-3 ,4, 5 - trifluoro-N-(2-hydroxy-3 - morpholin-4-yl-propoxy)- benzamide
146 3,4,5-Trifluoro-N-(2- C2ιH23F3IN3O4 566.0 (M+1)
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
fluoro-4-iodo-phenylamino)- N-( 1 -hydroxymethyl- cyclopropylmethoxy)- benzamide
221 4,5-Difluoro-2-(2-fluoro-4- CI8H16F3ΓN2O3 493.1 (M+1) iodo-phenylamino)-N-(l- hydroxymethyl- cyclopropylmethoxy)- benzamide
222 2-(2,4-Difluoro- C18HιeF4N2O3 385.4 (M+1) phenylamino)-3 ,4-difluoro- N-( 1 -hydroxymethyl- cyclopropylmethoxy)- benzamide
223 2-(4-Bromo-2-fluoro- Cι8H1eBrF3N2O3 445.3/447.3 (M+1) phenylamino)-3 ,4-difluoro- N-( 1 -hydroxymethyl- cyclopropylmethoxy)- benzamide
224 2-(4-Chloro-2-fluoro- C18Hi6ClF3N2O3 401.4 (M+1) phenylamino)-3 , 4-difluoro- N-( 1 -hydroxymethyl- cyclopropylmethoxy)- benzamide
225 5-Chloro-2-(2,4-difluoro- Cι8H15ClF4N2O3 419.1 (M+1) phenylamino)-3 ,4-difluoro- N-( 1 -hydroxymethyl- cyclopropylmethoxy)- benzamide
226 2-(2,4-Difluoro- C17H16F4N2O4 389.4 (M+1) phenylamino)-3,4-difluoro- N-(2 -hydroxy-3 -methoxy-
Figure imgf000183_0001
Figure imgf000184_0001
EXAMPLE 236 3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino -N-((S)-3-hydroxy-2-methylamino- propoxy)-b enzamide Step A: N-Boc-O-Benzyl-L-Serine (8.86 g, 30.0 mmol) was dissolved in tetrahydrofuran (94 mL) and the resultant solution was cooled with a 0 °C ice bath. Methyl iodide (15.0 mL, 241 mmol) was added in one portion. After 5 min, sodium hydride (60 % dispersion in mineral oil, 3.6 g, 90 mmol) was added in three portions during 10 min. The resultant reaction mixture was stirred under nitrogen for 76 h while the cooling bath temperature was maintained at 0 °C. The reaction mixture was diluted with cold (0-5 °C) ethyl acetate (150 mL) and water (1.5 mL) was added dropwise over 10 min. The cooling bath temp was allowed to slowly warm to ambient temperature overnight. The reaction mixture was concentrated to a viscous oil on a rotary evaporator without heating. The residue was partitioned between ether (100 mL) and water (300 mL). The ethereal layer was further washed with saturated aqueous sodium bicarbonate (150 mL). The combined aqueous portions were acidified to pH 3 using aqueous citric acid (2 M) and were extracted with ethyl acetate (3 x 150 mL). The combined extracts were washed with water (2 x 150 mL) and 5% aqueous sodium thiosulfate (150 mL), dried over magnesium sulfate and concentrated on a rotary evaporator (without heating) to afford (S)-3-Benzyloxy-2-(tert-butoxycarbonyl-methyl-amino)- propionic acid as viscous, colorless oil (8.98 g). Step B: The acid prepared in Step A (8.95 g, 28.9 mmol) was dissolved in methanol (50 mL) and dichloromethane (50 mL). The resultant solution was cooled to 0 °C. Trimethylsilyldiazomethane (2.0 M in hexane, 26 mL) was added dropwise over 1 h and the resultant reaction mixture was stirced an additional h at 0 °C. An additional portion of trimethylsilyldiazomethane (2.0 M in hexane, 3 mL) was added and the reaction was stirced an additional 30 min at 0 °C. The reaction mixture was concentrated in vacuo, taking care not to heat the solution above 20 °C. The residual liquid was dissolved in tetrahydrofuran-methanol (3:1, 200 mL) and the resultant solution was cooled to 0 °C. A solution of lithium borohydride (2.0 M in tetrahydrofuran, 20 mL) was added dropwise over 30 min. The reaction mixture was stirced and additional 1 h at 0 °C and 1 h at ambient temperature. An additional portion of lithoum borohydride solution (20 mL) was added and the reaction mixture was stirred overnight . Water (30 mL) was cautiously added with vigorous stircing . After gas evolution had subsided, 50% aqueous sodium hydroxide (1 mL) was added and the stircing was continued for 20 min. The reaction mixture was concentrated in vacuo to about 1/4 volume and was diluted with ethyl acetate (300 mL) and washed with water (50 mL), saturated aqueous ammonium chloride (50 mL) and saturated brine (50 mL). The extracts were dried over magnesium sulfate and concentrated in vacuo. Chromatography ofthe residual oil (40% ethyl acetate in hexanes) on silica gel provided the product ((R)-l-Benzyloxymethyl-2-hydroxy-ethyl)-methyl-carbamic acid tert- butyl ester (6.02 g, 68% from N-Boc-O-Benzyl serine) as a colorless oil: 1H
NMR (400 MHz, CDC13) δ 7.39-7.28 (m, 5 H), 4.55 (ABquartet, J = 8.0 Hz, Δv =16.4 Hz, 2 H), 4.13 (br s, 1 H), 3.85-3.55 (cm, 4 H), 2.86 (s, 3 H), 1.45 (s, 9 H); [α]D = +77 (methanol, c = 1 mg/mL); MS (APCI+) 296.2 (M+1, 10%), 222.1 ( +I-C4H10O, 60%), 196.1 (M+l-C5H8O2, 100%). Step C, D: According to the procedure of Preparation 74, ((R)-l-
Benzyloxymethyl-2-hydroxy-ethyl)-methyl-carbamic acid tert-butyl ester can be converted to ((S)-2-Aminooxy-l-benzyloxymethyl-ethyl)-methyl-carbamic acid tert-butyl ester. Step E: [(S)-l-Benzyloxymethyl-2-({ l-[3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-phenyl]-methanoyl}-aminooxy)-ethyl]-methyl-carbamic acid tert- butyl ester can be prepared from to ((S)-2-Aminooxy-l-benzyloxymethyl-ethyl)- methyl-carbamic acid tert-butyl ester and 3,4-Difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzoic acid by the procedure of Example 80, Step A. Step F: Treatment ofthe product of Step E with iodotrimethylsilane followed by a workup with aqueous hydrochloric acid will provide 3,4-Difluoro-2-(2-fluoro-4- iodo-phenylamino)-N-((S)-3-hydroxy-2-methylamino-propoxy)-benzamide, which may be isolated as a pharmaceutically acceptable salt.
EXAMPLE 237 3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-((R -3-hydroxy-2-methylamino- propoxyl-benzamide
Step A: Treatment of ((R)-l-Benzyloxymethyl-2-hydroxy-ethyl)-methyl-carbamic acid tert-butyl ester with tert-butyldimethylsilyl chloride and imidazole in dimethylformamide will afford [(S)-l-Benzyloxymethyl-2-(tert-butyl-dimethyl- silanyloxy)-ethyl]-methyl-carbamic acid tert-butyl ester. Step B: Exposure ofthe compound prepared in Step A to a pressurized atmosphere of hydrogen in the presence of activated palladium on charcoal will provide [(S)-2-(tert-Butyl-dimethyl-silanyloxy)- 1 -hydroxymethyl-ethyl]-methyl- carbamic acid tert-butyl ester. Step C,D: The compound of step B can be converted to [(S)-l-Aminooxymethyl- 2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-methyl-carbamic acid tert-butyl ester by the general procedure of Preparation 74.
Step E: [(S)-2-(tert-Butyl-dimethyl-silanyloxy)-l-({ l-[3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-phenyl]-methanoyl}-aminooxymethyl)-ethyl]-methyl- carbamic acid tert-butyl ester can be prepared by the procedure of Example 80, Step A.
Step F: Treatment ofthe product of Step E with iodotrimethylsilane followed by a workup with tetrabutylammonium fluoride will provide 3,4-Difluoro-2-(2- fluoro-4-iodo-phenylamino)-N-((R)-3-hydroxy-2-methylamino-propoxy)- benzamide, which may be isolated as a pharmaceutically acceptable salt.
EXAMPLE 238
(S)- and (R)-5-Chloro-3.4-Difluoro-2-(2-fluoro-4-iodo-ρhenylamino)-N-(3- hydroxy-2-methylamino-propoxy)-benzamide (S)- and (R)-5-Chloro-3 ,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3 - hydroxy-2-methylamino-propoxy)-benzamide may be prepared from 5-Chloro- 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid by analogy to examples 236 and 237 respectively.
EXAMPLE 239 (S - and (R -5-Chloro-2-(2-chloro-4-iodo-phenylamino -3.4-diftuoro-N- 3- hydroxy-2-methylamino-propoxy)-benzamide (S)- and (R)-5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3 ,4-difluoro-N- (3-hydroxy-2-methylamino-propoxy)-benzamide may be prepared from 5-chloro-
2-(2-chloro-4-iodo-phenylamino)-3, 4-difluoro-benzoic acid by analogy to examples 236 and 237 respectively.
EXAMPLE 240 3.4-Difluoro-2-(2-fluoro-4-iodo-phenylamino -N-(2-hydroxy-3-methylamino- propoxyVbenzamide Step A: N-(tert-butoxycarbonyl)-N-methyl-2,3-epoxypropylamine (available by the literature procedure: Edwards, M. L.; Snyder, R. D.; Stemerick, D. M. J. Med. Chem. 1991, 34, 2414) can be converted to (3-aminooxy-2-hydroxy-propyl)- methyl-carbamic acid tert-butyl ester by the general procedure of example 56.
Step B, C: 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- methylamino-propoxy)-benzamide can be prepared from (3-aminooxy-2-hydroxy- propyl)-methyl-carbamic acid tert-butyl ester and 3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzoic acid by the general procedure of example 236, steps E and F.
EXAMPLE 241 Cellular Assay for Measuring MEK Inhibition
The evaluation ofthe compounds as MEK inhibitors was performed in an assay that measures their ability to inhibit phosphorylation of MAP kinase (ERK) in murine colon 26 (C26) carcinoma cells. Since ERK1 and ERK2 represent the only known substrates for MEK, measurement of inhibition of ERK phosphorylation in cells provides direct readout of cellular MEK inhibition by the compounds ofthe invention. Briefly, the assay involves treating exponentially growing C26 cells with varying concentrations ofthe test compound (or vehicle control) for one hour at 37° C. Cells are then rinsed free of compound/vehicle and lysed in a solution containing 70 mMNaCl, 50 mM glycerol phosphate, 10 mM HEPES, pH 7.4, 1% Triton X-100, 1 mMNa3VO4, 100 μM PMSF, 10 μM leupeptin and 10 μM pepstatin. Supernatants are then subjected to gel electrophoresis and Western blotting using a primary antibody recognizing dually phosphorylated ERK1 and ERK2. To evaluate total MAPK levels, blots were subsequently 'stripped' and re-probed with a 1:1 mixture of polyclonal antibodies recognizing unphosphorylated ERKl and ERK2.
The inhibition data generated by the above protocol is disclosed in Table 1. If several concentrations of inhibitor were tested, IC50 values (the concentration which gives 50% inhibition) were determined graphically from the dose response curve for % inhibition. Otherwise, percent inhibitions at measured concentrations are reported.
Table 8. Cellular Inhibition of ERK Phosphorylation by Compounds ofthe
Invention
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
EXAMPLE 242 Carrageenan-induced Footpad Edema (CFE) Rat Model
Male outbred Wistar rats (135-150 g, Charles River Labs) were dosed orally with 10 ml/kg vehicle or test compound one hour prior to administration of a sonicated suspension of carrageenan (1 mg/0.1 ml saline). Carcageenan was injected into the subplantar region ofthe right hind paw. Paw volume was determined by mercury plethysmography immediately after injection and again five hours after carcageenan injection. Percent inhibition of edema was determined, and the ID40 calculated by linear regression. Differences in swelling compared to control animals were assessed by a 1-way ANOVA, followed by
Dunnett's test.
EXAMPLE 243
Collagen-Induced Arthritis in Mice
Type II collagen-induced arthritis (CIA) in mice is an experimental model of arthritis that has a number of pathologic, immunologic, and genetic features in common with rheumatoid arthritis. The disease is induced by immunization of DBA/1 mice with 100 μg type II collagen, which is a major component of joint cartilage, delivered intradermally in Freund's complete adjuvant. The disease susceptibility is regulated by the class H MHC gene locus, which is analogous to the association of rheumatoid arthritis with HLA-DR4.
A progressive and inflammatory arthritis develops in the majority of mice immunized, characterized by paw width increases of up to 100%. A test compound is administered to mice in a range of amounts, such as 20, 60, 100, and
200 mg/kg body weight/day. The duration of the test can be several weeks to a few months, such as 40, 60, or 80 days. A clinical scoring index is used to assess disease progression from erythema and edema (stage 1), joint distortion (stage 2), to joint ankylosis (stage 3). The disease is variable in that it can affect one or all paws in an animal, resulting in a total possible score of 12 for each mouse.
Histopathology of an arthritic joint reveals synovitis, pannus formation, and cartilage and bone erosions. All mouse strains that are susceptible to CIA are high antibody responders to type II collagen, and there is a marked cellular response to cπ. EXAMPLE 244 SCW-induced monoarticular arthritis
Arthritis is induced as described by Schwab, et al, Infection and Immunity, 59:4436-4442 (1991) with minor modifications. Rats receive 6 μg sonicated SCW [in 10 μl Dulbecco's PBS (DPBS)] by an intraarticular injection into the right tibiotalar joint on day 0. On day 21, the DTH is initiated with 100 μg of SCW (250 μl) administered i.v. For oral compound studies, compounds are suspended in vehicle (0.5% hydroxypropyl-methylcellulόse/0.2% Tween 80), sonicated, and administered twice daily (10 ml/kg volume) beginning 1 hr prior to reactivation with SCW. Compounds are administered in amounts between 10 and
500 mg/kg body weight/day, such as 20, 30, 60, 100, 200, and 300 mg/kg/day. Edema measurements are obtained by determining the baseline volumes ofthe sensitized hindpaw before reactivation on day 21, and comparing them with volumes at subsequent time points such as day 22, 23, 24, and 25. Paw volume is determined by mercury plethysmography.
EXAMPLE 245
Mouse ear-heart transplant model Fey, T. A et al. describe methods for transplanting split-heart neonatal cardiac grafts into the ear pinna of mice and rats (J Pharm. and Toxic. Meth. 39:9-17 (1998)). Compounds are dissolved in solutions containing combinations of absolute ethanol, 0.2% hydroxypropyl methylcellulose in water, propylene glycol, cremophor, and dextrose, or other solvent or suspending vehicle. Mice are dosed orally or intraperitoneally once, twice or three times daily from the day of transplant (day 0) through day 13 or until grafts have been rejected. Rats are dosed once, twice, or three times daily from day 0 through day 13. Each animal is anesthetized and an incision is made at the base ofthe recipient ear, cutting only the dorsal epidermis and dermis. The incision is spread open and down to the cartilage parallel to the head, and sufficiently wide to accommodate the appropriate tunneling for a rat or insertion tool for a mouse. A neonatal mouse or rat pup less than 60 hours old is anesthetized and cervically dislocated. The heart is removed from the chest, rinsed with saline, bisected longitudinally with a scalpel, and rinsed with sterile saline. The donor heart fragment is placed into the preformed tunnel with the insertion tool and air or residual fluid is gently expressed from the tunnel with light pressure. No suturing, adhesive bonding, bandaging, or treatment with antibiotics is required. Implants are examined at 10-20-fold magnification with a stereoscopic dissecting microscope without anesthesia. Recipients whose grafts are not visibly beating may be anesthetized and evaluated for the presence of electrical activity using Grass E-2 platinum subdermal pin microelectodes placed either in the pinna or directly into the graft and a tachograph. Implants can be examined 1-4 times a day for 10, 20, 30 or more days. The ability of a test compound to ameliorate symptoms of transplant rejection can be compared with a control compound such as cyclosporine, tacrolimus, or orally-administered lefluonomide.
EXAMPLE 246
The analgesic activity ofthe compounds ofthe present invention was assessed by a test with rats. Rats weighing from 175 to 200 g were injected with carrageenan (2% in 0.9% sodium chloride aqueous solution, 100 μL injection volume) into the footpad of one hind limb. The rats were placed on a glass plate with illumination from a halogen lamp placed directly under the injected paw.
The time (in seconds) from beginning illumination until the hindlimb was withdrawn from the glass was measured and scored as Paw Withdrawal Latency (PWL). Drug substances were given by oral gavage injection 2 V-i hours after carrageenan injection to the footpad. PWL was measured prior to carrageenan injection, just prior to drug injection, and 1, 2 (and sometimes 3) hours after drug injection.
Carrageenan (a polysaccharide extracted from seaweed) causes a sterile inflammation when injected under the skin. Injection into the rat footpad causes little or no spontaneous pain-related behavior but induces hyperalgesia (pain- related behavioral responses of greater intensity than expected) to peripheral thermal or mechanical stimuli. This hyperalgesia is maximal 2 to 3 hours after injection. Treatment of rats with various analgesic drugs reduces hyperalgesia measured in this way and is a conventional test for detection of analgesic activity in rats. (Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77-88 and Kayser V, Guilbaud G. Local and remote modifications of nociceptive sensitivity during carcageenan-induced inflammation in the rat. Pain 1987;28:99-108). Untreated rats had a PWL of approximately 10 seconds. Carrageenan injection reduced PWL to approximately 3 seconds for at least 4 hours, indicating thermal hyperalgesia. Inhibition ofthe carcageenan thermal hyperalgesia response was determined by the difference between reduced PWL prior to drug and subsequent to drug treatment, and was expressed as percent inhibition ofthe response. Administration of MEK inhibitors dose-dependently reduced thermal hyperalgesia (Table 9).
In Table 9, doses were given by oral gavage (PO) and inhibition ofthe response was measured 1 hour (1 hr), 2 hours (2 hr) or in some cases, 3 hours (3 hr) after drug administration. Inhibition indicates and analgesic effect.
TABLE 9 Administration of MEK Inhibitors to Rats Reduces Thermal Hyperalgesia from
Intraplantar Carcageenan.
Figure imgf000199_0001

Claims

CLALMS
What is claimed is:
A compound of formula
Figure imgf000200_0001
wherein
Rl is hydrogen, halogen, or nitro; 2 is hydrogen or fluorine;
R3 is hydrogen or fluorine; R4 is hydrogen, iodine, bromine, chlorine, or fluorine;
R5 is hydrogen, halogen, hydroxy, C g alkyl, C alkoxy, trifluoromethyl, or cyano; n is 1 to 5;
Rg, R7, Rg, R9, and RIQ are independently hydrogen, C g alkyl, C3_g cycloalkyl, hydroxy, C g alkoxy, perhalo(Cι_3)alkyl, hydroxy(Cι_ g)alkyl, (Cι_5)alkoxy(Cι _5)alkyl, [(C1. )alkyl]2aminomethyl, (C2_
7)heterocycle(Cι_5)alkyl, or aryloxy(Cι_5)alkyl, or may be independently joined to complete a 3-10 member cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, NH, and N-alkyl, wherein R7 and Rg are independently selected for n>l;
Ra and Rb are independently hydrogen or C 1.4 alkyl;
W is O or NRa; R l is hydrogen, Cι_ alkyl, C2_ alkenyl, C3_ cycloalkyl, hydroxy(C _g)alkyl,
(Cι_5)alkoxy(Cι_5)alkyl, phenyl, C2.7 heteroaryl, (Cι_g)alkylcarbonyl,
(phenyl)carbonyl, (phenyl)(Cι_3 alkyl)carbonyl, ortrifluoro(Cι_g)alkyl; wherein the above alkyl, alkoxy, cycloalkyl, heteroaryl, and phenyl groups can be optionally substituted with between 1 and 5 substituents independently selected from the group consisting of hydroxy, amino, monoalkylamino, dialkylamino, halogen, cyano, (Cι_3)alkoxy, COOR, OCORa, CONRaRb,
NRaCORb, SO, SO2, SO4, and SO2NRaRb; and pharmaceutically acceptable salts; provided that when i 1 is phenyl and n is 1, W cannot be O; further provided that the compound is not
5-Bromo-N-(2-diethylamino-ethoxy)-3,4-difluoro-(4-iodo-2-methyl- phenylamino)-benzamide;
5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; or
5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)- 3,4-difluoro-benzamide.
2. The compound of Claim 1 wherein i is hydrogen or halogen.
3. The compound of Claim 2 wherein halogen is fluorine, bromine or chlorine.
4. The compound of Claim 1 wherein R2 is fluorine.
5. The compound of Claim 1 wherein R3 is fluorine.
6. The compound of Claim 1 wherein R4 is iodine.
7. The compound of Claim 1 wherein R5 is fluorine, chlorine, or methyl.
8. The compound of claim 1 wherein n is 1 or 2.
. The compound of claim 1 wherein Rg, R7, Rg, R9, RIQ, and Ri 1 are hydrogen.
10. The compound of claim 1 wherein Rg, R7, Rg, R9, and RIQ are hydrogen.
11. The compound of claim 1 wherein Rg, R7, R9, Rχo, and Ri 1 are hydrogen.
12. The compound of claim 1 wherein W is oxygen.
13. The compound of claim 1 wherein W is NRa and Ra is hydrogen.
14. The compound of claim 1 wherein Ri 1 is methyl or phenyl.
15. The compound of Claim 1 wherein the compound is of formula
Figure imgf000202_0001
wherein
Rl is hydrogen or halogen;
R5 is hydrogen, halogen, or Cμg alkyl;
Rg, R7, Rg, R9, and RIQ are independently hydrogen, Cι_g alkyl, hydroxy, C _ alkoxy, perhdo(Cι _3)alkyl, (C2_7)heterocycle(Cι _5)alkyl, or aryloxy(C _ 5)alkyl, or may be independently joined to complete a 3-10 member cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, NH, and N-alkyl, wherein R7 and Rg are independently selected for n>l; and l is hydrogen, C _g alkyl, C2-6 alkenyl, (Cι_5)alkoxy(Cι_5)alkyl, phenyl, (Cι.g)alkylcarbonyl, ortrifluoro(Cι_g)alkyl.
16. The compound of Claim 15 wherein Ri is hydrogen.
17. The compound of Claim 15 wherein R3 is hydrogen.
18. The compound of Claim 15 wherein R3 is fluorine.
19. The compound of Claim 15 wherein R4 is iodine.
20. The compound of Claim 15 wherein R5 is fluorine, chlorine, or methyl.
21. The compound of Claim 15 wherein n is 1 or 2.
22. The compound of claim 15 wherein Rg, R7, Rg, R9, RIQ, and Ri 1 are hydrogen.
23. The compound of claim 15 wherein Rg, R7, Rg, R9, and R o are hydrogen.
24. The compound of claim 15 wherein Rg, R7, R9, RIQ, and Ri 1 are hydrogen.
25. The compound of claim 15 wherein W is O.
26. The compound of claim 15 wherein W is NRa and Ra is hydrogen.
27. The compound of claim 15 wherein i i is methyl or phenyl.
28. A compound of Claim 1 wherein the compound is of formula
Figure imgf000204_0001
wherein is hydrogen or halogen;
R5 is fluorine, chlorine, or methyl; and n is 1 or 2.
29. A compound of Claim 1 wherein the compound is of formula
Figure imgf000204_0002
wherein i is hydrogen or halogen; and
R5 is fluorine, chlorine, or methyl.
30. A compound of Claim 1 wherein the compound is of formula
Figure imgf000205_0001
wherein
Rl is hydrogen or halogen; and
Rζ is fluorine, chlorine, or methyl.
31. A compound of Claim 1 wherein the compound is of formula
Figure imgf000205_0002
wherein
Rl is hydrogen or halogen; and
Rζ is fluorine, chlorine, or methyl.
32. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
33. A method of treating a proliferative disease in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.
34. A method of claim 33 wherein the proliferative disease is selected from the group consisting of cancer, restenosis, psoriasis, and atherosclerosis.
35. A method of treating psoriasis in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim
1.
36. A method of treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.
37. A method of claim 36 wherein the cancer is MEK-related.
38. A method of claim 36 wherein the cancer is brain, breast, lung, ovarian, pancreatic, prostate, renal, or colorectal cancer.
39. A method of treating osteoarthritis in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.
40. A method of treating rheumatoid arthritis in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.
41. A method of treating heart failure in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.
42. A method of treating chronic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim
1.
43. The method of claim 42, wherein the chronic pain is selected from the group consisting of neuropathic pain, idiopathic pain, and pain associated with chronic alcoholism, vitamin deficiency, uremia, and hypothyroidism.
44. The method of claim 42, wherein the chronic pain is associated with inflammation.
45. The method of claim 42, wherein the chronic pain is associated with arthritis.
46. The method of claim 42, wherein the chronic pain is associated with postoperative pain.
47. A method of treating neuropathic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.
48. The method of claim 47, wherein the neuropathic pain is associated with a condition selected from the group consisting of inflammation, postoperative pain, phantom limb pain, burn pain, gout, trigeminal neuralgia, acute herpetic and postherpetic pain, causalgia, diabetic neuropathy, plexus avulsion, neuroma, vasculitis, viral infection, crush injury, constriction injury, tissue injury, limb amputation, post-operative pain, arthritis pain, and nerve injury between the peripheral nervous system and the central nervous system.
49. A method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1 in combination with radiation therapy.
50. A method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1 in combination with at least one chemotherapeutic agent.
51. A method of claim 50 wherein the chemotherapeutic agent is a mitotic inhibitor.
52. A method of claim 51 wherein the mitotic inhibitor is selected from the group consisting of paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, and vinflunine.
53. A crystalline Form I N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro- 4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 7.1, 19.2, or 32.1.
54. A crystalline Form I N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro- 4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 7.1, 19.2, and 32.1.
55. A crystalline Form I N-(2,3 -Dihydroxy-propoxy)-3 ,4-difluoro-2-(2-fluoro- 4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 7.1, 14.1, 15.3, 15.8, 16.9, 18.1, 19.2, 20.3, 21.4, 22.3, 23.4, 24.5, 25.5, 26.2, 26.8, 27.8, 28.3, 29.5, 32.1, 33.2, 33.6, 40.0, 42.9, and 44.1.
56. A crystalline Form I N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro- 4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 7.078, 14.123, 15.280, 15.836, 16.880, 18.082, 19.162, 20.279, 21.360, 22.325, 23.400, 24.522, 25.480, 26.159, 26.801, 27.842,
28.280, 29.475, 32.118, 33.248, 33.645, 40.008, 42.885, and 44.095.
57. A crystalline Form π N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 11.6, 12.6 or 24.9.
58. A crystalline Form II N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 11.6, 12.6 and 24.9.
59. A crystalline Form II N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using
CuKα radiation: 11.6, 12.6, 15.6, 17.3, 17.9, 20.3, 21.1, 22.1, 24.9, 25.9, 26.7, 27.8, 30.1, 30.9, 33.8, 35.4, 38.2, 39.3, 40.8, 41.6, 43.6, and 47.0.
60. A crystalline Form II N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 11.582, 12.598, 15.622, 17.302, 17.886, 20.345, 21.140,
22.137, 24.855, 25.885, 26.699, 27.842, 30.059, 30.948, 33.799, 35.399, 38.242, 39.282, 40.755, 41.641, 43.570, and 46.958.
61. A crystalline Form I N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 10.6, 13.7, 19.0 or 23.7.
62. A crystalline Form I N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using
CuKα radiation: 10.6, 13.7, 19.0 and 23.7.
63. A crystalline Form I N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 10.6, 13.7, 14.6, 17.3, 18.0, 18.2, 98.0, 19.3, 20.1, 21.0, 21.9, 22.4, 23.7, 24.0, 24.9, 26.3, 27.6, 28.0, 30.1, 32.1, 32.3, 32.9, 35.8, and 37.7.
64. A crystalline Form I N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using
CuKα radiation: 10.560, 13.720, 14.619, 17.258, 17.958, 18.219, 18.998, 19.258, 20.142, 21.002, 21.940, 22.360, 23.680, 24.043, 24.919, 26.278,
27.603, 28.024, 30.100, 32.142, 32.298, 32.938, 35.841, and 37.660.
65. A crystalline Form II N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 5.5 or 19.6. .
66. A crystalline Form II N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 5.5 and 19.6.
67. A crystalline Form II N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 5.5, 10.7, 16.5, 19.6, 22.0, 22.5, 23.6, 24.1, 25.0, 26.2, 27.6, 29.1, 30.5, 31.7, 33.3, and 39.0.
68. A crystalline Form LI N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using
CuKα radiation: 5.482, 10.721, 16.478, 19.563, 22.019, 22.478, 23.621, 24.100, 24.959, 26.181, 27.621, 29.081, 30.476, 31.698, 33.263, and 39.020.
69. A crystalline Form I N-[(S)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 10.5, 13.7, 19.0, or 23.6.
70. A crystalline Form I N-[(S)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 10.5, 13.7, 19.0, and 23.6.
71. A crystalline Form I N-[(S)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 10.548, 13.703, 17.887, 18.958, 20.122, 21.950, 22.321, 23.640, 24.803, 26.244, 27.570, 28.000, 29.566, 32.234, 32.769, 35.804,
37.641, 41.402, 41.956, and 44.600.
72. A crystalline Form I N-[(S)-2,3-Dihydroxy-proρoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using
CuKα radiation: 10.548, 13.703, 17.887, 18.958, 20.122, 21.950, 22.321,
23.640, 24.803, 26.244, 27.570, 28.000, 29.566, 32.234, 32.769, 35.804,
37.641, 41.402, 41.956, and 44.600.
73. A crystalline Form II N-[(S)-2,3-Dihydroxy-propoxy]-3 ,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 5.6 or 19.6.
74. A crystalline Form II N-[(S)-2,3-Dihydroxy-ρropoxy]-3 ,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing at least one ofthe following 20 values measured using CuKα radiation: 5.6 and 19.6.
75. A crystalline Form II N-[(S)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using CuKα radiation: 5.6, 10.7, 16.5, 19.6, 20.9, 22.0, 23.7, 24.2, 25.0, 26.2, 27.7, 28.0, 29.1, 31.7, 32.8, 33.3, 34.1, 42.0, and 42.3.
76. A crystalline Form II N-[(S)-2,3-Dihydroxy-propoxy]-3 ,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide having an X-ray diffraction powder diffraction containing the following 20 values measured using
CuKα radiation: 5.550, 10.763, 16.485, 19.636, 20.922, 22.043, 23.683, 24.153, 24.996, 26.236, 27.680, 28.037, 29.120,31.718, 32.794, 33.314, 34.085, 41.999, and 42.278.
77. A compound which is selected from the group consisting of
5-Chloro-2-(2-chloro-4-iodo-phenylamino)-Ν-(2,3-dihydroxy-propoxy)- 3,4-difluoro-benzamide; 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide; N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 5-Chloro-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 5-Chloro-N-((R)-2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methylamino- ethoxy)-benzamide; hydrochloride; N-((R)-2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide;
N-((S)-2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-((S)-2,3-dihydroxy- propoxy)-3 ,4-difluoro-benzamide; 5 -Chloro-2-(2-chloro-4-iodo-phenylamino)-N-((R)-2, 3 -dihy droxy- propoxy)-3,4-difluoro-benzamide; 5-Chloro-N-((S) 2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- 1 - hydroxymethyl-ethoxy)-benzamide; and
5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- N-(2-hydroxy-l- hydroxymethyl-ethoxy)-benzamide.
78. A compound which is selected from the group consisting of
3,4,5-Trifluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; 3,4-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)- benzamide; 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(2-hydroxy-ethoxy)- benzamide; -Fluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-ethoxy)- benzamide; -Chloro-3,4-difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-phenylamino)- benzamide; -Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- ethoxy)-benzamide; -Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- ethoxy)-benzamide; ,5-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; -Bromo-3,4-difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy- ethoxy)-benzamide; -Chloro-3,4-difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Bromo-4-fluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -(2-Chloro-4-iodo-phenylamino)-4,5-difluoro-N-(2-hydroxy-ethoxy)- benzamide; ,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide; -Bromo-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- ethoxy)-benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy- ethoxy)-benzamide; ,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide; -(4-Bromo-2-fluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)- benzamide; -(4-Bromo-2-fluoro-phenylamino)-4,5-difluoro-N-(2-hydroxy-ethoxy)- benzamide; -(4-Chloro-2-fluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)- benzamide; ,4-Difluoro-2-(2-fluoro-phenylamino)-N-(2-hydroxy-ethoxy)- benzamide; -Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N -(2-hydroxy- ethoxy)-b enzamide; -(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)- benzamide; -Fluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; -Chloro-3,4-difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(3-hydroxy-propoxy)- benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy- propoxy)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-propoxy)- benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(4-hydroxy-butoxy)- benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-
3,4-difluoro-benzamide; -Chloro-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Chloro-N-(3,4-dihydroxy-butoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-
3 ,4-difluoro-benzamide; N-(2,2-Dimethyl-l,3-dioxolan-4-ylmethoxy)-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide; N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 5-Bromo-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 5-Chloro-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; N-(2,3-Dihydroxy-propoxy)-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)- benzamide; N-(2,3-Dihydroxy-propoxy)-3,4,5-trifluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 2-(4-Bromo-2-fluoro-phenylamino)-N-(2,3-dihydroxy-propoxy)-3,4- difluoro-benzamide; 2-(4-Chloro-2-fluoro-phenylamino)-N-(2,3-dihydroxy-propoxy)-3,4- difluoro-benzamide; N-(2,2-Dimethyl-l,3-dioxinan-5-yloxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- 1 - hydroxymethyl-ethoxy)-benzamide; 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)- N-(2-hydroxy-l- hydroxymethyl-ethoxy)-benzamide; N-((R)-2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; N-((S)-2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-((R)-2,3-dihydroxy- propoxy)-3,4-difluoro-benzamide; 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-((S)-2,3-dihydroxy- propoxy)-3 ,4-difluoro-benzamide; -Chloro-N-((R)-2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4- iodo-phenylamino)-benzamide; -Chloro-N-((S) 2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; -(4-Bromo-2-fluoro-phenylamino)-N-((R)-2,3-dihydroxy-propoxy)-3,4- difluoro-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-vinyloxy-ethoxy)- benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-vinyloxy-ethoxy)- benzamide; -Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-vinyloxy-ethoxy)- benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-vinyloxy-ethoxy)- benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-vinyloxy- ethoxy)-b enzamide; -Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-vinyloxy- ethoxy)-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-
1 , 1 -dimethyl-ethoxy)-benzamide; ,4-Difluoro-N-(2-hydroxy- 1 , 1 -dimethyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)- N-(2-hydroxy-l, 1- dimethyl-ethoxy)-benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-
1, l-dimethyl-ethoxy)-benzamide; 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl- propoxy)-benzamide; ,4-Difluoro-N-(2-hydroxy-3-methoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- methoxy-propoxy)-benzamide; ,4-Difluoro-N-(l-hydroxymethyl-cyclopropylmethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(l- hydroxymethyl-cycloρropylmethoxy)-benzamide; 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide; 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3,3,3- trifluoro-2-hydroxy-propoxy)-benzamide; 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide; 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2- hydroxymethyl-cyclopropylmethoxy)-benzamide; N-(2,3-Dihydroxy-3-methyI-butoxy)-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide; 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-phenylamino- ethoxy)-b enzamide; 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methylamino- ethoxy)-benzamide; 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methylamino- ethoxy)-benzamide; hydrochloride; 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2,2,2-trifluoro- ethylamino)-ethoxy]-benzamide; hydrochloride; 2-(2-Chloro-4-iodo-phenylamino)-4-fϊuoro-N-(2-hydroxy-ethoxy)-N- methyl-benzamide; Acetic acid 2-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)- benzoylaminooxy]-ethyl ester; [3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-(4-hydroxy- isoxazolidin-2-yl)-methanone; 5 -Bromo-N-(2, 3 -dihydroxy-propoxy)-3 , 4-difluoro-2-(2-fluoro- ρhenylamino)-benzamide; N-(2,3-Dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-phenylamino)- benzamide; 2-(2-Chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-3,4- difluoro-benzamide; 2-(2-Chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-3,4,5- trifluoro-benzamide; 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2,3-dihydroxy-propoxy)-
3 , 4-difluoro-benzamide; N-(2,3 -Dihydroxy-propoxy)-3 ,4-difluoro-2-(4-iodo-2-methyl- ρhenylamino)-benzamide; N-(2,3-Dihydroxy-propoxy)-3,4,5-trifluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; 5-Bromo-N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; 2-(2-Chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-3,4- difluoro-benzamide; 2-(2-Chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-3,4,5- trifluoro-benzamide; 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(3,4-dihydroxy-butoxy)-
3, 4-difluoro-benzamide; N-(3 ,4-Dihydroxy-butoxy)-3 ,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; N-(3,4-Dihydroxy-butoxy)-3,4,5-trifluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; 5-Bromo-N-(3,4-dihydroxy-butoxy)-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide; 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy- propoxy)-benzamide; 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-propoxy)- benzamide; 3 ,4, 5-Trifluoro-N-(3 -hydroxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-propoxy)- benzamide; -Bromo-3,4-difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; ,4-Difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-butoxy)- benzamide; -(2-Chloro-4-iodo-phenylamino)-3 ,4, 5 -trifluoro-N-(2-hydroxy-butoxy)- benzamide; ,4,5-Trifluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy- butoxy)-benzamide; -Bromo-3,4-difluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; ,4-Difluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy- butoxy)-benzamide; -Chloro-3,4-difluoro-N-(2-hydroxy-butoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)- benzamide; -Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- butoxy)-benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- butoxy)-benzamide; ,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-butoxy)- benzamide; 5-Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy- butoxy)-benzamide; -(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-butoxy)- benzamide; -(4-Bromo-2-fluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-butoxy)- benzamide; -Chloro-3,4-difluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(2-hydroxy- 1 -methyl- ethoxy)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3 ,4, 5-trifluoro-N-(2-hydroxy- 1 -methyl- ethoxy)-b enzamide; ,4, 5 -Trifluoro-N-(2-hydroxy- 1 -methyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-l- methyl-ethoxy)-benzamide; -Bromo-3,4-difluoro-N-(2-hydroxy-l-methyl-ethoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; -(4-Chloro-2-fluoro-phenylamino)-3 ,4-difluoro-N-(2-hydroxy- 1 -methyl- ethoxy)-benzamide; ,4-Difluoro-N-(2-hydroxy- 1 -methyl-ethoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-l- methyl-ethoxy)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l-methyl- ethoxy)-benzamide; -Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l- methyl-ethoxy)-benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-l- methyl-ethoxy)-benzamide; , 5 -Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- 1 -methyl- ethoxy)-b enzamide; 5-Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-l- methyl-ethoxy)-benzamide; -(2,4-Difluoro-phenylamino)-3 ,4-difluoro-N-(2-hydroxy- 1 -methyl- ethoxy)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-methoxy-ethoxy)- benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-methoxy-ethoxy)- benzamide; ,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)- benzamide; -Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy- ethoxy)-benzamide; ,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy-ethoxy)- benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-methoxy- ethoxy)-b enzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-methoxy- ethoxy)-benzamide; -Chloro-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methoxy- ethoxy)-benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-methoxy- ethoxy)-b enzamide; -(2-Chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(2-hydroxy-3 - morpholin-4-yl-propoxy)-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide; ,4,5-Trifluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; -Bromo-3,4-difluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4- iodo-2-methyl-phenylamino)-benzamide; ,4-Difluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide; -Chloro-3,4-difluoro-N-(2-hydroxy-3-morpholin-4-yl-propoxy)-2-(4- iodo-2-methyl-phenylamino)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3 - morpholin-4-yl-propoxy)-benzamide; -Chloro-3, 4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide; ,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide; -Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- morpholin-4-yl-propoxy)-benzamide; -(4-Chloro-2-fluoro-phenylamino)-3 ,4-difluoro-N-(2-hydroxy-3 - morpholin-4-yl-propoxy)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-propoxy)- benzamide; ,4,5-Trifluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy- propoxy)-benzamide; -Bromo-3,4-difluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-propoxy)- benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy- propoxy)-benzamide; ,4-Difluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl-phenylamino)- benzamide; -Chloro-3,4-difluoro-N-(2-hydroxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy- propoxy)-benzamide; -Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy- propoxy)-benzamide; -(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-propoxy)- benzamide; -(4-Chloro-2-fluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-propoxy)- benzamide; ,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-propoxy)- benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide; ,4,5-Trifluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Bromo-3,4-difluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-2- methyl-propoxy)-benzamide; ,4-Difluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-2- methyl-propoxy)-benzamide; -Chloro-3,4-difluoro-N-(2-hydroxy-2-methyl-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2-methyl- propoxy)-benzamide; -Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2- methyl-propoxy)-benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-2- methyl-propoxy)-benzamide; 5-Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-2- methyl-propoxy)-benzamide; -(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide; -(4-Bromo-2-fluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-2-methyl- propoxy)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide; ,4,5-Trifluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide; -Bromo-3,4-difluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; ,4-Difluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide; -Chloro-3,4-difluoro-N-(2-hydroxy-3-phenoxy-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide; -Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide; ,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide; 5-Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide; 2-(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-3-phenoxy- propoxy)-benzamide; -(4-Chloro-2-fluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- phenoxy-propoxy)-benzamide; ,4-Difluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-2,2- dimethyl-propoxy)-benzamide; ,4,5-Trifluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2-methyl- phenylamino)-benzamide; -Chloro-2-(2-chloro-4-iodo-phenylamino)-3 ,4-difluoro-N-(3 -hydroxy-
2,2-dimethyl-propoxy)-benzamide; -Chloro-3,4-difluoro-N-(3-hydroxy-2,2-dimethyl-propoxy)-2-(4-iodo-2- methyl-phenylamino)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3-hydroxy-2,2- dimethyl-propoxy)-benzamide; -Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(3-hydroxy-2,2- dimethyl-propoxy)-benzamide; ,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy- ethoxy)-ethoxy]-benzamide; ,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2-methoxy- ethoxy)-ethoxy]-benzamide; -Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[2-(2- methoxy-ethoxy)-ethoxy]-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-[2-(2-methoxy-ethoxy)- ethoxy]-benzamide; -(2-ChIoro-4-iodo-phenylamino)-3,4,5-trifluoro-N-[2-(2-methoxy- ethoxy)-ethoxy]-benzamide; -Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-[2-(2- methoxy-ethoxy)-ethoxy]-benzamide; ,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide; 5-Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(3,3,3-trifluoro-2- hydroxy-propoxy)-benzamide; 2-(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(3,3,3-trifluoro-2-hydroxy- propoxy)-benzamide; -(4-Chloro-2-fluoro-phenylamino)-3 ,4-difluoro-N-(3 ,3 ,3 -trifluoro-2- hydroxy-propoxy)-benzamide; -Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(2- hydroxymethyl-cyclopropylmethoxy)-benzamide; -(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide; -(4-Chloro-2-fIuoro-phenylamino)-3,4-difluoro-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide; ,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxymethyl- cyclopropylmethoxy)-benzamide; ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hydroxymethyl- cyclopropylmethoxy)-benzamide; ,4, 5 -Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-( 1 -hydroxymethyl- cyclopropylmethoxy)-benzamide; -Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l- hydroxymethyl-cyclopropylmethoxy)-benzamide; ,5-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide; -(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(l-hydroxymethyl- cyclopropylmethoxy)-benzamide; -(4-Bromo-2-fluoro-phenylamino)-3 ,4-difluoro-N-( 1 -hydroxymethyl- cyclopropylmethoxy)-benzamide; 2-(4-Chloro-2-fluoro-phenylamino)-3 ,4-difluoro-N-( 1 -hydroxymethyl- cyclopropylmethoxy)-benzamide; 5-Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(l- hydroxymethyl-cyclopropylmethoxy)-benzamide; 2-(2,4-Difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-3-methoxy- propoxy)-benzamide; 5-Chloro-2-(2,4-difluoro-phenylamino)-3,4-difluoro-N-(2-hydroxy-3- methoxy-propoxy)-benzamide; 2-(4-Bromo-2-fluoro-phenylamino)-3 ,4-difluoro-N-(2-hydroxy-3 - methoxy-propoxy)-benzamide; 2-(4-Chloro-2-fluoro-phenylamino)-3 ,4-difluoro-N-(2-hydroxy-3 - methoxy-propoxy)-benzamide; , 4, 5 -Trifluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenylamino- ethoxy)-benzamide; -Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2- phenylamino-ethoxy)-benzamide; -(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-phenylamino- ethoxy)-b enzamide; -(2-Chloro-4-iodo-phenylamino)-3 ,4, 5 -trifluoro-N-(2-phenylamino- ethoxy)-benzamide; ,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenylamino- ethoxy)-b enzamide; 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2- phenylamino-ethoxy)-benzamide; 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-((S)-3-hydroxy-2- methylamino-propoxy)-b enzamide; 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-((R)-3-hydroxy-2- methylamino-propoxy)-benzamide; (S)-5-Chloro-3,4-Difluoro-2-(2-fluoro-4-iodo-ρhenylamino)-N-(3- hydroxy-2-methylamino-propoxy)-benzamide; (R)-5 -Chloro-3 ,4-Difluoro-2-(2-fluoro-4-iodo-ρhenylamino)-N-(3 - hydroxy-2-methylamino-propoxy)-benzamide; (S)-5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3- hydroxy-2-methylamino-propoxy)-benzamide; (R)-5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3- hydroxy-2-methylamino-propoxy)-benzamide; and 3 ,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-3 - methylamino-propoxy)-benzamide.
PCT/US2001/022331 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids Ceased WO2002006213A2 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
HU0302781A HU230251B1 (en) 2000-07-19 2001-07-12 Ester derivatives of 4-iodo phenylamino benzhydroxamic acids and pharmaceutical compositions containing them
HK03108249.9A HK1055943B (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
DZ013401A DZ3401A1 (en) 2000-07-19 2001-07-12 OXYGEN ESTERS OF 4-IODOPHENYLAMINO BENZHYDROXAMIC ACIDS
BRPI0112584-2 BRPI0112584B8 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical composition and combination
EA200300065A EA005818B1 (en) 2000-07-19 2001-07-12 Oxygenated esters of phenylamino benzhydroxamic acids
CA002416685A CA2416685C (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US10/333,399 US6960614B2 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
ES01952778.7T ES2461854T3 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodophenylamino-benzhydroxamic acids
AU2001273498A AU2001273498B2 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
PL365775A PL203387B1 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SK42-2003A SK288317B6 (en) 2000-07-19 2001-07-12 Oxygenated 4-iodophenylaminobenzhydroxamic acid esters
NZ524120A NZ524120A (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SI200131033T SI1301472T1 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP01952778.7A EP1301472B1 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
APAP/P/2003/002742A AP2003002742A0 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
HR20030083A HRP20030083A2 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
DK01952778.7T DK1301472T3 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo-phenylamino-benzhydroxamic acids
AU7349801A AU7349801A (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
KR1020037000810A KR100773621B1 (en) 2000-07-19 2001-07-12 Oxygenated Ester of 4-iodo Phenylamino Benzhydroxamic Acid
IL15381701A IL153817A0 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EEP200300030A EE05450B1 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodophen laminobenzh droxamic acids, their crystalline forms and pharmaceutical compositions and their use
JP2002512119A JP3811775B2 (en) 2000-07-19 2001-07-12 Oxygenated ester of 4-iodophenylaminobenzhydroxamic acid
APAP/P/2001/002217A AP2001002217A0 (en) 2000-07-19 2001-07-12 4-IODOPHENYLAMINO BENZHYDROXAMIC ACID OXYGENES ESTERS
UA2003021455A UA76425C2 (en) 2000-07-19 2001-12-07 Oxygenated esters of 4-iodophenylamino benzhydroxamic acids, crystalline form (variants), pharmaceutical composition on their basis
IS6666A IS6666A (en) 2000-07-19 2002-12-31 Oxidized esters of 4-iodine phenylamino benzhydroxamic acids
NO20030249A NO328436B1 (en) 2000-07-19 2003-01-17 Oxygenated esters of 4-iodo-phenylamino-benzohydroxamic acids
BG107564A BG66386B1 (en) 2000-07-19 2003-02-17 OXYGENED ESTERS OF 4-IODO PHENYLAMINE BENZHYDROXAMIDIC ACIDS
US11/102,307 US7411001B2 (en) 2000-07-19 2005-04-07 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21937200P 2000-07-19 2000-07-19
US60/219,372 2000-07-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/102,307 Continuation US7411001B2 (en) 2000-07-19 2005-04-07 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids

Publications (2)

Publication Number Publication Date
WO2002006213A2 true WO2002006213A2 (en) 2002-01-24
WO2002006213A3 WO2002006213A3 (en) 2002-05-23

Family

ID=22819013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022331 Ceased WO2002006213A2 (en) 2000-07-19 2001-07-12 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids

Country Status (43)

Country Link
US (2) US6960614B2 (en)
EP (1) EP1301472B1 (en)
JP (1) JP3811775B2 (en)
KR (1) KR100773621B1 (en)
CN (1) CN1219753C (en)
AP (2) AP2003002742A0 (en)
AR (2) AR033542A1 (en)
AU (2) AU2001273498B2 (en)
BG (1) BG66386B1 (en)
BR (1) BRPI0112584B8 (en)
CA (1) CA2416685C (en)
CZ (1) CZ303815B6 (en)
DK (1) DK1301472T3 (en)
DZ (1) DZ3401A1 (en)
EA (1) EA005818B1 (en)
EC (1) ECSP034430A (en)
EE (1) EE05450B1 (en)
ES (1) ES2461854T3 (en)
GE (1) GEP20053496B (en)
GT (1) GT200100141A (en)
HR (1) HRP20030083A2 (en)
HU (1) HU230251B1 (en)
IL (1) IL153817A0 (en)
IS (1) IS6666A (en)
MA (1) MA26930A1 (en)
MY (1) MY151458A (en)
NO (1) NO328436B1 (en)
NZ (1) NZ524120A (en)
OA (1) OA12333A (en)
PA (1) PA8522601A1 (en)
PE (1) PE20020664A1 (en)
PL (1) PL203387B1 (en)
PT (1) PT1301472E (en)
PY (1) PY0117288A (en)
SI (1) SI1301472T1 (en)
SK (1) SK288317B6 (en)
SV (1) SV2002000563A (en)
TN (1) TNSN01108A1 (en)
TW (1) TWI311551B (en)
UA (1) UA76425C2 (en)
WO (1) WO2002006213A2 (en)
YU (1) YU2503A (en)
ZA (1) ZA200300348B (en)

Cited By (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1262176A1 (en) * 2001-05-09 2002-12-04 Warner-Lambert Company Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2003084540A3 (en) * 2002-04-09 2004-04-01 Novartis Ag Compositions comprising mmp7 modulators for the treatment of chronic pain
US6770778B2 (en) 2002-01-23 2004-08-03 Pfizer Inc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
WO2005040098A1 (en) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US6891066B2 (en) 2002-01-23 2005-05-10 Warner-Lambert Company N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
WO2005054179A2 (en) 2003-12-03 2005-06-16 Leo Pharma A/S Hydroxamic acid esters and pharmaceutical use thereof
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2006061712A3 (en) * 2004-12-10 2006-07-27 Pfizer Use of mek inhibitors in treating abnormal cell growth
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2006134469A1 (en) * 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
WO2007054556A1 (en) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2007088345A1 (en) 2006-01-31 2007-08-09 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2007042885A3 (en) * 2005-10-07 2007-12-06 Pfizer Prod Inc Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
JP2008019277A (en) * 2002-03-13 2008-01-31 Array Biopharma Inc N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2008024724A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7485643B2 (en) 2003-11-19 2009-02-03 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
WO2009082687A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
WO2009085983A1 (en) * 2007-12-19 2009-07-09 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
WO2010003022A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
WO2010022725A1 (en) 2008-08-27 2010-03-04 Leo Pharma A/S Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
US7696218B2 (en) 2006-10-23 2010-04-13 Takeda San Diego, Inc. Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
WO2010051933A2 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US7745663B2 (en) 2004-07-26 2010-06-29 Chugai Seiyaku Kabushiki Kaisha 5-Substituted-2-phenylamino benzamides as MEK inhibitors
US7759518B2 (en) 2005-07-21 2010-07-20 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US7803839B2 (en) 2005-10-07 2010-09-28 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
EP2298768A1 (en) 2004-06-11 2011-03-23 Japan Tobacco, Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
US7923460B2 (en) 2003-04-12 2011-04-12 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
WO2011047788A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
US7956191B2 (en) 2004-10-20 2011-06-07 Merck Serono Sa 3-arylamino pyridine derivatives
US7999006B2 (en) 2006-12-14 2011-08-16 Exelixis, Inc. Methods of using MEK inhibitors
US8003651B2 (en) 2006-07-06 2011-08-23 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2361905A1 (en) 2005-05-18 2011-08-31 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US8030317B2 (en) 2006-12-20 2011-10-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8063085B2 (en) 2007-12-20 2011-11-22 Hoffmann-La Roche Inc. Substituted hydantoins
US8084645B2 (en) * 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
RU2439053C1 (en) * 2010-08-03 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Diarylamines and synthesis method thereof
RU2444524C2 (en) * 2006-08-21 2012-03-10 Дженентек, Инк. Azabenzothiophenyl compounds and methods of use
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
WO2012059041A1 (en) 2010-11-02 2012-05-10 Centaurus Biopharma Co., Ltd. Novel 6-arylamino pyridone carboxamide as mek inhibitors
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US8258152B2 (en) 2007-06-12 2012-09-04 Genentech, Inc. N-substituted azaindoles and methods of use
US8293763B2 (en) 2007-12-19 2012-10-23 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
WO2012160130A1 (en) 2011-05-25 2012-11-29 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2012162293A1 (en) * 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8350037B2 (en) 2007-07-23 2013-01-08 Ucb Pharma, S.A. Thieno-pyridine derivatives as MEK inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8404725B2 (en) 2008-08-04 2013-03-26 Merck Patent Gmbh Phenylamino isonicotinamide compounds
WO2013066483A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
US8487101B2 (en) 2008-01-21 2013-07-16 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
WO2013107283A1 (en) 2012-01-17 2013-07-25 Tianjin Binjiang Pharma, Inc. Benzoheterocyclic compounds and use thereof
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2013178581A1 (en) 2012-05-31 2013-12-05 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8637491B2 (en) 2008-06-19 2014-01-28 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
US8680114B2 (en) 2003-11-21 2014-03-25 Array Biopharma, Inc. AKT protein kinase inhibitors
WO2014085381A1 (en) 2012-11-29 2014-06-05 Novartis Ag Pharmaceutical combinations
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
WO2014133071A1 (en) 2013-02-27 2014-09-04 第一三共株式会社 Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
WO2014160160A2 (en) 2013-03-13 2014-10-02 Novartis Ag Antibody drug conjugates
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
US8937068B2 (en) 2005-11-11 2015-01-20 Zentaris Gmbh Pyridopyrazine derivatives and their use
WO2015038743A1 (en) * 2013-09-11 2015-03-19 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
WO2015134652A1 (en) 2014-03-04 2015-09-11 Bahram Valamehr Improved reprogramming methods and cell culture platforms
US9150548B2 (en) 2011-04-01 2015-10-06 Genentech, Inc. Combinations of AKT inhibitor compounds and vemurafenib, and methods of use
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016075670A1 (en) 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016103155A1 (en) 2014-12-23 2016-06-30 Novartis Ag Triazolopyrimidine compounds and uses thereof
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2968345A4 (en) * 2013-03-13 2016-08-17 Univ Michigan DOUBLE MEK / PI3K INHIBITORS AND THERAPEUTIC PROCESSES USING SAME
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
WO2016151499A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
WO2017037579A1 (en) 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof
WO2017072662A1 (en) 2015-10-29 2017-05-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
US9732319B2 (en) 2010-12-22 2017-08-15 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
WO2017221100A1 (en) 2016-06-20 2017-12-28 Novartis Ag Imidazopyrimidine compounds useful for the treatment of cancer
WO2018009638A1 (en) 2016-07-06 2018-01-11 The Regents Of The University Of Michigan MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
WO2018163051A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods of treatment of cancer with reduced ubb expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018198091A1 (en) 2017-04-28 2018-11-01 Novartis Ag Antibody conjugates comprising toll-like receptor agonist and combination therapies
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP3405568A1 (en) 2016-01-20 2018-11-28 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US10287606B2 (en) 2015-11-04 2019-05-14 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
EP3514178A1 (en) 2013-03-15 2019-07-24 Novartis AG Antibody drug conjugates
US10500193B2 (en) 2011-11-02 2019-12-10 Synta Pharmaceuticals Corporation Combination therapy of HSP90 inhibitors with platinum-containing agents
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020012334A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020021322A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
WO2020035779A1 (en) 2018-08-17 2020-02-20 Novartis Ag Urea compounds and compositions as smarca2/brm atpase inhibitors
WO2020064693A1 (en) 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020106647A2 (en) 2018-11-19 2020-05-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US10752594B2 (en) 2013-03-14 2020-08-25 Sumitomo Dainippon Pharma Oncology, Inc. JAK1 and ALK2 inhibitors and methods for their use
US10766865B2 (en) 2012-10-16 2020-09-08 Sumitomo Dainippon Pharma Oncology, Inc. PKM2 modulators and methods for their use
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10875864B2 (en) 2011-07-21 2020-12-29 Sumitomo Dainippon Pharma Oncology, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
WO2021043724A1 (en) 2019-09-02 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia
WO2021057853A1 (en) 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
US11096964B2 (en) 2016-01-20 2021-08-24 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2021206167A1 (en) 2020-04-10 2021-10-14 大鵬薬品工業株式会社 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor
WO2021252920A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3936121A1 (en) 2015-03-31 2022-01-12 The General Hospital Corporation Self assembling molecules for targeted drug delivery
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022033492A1 (en) 2020-08-10 2022-02-17 Novartis Ag Quinoline compounds and compositions for inhibiting ezh2
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4039256A1 (en) 2013-11-11 2022-08-10 Amgen Inc. Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
US11414396B2 (en) 2012-10-12 2022-08-16 Exelixis, Inc. Process for making compounds for use in the treatment of cancer
WO2022177555A1 (en) 2021-02-17 2022-08-25 Springworks Therapeutics, Inc. Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022177556A1 (en) 2021-02-17 2022-08-25 Warner-Lambert Company Llc Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof
WO2022177557A1 (en) 2021-02-17 2022-08-25 Springworks Therapeutics, Inc. Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022243846A1 (en) 2021-05-18 2022-11-24 Novartis Ag Combination therapies
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11746103B2 (en) 2020-12-10 2023-09-05 Sumitomo Pharma Oncology, Inc. ALK-5 inhibitors and uses thereof
WO2023168203A1 (en) 2022-03-04 2023-09-07 Kinnate Biopharma Inc. Inhibitors of mek kinase
US11766436B2 (en) 2018-05-04 2023-09-26 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2023209611A1 (en) 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023223205A1 (en) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Solid state forms of mirdametinib and process for preparation thereof
US11827635B2 (en) 2019-05-21 2023-11-28 Amgen Inc. Solid state forms
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
US11905281B2 (en) 2017-05-22 2024-02-20 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11975002B2 (en) 2016-03-04 2024-05-07 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11993597B2 (en) 2017-09-08 2024-05-28 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US12011449B2 (en) 2016-09-19 2024-06-18 Novartis Ag Therapeutic combinations comprising a c-RAF inhibitor
US12083121B2 (en) 2018-06-12 2024-09-10 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
US12187703B2 (en) 2019-05-13 2025-01-07 Novartis Ag Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
US12583854B2 (en) 2018-06-11 2026-03-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3401A1 (en) * 2000-07-19 2002-01-24 Warner Lambert Co OXYGEN ESTERS OF 4-IODOPHENYLAMINO BENZHYDROXAMIC ACIDS
WO2002102232A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
JP2006508974A (en) * 2002-11-15 2006-03-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Combination chemotherapy comprising MEK inhibitor and capecitabine (CAPECITABINE) for treating cancer
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
CN101076335A (en) * 2004-08-18 2007-11-21 默克公司 Mitotic kinesin inhibitors
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
ES2376771T3 (en) * 2006-08-21 2012-03-16 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
US8278105B2 (en) * 2008-09-09 2012-10-02 University Of Southern California Induction, propagation and isolation of liver progenitor cells
ES2557316T3 (en) 2009-09-08 2016-01-25 F. Hoffmann-La Roche Ag 4-substituted pyridine-3-yl-carboxamide compounds and methods of use
AU2010298277B2 (en) * 2009-09-23 2014-07-03 Novartis Ag Combination
KR101489045B1 (en) * 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Combinations of a pi3k inhibitor and a mek inhibitor
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
PH12012501662A1 (en) 2010-02-18 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Triazolo [4,5 - b] pyridin derivatives
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN102532089B (en) * 2011-12-22 2014-05-14 凯莱英医药集团（天津）股份有限公司 Method for preparing chirality glycerol acetonide
WO2014078669A1 (en) * 2012-11-15 2014-05-22 Duquesne University Of The Holy Ghost Carboxylic acid ester prodrug inhibitors of mek
EP2968375B1 (en) 2013-03-14 2019-06-12 MSD International GmbH Methods for preparing sglt2 inhibitors
CN104788365B (en) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 Pyrazinamide derivative, preparation method and application
CN105384754B (en) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 Heterocycle compound as kinases inhibitor and its preparation method and application
CN104906081A (en) * 2015-05-25 2015-09-16 上海中医药大学附属曙光医院 Application of compound in preparation of osteoarthritis therapeutic drug
CN105646438A (en) * 2015-12-22 2016-06-08 天津大学 Ketal sugar alcohol-based micromolecular gelator and preparation method and application thereof
CN112533602A (en) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 AXL kinase inhibitors and uses thereof
CN114524753B (en) * 2022-02-24 2024-03-26 安徽大学 Synthesis method of polysubstituted hydroxamic acid derivative
US11780800B1 (en) 2022-03-17 2023-10-10 Springworks Therapeutics, Inc. Fluorinated phenylamino compounds and pharmaceutical compositions
IL322816A (en) 2023-03-16 2025-10-01 Springworks Therapeutics Inc Dosage forms of mirdametinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037141A1 (en) 1998-12-22 2000-06-29 Warner-Lambert Company Combination chemotherapy
WO2000040327A1 (en) 1998-12-30 2000-07-13 The Lubrizol Corporation Emulsion compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368207A (en) * 1977-05-31 1983-01-11 Block Drug Company Inc. Higher alcohol toxicants effective against insects
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5783202A (en) * 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
CA2290509A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
JP2002531539A (en) 1998-12-04 2002-09-24 ニューロサーチ、アクティーゼルスカブ Ion channel regulator
AU2180500A (en) 1998-12-15 2000-07-03 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
JP2002534380A (en) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Treatment of asthma with MEK inhibitors
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
JP2001055376A (en) 1999-01-13 2001-02-27 Warner Lambert Co Diaryl amine
CA2355470C (en) * 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
JP2003504400A (en) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Method for treating chronic pain using MEK inhibitor
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
DZ3401A1 (en) * 2000-07-19 2002-01-24 Warner Lambert Co OXYGEN ESTERS OF 4-IODOPHENYLAMINO BENZHYDROXAMIC ACIDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037141A1 (en) 1998-12-22 2000-06-29 Warner-Lambert Company Combination chemotherapy
WO2000040327A1 (en) 1998-12-30 2000-07-13 The Lubrizol Corporation Emulsion compositions

Cited By (336)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972298B2 (en) 2001-05-09 2005-12-06 Warner-Lambert Company Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor
EP1262176A1 (en) * 2001-05-09 2002-12-04 Warner-Lambert Company Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US6770778B2 (en) 2002-01-23 2004-08-03 Pfizer Inc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
US7078438B2 (en) 2002-01-23 2006-07-18 Warner-Lambert Company N-(4 substituted phenyl)-anthranilic acid hydroxamate esters
US6891066B2 (en) 2002-01-23 2005-05-10 Warner-Lambert Company N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
US7425637B2 (en) 2002-03-13 2008-09-16 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP2275102A1 (en) 2002-03-13 2011-01-19 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP2130537A1 (en) 2002-03-13 2009-12-09 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
US8003805B2 (en) 2002-03-13 2011-08-23 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US8513293B2 (en) 2002-03-13 2013-08-20 Array Biopharma Inc. Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
JP2012224649A (en) * 2002-03-13 2012-11-15 Array Biopharma Inc N3 alkylated benzimidazole derivative as mek inhibitor
US8178693B2 (en) 2002-03-13 2012-05-15 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US8193230B2 (en) 2002-03-13 2012-06-05 Array Biopharma Inc. Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
US8193229B2 (en) 2002-03-13 2012-06-05 Array Biopharma Inc. Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
JP2008163034A (en) * 2002-03-13 2008-07-17 Array Biopharma Inc N3 alkylated benzimidazole derivatives as MEK inhibitors
EP3000810A1 (en) 2002-03-13 2016-03-30 Array Biopharma, Inc. N3 alkylated benzimidazole derivative as mek inhibitor
EP2130536A1 (en) 2002-03-13 2009-12-09 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7973170B2 (en) 2002-03-13 2011-07-05 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US8193231B2 (en) 2002-03-13 2012-06-05 Array Biopharma Inc. Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
JP2008019277A (en) * 2002-03-13 2008-01-31 Array Biopharma Inc N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2003084540A3 (en) * 2002-04-09 2004-04-01 Novartis Ag Compositions comprising mmp7 modulators for the treatment of chronic pain
US7923460B2 (en) 2003-04-12 2011-04-12 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
US7230099B2 (en) 2003-09-03 2007-06-12 Array Biopharma, Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7511058B2 (en) 2003-09-03 2009-03-31 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US8084645B2 (en) * 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
KR101013932B1 (en) * 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 N-[(R) -2,3-dihydroxy-propoxy] -3,4-difluoro-2- (2-fluoro-4-iodophenylamino) -benzamide polymorph form
JP2007509125A (en) * 2003-10-21 2007-04-12 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Polymorph of N-[(R) -2,3-dihydroxy-propoxy] -3,4-difluoro-2- (2-fluoro-4-iodo-phenylamino) -benzamide
WO2005040098A1 (en) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7060856B2 (en) 2003-10-21 2006-06-13 Warner-Lambert Company Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US8211920B2 (en) 2003-11-19 2012-07-03 Array Biopharma Inc. 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7576072B2 (en) 2003-11-19 2009-08-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7598383B2 (en) 2003-11-19 2009-10-06 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8431574B2 (en) 2003-11-19 2013-04-30 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7485643B2 (en) 2003-11-19 2009-02-03 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
EP2251327A2 (en) 2003-11-19 2010-11-17 Array Biopharma, Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8101611B2 (en) 2003-11-19 2012-01-24 Array Biopharma Inc. Substituted pyridazines inhibitors of MEK
US8268852B2 (en) 2003-11-19 2012-09-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7772234B2 (en) 2003-11-19 2010-08-10 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8680114B2 (en) 2003-11-21 2014-03-25 Array Biopharma, Inc. AKT protein kinase inhibitors
WO2005054179A3 (en) * 2003-12-03 2005-08-04 Leo Pharma As Hydroxamic acid esters and pharmaceutical use thereof
US8034811B2 (en) 2003-12-03 2011-10-11 Leo Pharma A/S Hydroxamic acid esters and pharmaceutical use thereof
WO2005054179A2 (en) 2003-12-03 2005-06-16 Leo Pharma A/S Hydroxamic acid esters and pharmaceutical use thereof
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US8835443B2 (en) 2004-06-11 2014-09-16 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP2298768A1 (en) 2004-06-11 2011-03-23 Japan Tobacco, Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
US8575391B2 (en) 2004-07-26 2013-11-05 Chugai Seiyaku Kabushiki Kaisha 5-substituted-2-phenylamino benzamides as MEK inhibitors
US7745663B2 (en) 2004-07-26 2010-06-29 Chugai Seiyaku Kabushiki Kaisha 5-Substituted-2-phenylamino benzamides as MEK inhibitors
US8198457B2 (en) 2004-10-20 2012-06-12 Merck Serono S.A. 3-arylamino pyridine derivatives
US8841459B2 (en) 2004-10-20 2014-09-23 Merck Serono Sa 3-arylamino pyridine derivatives
US8524911B2 (en) 2004-10-20 2013-09-03 Merck Serono Sa 3-arylamino pyridine derivatives
US7956191B2 (en) 2004-10-20 2011-06-07 Merck Serono Sa 3-arylamino pyridine derivatives
WO2006061712A3 (en) * 2004-12-10 2006-07-27 Pfizer Use of mek inhibitors in treating abnormal cell growth
EP2361905A1 (en) 2005-05-18 2011-08-31 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
US8299076B2 (en) 2005-05-18 2012-10-30 Array Biopharma Inc. Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
EP2364973A1 (en) 2005-05-18 2011-09-14 Array Biopharma, Inc. Heterocyclic inhibitors of MEK and Methods of use thereof
WO2006134469A1 (en) * 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
US7759518B2 (en) 2005-07-21 2010-07-20 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US8829052B2 (en) 2005-07-21 2014-09-09 Ardea Biosciences, Inc. Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK
US7915250B2 (en) 2005-10-07 2011-03-29 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7803839B2 (en) 2005-10-07 2010-09-28 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
US8362002B2 (en) 2005-10-07 2013-01-29 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
WO2007042885A3 (en) * 2005-10-07 2007-12-06 Pfizer Prod Inc Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
US11597699B2 (en) 2005-10-07 2023-03-07 Exelixis, Inc. MEK inhibitors and methods of their use
US8937068B2 (en) 2005-11-11 2015-01-20 Zentaris Gmbh Pyridopyrazine derivatives and their use
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2007054556A1 (en) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
US8394822B2 (en) 2006-01-31 2013-03-12 Ucb Pharma, S.A. Thieno-pyridine derivatives as MEK inhibitors
US8283359B2 (en) 2006-01-31 2012-10-09 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
WO2007088345A1 (en) 2006-01-31 2007-08-09 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
US8604051B2 (en) 2006-01-31 2013-12-10 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8003651B2 (en) 2006-07-06 2011-08-23 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8853199B2 (en) 2006-07-06 2014-10-07 Array Biopharma, Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
US9359340B2 (en) 2006-07-06 2016-06-07 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8846681B2 (en) 2006-07-06 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2444524C2 (en) * 2006-08-21 2012-03-10 Дженентек, Инк. Azabenzothiophenyl compounds and methods of use
US7893085B2 (en) 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
KR101475088B1 (en) * 2006-08-21 2014-12-23 제넨테크, 인크. Aza-benzothiophenyl compounds and methods of use
WO2008024724A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US7696218B2 (en) 2006-10-23 2010-04-13 Takeda San Diego, Inc. Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
US7943626B2 (en) 2006-10-23 2011-05-17 Takeda Pharmaceutical Company Limited Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
US8088783B2 (en) 2006-10-23 2012-01-03 Qing Dong MAPK/ERK kinase inhibitors
US7999006B2 (en) 2006-12-14 2011-08-16 Exelixis, Inc. Methods of using MEK inhibitors
US8030317B2 (en) 2006-12-20 2011-10-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US8470837B2 (en) 2006-12-20 2013-06-25 Takeda Pharmaceutical Company Limted MAPK/ERK kinase inhibitors
US8258152B2 (en) 2007-06-12 2012-09-04 Genentech, Inc. N-substituted azaindoles and methods of use
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8350037B2 (en) 2007-07-23 2013-01-08 Ucb Pharma, S.A. Thieno-pyridine derivatives as MEK inhibitors
US8293763B2 (en) 2007-12-19 2012-10-23 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
EP2690101A1 (en) 2007-12-19 2014-01-29 Genentech, Inc. 5-Anilinoimidazopyridines and Methods of Use
US8288408B2 (en) 2007-12-19 2012-10-16 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
US7923456B2 (en) 2007-12-19 2011-04-12 Genentech, Inc. 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase
WO2009085983A1 (en) * 2007-12-19 2009-07-09 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
AU2008343065B2 (en) * 2007-12-19 2012-04-05 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
US8063085B2 (en) 2007-12-20 2011-11-22 Hoffmann-La Roche Inc. Substituted hydantoins
AU2008340247B2 (en) * 2007-12-21 2012-11-15 Genentech, Inc. Azaindolizines and methods of use
US8486963B2 (en) 2007-12-21 2013-07-16 Genentech, Inc. Azaindolizines and methods of use
WO2009082687A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8487101B2 (en) 2008-01-21 2013-07-16 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
US8637491B2 (en) 2008-06-19 2014-01-28 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
WO2010003022A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
US8492427B2 (en) 2008-07-01 2013-07-23 Genentech, Inc. Isoindolones derivatives as MEK kinase inhibitors and methods of use
US8404725B2 (en) 2008-08-04 2013-03-26 Merck Patent Gmbh Phenylamino isonicotinamide compounds
WO2010022725A1 (en) 2008-08-27 2010-03-04 Leo Pharma A/S Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
WO2010051933A2 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047788A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
US8637246B2 (en) 2010-02-25 2014-01-28 Dana-Farber Cancer Institute, Inc. BRAF mutations conferring resistance to BRAF inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US9279144B2 (en) 2010-02-25 2016-03-08 Dana-Farber Cancer Institute, Inc. Screening method for BRAF inhibitors
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US12522872B2 (en) 2010-03-09 2026-01-13 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
RU2439053C1 (en) * 2010-08-03 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Diarylamines and synthesis method thereof
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
WO2012059041A1 (en) 2010-11-02 2012-05-10 Centaurus Biopharma Co., Ltd. Novel 6-arylamino pyridone carboxamide as mek inhibitors
US9732319B2 (en) 2010-12-22 2017-08-15 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
US10844356B2 (en) 2010-12-22 2020-11-24 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
US12415989B2 (en) 2010-12-22 2025-09-16 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
US9717730B2 (en) 2011-04-01 2017-08-01 Genentech, Inc. Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
US9150548B2 (en) 2011-04-01 2015-10-06 Genentech, Inc. Combinations of AKT inhibitor compounds and vemurafenib, and methods of use
US9150549B2 (en) 2011-04-01 2015-10-06 Genentech, Inc. Combinations of AKT inhibitor compounds and erlotinib, and methods of use
US9346789B2 (en) 2011-04-01 2016-05-24 Genentech, Inc. Combinations of AKT inhibitor compounds and abiraterone, and methods of use
US10092567B2 (en) 2011-04-01 2018-10-09 Genentech, Inc. Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
US9610289B2 (en) 2011-04-01 2017-04-04 Genentech, Inc. Combinations of AKT inhibitor compounds and erlotinib, and methods of use
WO2012162293A1 (en) * 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
WO2012160130A1 (en) 2011-05-25 2012-11-29 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
US9833439B2 (en) 2011-05-25 2017-12-05 Universite Paris Descartes ERK inhibitors for use in treating spinal muscular atrophy
US10875864B2 (en) 2011-07-21 2020-12-29 Sumitomo Dainippon Pharma Oncology, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
WO2013066483A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US10500193B2 (en) 2011-11-02 2019-12-10 Synta Pharmaceuticals Corporation Combination therapy of HSP90 inhibitors with platinum-containing agents
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
US9290468B2 (en) 2012-01-17 2016-03-22 Shanghai Kechow Pharma, Inc. Benzoheterocyclic compounds and use thereof
US9937158B2 (en) 2012-01-17 2018-04-10 Shanghai Kechow Pharma, Inc. Benzoheterocyclic compounds and use thereof
WO2013107283A1 (en) 2012-01-17 2013-07-25 Tianjin Binjiang Pharma, Inc. Benzoheterocyclic compounds and use thereof
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2013178581A1 (en) 2012-05-31 2013-12-05 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
US11414396B2 (en) 2012-10-12 2022-08-16 Exelixis, Inc. Process for making compounds for use in the treatment of cancer
US10766865B2 (en) 2012-10-16 2020-09-08 Sumitomo Dainippon Pharma Oncology, Inc. PKM2 modulators and methods for their use
WO2014085381A1 (en) 2012-11-29 2014-06-05 Novartis Ag Pharmaceutical combinations
US9446043B2 (en) 2012-11-29 2016-09-20 Novartis Ag Pharmaceutical combinations
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
WO2014133071A1 (en) 2013-02-27 2014-09-04 第一三共株式会社 Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway
US10139415B2 (en) 2013-02-27 2018-11-27 Daiichi Sankyo Company, Limited Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
US9611258B2 (en) 2013-03-13 2017-04-04 The Regents Of The University Of Michigan Dual MEK/PI3K inhibitors and therapeutic methods using the same
EP2968345A4 (en) * 2013-03-13 2016-08-17 Univ Michigan DOUBLE MEK / PI3K INHIBITORS AND THERAPEUTIC PROCESSES USING SAME
WO2014160160A2 (en) 2013-03-13 2014-10-02 Novartis Ag Antibody drug conjugates
US10752594B2 (en) 2013-03-14 2020-08-25 Sumitomo Dainippon Pharma Oncology, Inc. JAK1 and ALK2 inhibitors and methods for their use
EP3514178A1 (en) 2013-03-15 2019-07-24 Novartis AG Antibody drug conjugates
WO2015038743A1 (en) * 2013-09-11 2015-03-19 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
US11465978B2 (en) 2013-09-11 2022-10-11 The Administrators Of The Tulane Educational Fund Anthranilic amides and the use thereof
EP4039256A1 (en) 2013-11-11 2022-08-10 Amgen Inc. Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
EP4647498A2 (en) 2014-03-04 2025-11-12 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
WO2015134652A1 (en) 2014-03-04 2015-09-11 Bahram Valamehr Improved reprogramming methods and cell culture platforms
EP3805369A1 (en) 2014-03-04 2021-04-14 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
EP3604499A1 (en) 2014-03-04 2020-02-05 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
US11268069B2 (en) 2014-03-04 2022-03-08 Fate Therapeutics, Inc. Reprogramming methods and cell culture platforms
US12264322B2 (en) 2014-06-04 2025-04-01 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
US10954529B2 (en) 2014-06-04 2021-03-23 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
EP3662903A2 (en) 2014-10-03 2020-06-10 Novartis AG Combination therapies
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016075670A1 (en) 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016103155A1 (en) 2014-12-23 2016-06-30 Novartis Ag Triazolopyrimidine compounds and uses thereof
US12385012B2 (en) 2015-01-26 2025-08-12 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11634688B2 (en) 2015-01-26 2023-04-25 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2016151499A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
EP3936121A1 (en) 2015-03-31 2022-01-12 The General Hospital Corporation Self assembling molecules for targeted drug delivery
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
WO2017037579A1 (en) 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof
EP4241850A2 (en) 2015-08-28 2023-09-13 Novartis AG Mdm2 inhibitors and combinations thereof
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
US12351831B2 (en) 2015-10-16 2025-07-08 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
WO2017072662A1 (en) 2015-10-29 2017-05-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
EP3797797A1 (en) 2015-10-29 2021-03-31 Novartis AG Antibody conjugates comprising toll-like receptor agonist
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11352607B2 (en) 2015-11-04 2022-06-07 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US11162076B2 (en) 2015-11-04 2021-11-02 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11162075B2 (en) 2015-11-04 2021-11-02 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10287606B2 (en) 2015-11-04 2019-05-14 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US11072781B2 (en) 2015-11-04 2021-07-27 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US10947505B2 (en) 2015-11-04 2021-03-16 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US12410403B2 (en) 2015-11-04 2025-09-09 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US12419870B2 (en) 2016-01-20 2025-09-23 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US12281329B2 (en) 2016-01-20 2025-04-22 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US11096964B2 (en) 2016-01-20 2021-08-24 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US11413309B2 (en) 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3405568A1 (en) 2016-01-20 2018-11-28 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US11975002B2 (en) 2016-03-04 2024-05-07 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
WO2017221100A1 (en) 2016-06-20 2017-12-28 Novartis Ag Imidazopyrimidine compounds useful for the treatment of cancer
US11548897B2 (en) 2016-06-20 2023-01-10 Novartis Ag Crystalline forms of a triazolopyrimidine compound
WO2018009638A1 (en) 2016-07-06 2018-01-11 The Regents Of The University Of Michigan MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME
EP4086250A2 (en) 2016-07-06 2022-11-09 The Regents Of The University Of Michigan Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
US10919877B2 (en) 2016-07-06 2021-02-16 The Regents Of The University Of Michigan Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
US12011449B2 (en) 2016-09-19 2024-06-18 Novartis Ag Therapeutic combinations comprising a c-RAF inhibitor
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
WO2018163051A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods of treatment of cancer with reduced ubb expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018198091A1 (en) 2017-04-28 2018-11-01 Novartis Ag Antibody conjugates comprising toll-like receptor agonist and combination therapies
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US12036227B2 (en) 2017-05-02 2024-07-16 Novartis Ag Combination therapy
EP4272740A1 (en) 2017-05-02 2023-11-08 Novartis AG Combination therapy comprising a raf inhibitor and trametinib
US11905281B2 (en) 2017-05-22 2024-02-20 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
US11993597B2 (en) 2017-09-08 2024-05-28 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
US12440491B2 (en) 2018-05-04 2025-10-14 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11766436B2 (en) 2018-05-04 2023-09-26 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US12583854B2 (en) 2018-06-11 2026-03-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US12083121B2 (en) 2018-06-12 2024-09-10 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
EP4306111A2 (en) 2018-07-10 2024-01-17 Novartis AG 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020012334A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
EP4545100A2 (en) 2018-07-25 2025-04-30 Advanced Accelerator Applications S.A. Stable, concentrated radionuclide complex solutions
EP4541379A2 (en) 2018-07-25 2025-04-23 Advanced Accelerator Applications S.A. Stable, concentrated radionuclide complex solutions
EP4640241A2 (en) 2018-07-25 2025-10-29 Advanced Accelerator Applications S.A. Stable, concentrated radionuclide complex solutions
EP4541381A2 (en) 2018-07-25 2025-04-23 Advanced Accelerator Applications S.A. Stable, concentrated radionuclide complex solutions
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020021322A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
EP4541380A2 (en) 2018-07-25 2025-04-23 Advanced Accelerator Applications S.A. Stable, concentrated radionuclide complex solutions
EP4545101A2 (en) 2018-07-25 2025-04-30 Advanced Accelerator Applications S.A. Stable, concentrated radionuclide complex solutions
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
WO2020035779A1 (en) 2018-08-17 2020-02-20 Novartis Ag Urea compounds and compositions as smarca2/brm atpase inhibitors
EP4219488A1 (en) 2018-08-17 2023-08-02 Novartis AG Method for the preparation of urea compounds as smarca2/brm-atpase inhibitors
WO2020064693A1 (en) 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
US12582657B2 (en) 2018-11-19 2026-03-24 Amgen Inc. Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
EP4685160A2 (en) 2018-11-19 2026-01-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020106647A2 (en) 2018-11-19 2020-05-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
US11918584B2 (en) 2018-11-19 2024-03-05 Amgen Inc. Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
US12280056B2 (en) 2018-11-19 2025-04-22 Amgen Inc. Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP4606433A2 (en) 2019-02-12 2025-08-27 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US12187703B2 (en) 2019-05-13 2025-01-07 Novartis Ag Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
US12415806B1 (en) 2019-05-21 2025-09-16 Amgen Inc. Solid state forms
US11827635B2 (en) 2019-05-21 2023-11-28 Amgen Inc. Solid state forms
US12398133B2 (en) 2019-05-21 2025-08-26 Amgen Inc. Solid state forms
US12421234B1 (en) 2019-05-21 2025-09-23 Amgen Inc. Solid state forms
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
WO2021043724A1 (en) 2019-09-02 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia
WO2021057853A1 (en) 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021206167A1 (en) 2020-04-10 2021-10-14 大鵬薬品工業株式会社 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor
WO2021252920A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022033492A1 (en) 2020-08-10 2022-02-17 Novartis Ag Quinoline compounds and compositions for inhibiting ezh2
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US11746103B2 (en) 2020-12-10 2023-09-05 Sumitomo Pharma Oncology, Inc. ALK-5 inhibitors and uses thereof
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
EP4294526A1 (en) * 2021-02-17 2023-12-27 Springworks Therapeutics, Inc. Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US12037306B2 (en) 2021-02-17 2024-07-16 Warner-Lambert Company Llc Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US11884610B2 (en) 2021-02-17 2024-01-30 Springworks Therapeutics, Inc. Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022177555A1 (en) 2021-02-17 2022-08-25 Springworks Therapeutics, Inc. Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US12275688B2 (en) 2021-02-17 2025-04-15 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
EP4294525A1 (en) * 2021-02-17 2023-12-27 Springworks Therapeutics, Inc. Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022177556A1 (en) 2021-02-17 2022-08-25 Warner-Lambert Company Llc Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof
US12090128B2 (en) 2021-02-17 2024-09-17 Springworks Therapeutics, Inc. Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof
WO2022177557A1 (en) 2021-02-17 2022-08-25 Springworks Therapeutics, Inc. Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
US11427534B1 (en) 2021-02-17 2022-08-30 Springworks Therapeutics, Inc. Solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11453641B2 (en) 2021-02-17 2022-09-27 Warner-Lambert Company Llc Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US12357597B2 (en) 2021-02-17 2025-07-15 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
WO2022243846A1 (en) 2021-05-18 2022-11-24 Novartis Ag Combination therapies
US11780862B2 (en) 2022-03-04 2023-10-10 Kinnate Biopharma Inc. Inhibitors of MEK kinase
US12122800B2 (en) 2022-03-04 2024-10-22 Kinnate Biopharma Inc. Inhibitors of MEK kinase
WO2023168203A1 (en) 2022-03-04 2023-09-07 Kinnate Biopharma Inc. Inhibitors of mek kinase
WO2023209611A1 (en) 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023223205A1 (en) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Solid state forms of mirdametinib and process for preparation thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
MY151458A (en) 2014-05-30
EE05450B1 (en) 2011-08-15
CA2416685A1 (en) 2002-01-24
TWI311551B (en) 2009-07-01
EA200300065A1 (en) 2003-10-30
OA12333A (en) 2004-04-06
HUP0302781A3 (en) 2013-06-28
EA005818B1 (en) 2005-06-30
TNSN01108A1 (en) 2005-11-10
KR100773621B1 (en) 2007-11-05
DK1301472T3 (en) 2014-04-07
CZ303815B6 (en) 2013-05-15
PA8522601A1 (en) 2003-05-14
BG107564A (en) 2003-09-30
CN1446197A (en) 2003-10-01
PL365775A1 (en) 2005-01-10
SV2002000563A (en) 2002-08-26
AU2001273498B2 (en) 2006-08-24
GEP20053496B (en) 2005-04-25
BG66386B1 (en) 2013-11-29
HU230251B1 (en) 2015-11-30
EE200300030A (en) 2004-10-15
ZA200300348B (en) 2004-04-13
EP1301472B1 (en) 2014-03-26
EP1301472A2 (en) 2003-04-16
US20050176820A1 (en) 2005-08-11
SI1301472T1 (en) 2014-05-30
BR0112584A (en) 2003-06-17
WO2002006213A3 (en) 2002-05-23
AP2001002217A0 (en) 2001-09-30
US7411001B2 (en) 2008-08-12
PT1301472E (en) 2014-05-15
HK1055943A1 (en) 2004-01-30
HRP20030083A2 (en) 2003-04-30
MA26930A1 (en) 2004-12-20
IL153817A0 (en) 2003-07-31
NO328436B1 (en) 2010-02-22
JP2004504294A (en) 2004-02-12
US20040054172A1 (en) 2004-03-18
BRPI0112584B1 (en) 2018-09-18
ECSP034430A (en) 2003-03-10
ES2461854T3 (en) 2014-05-21
SK288317B6 (en) 2015-11-03
PY0117288A (en) 2003-11-03
PE20020664A1 (en) 2002-08-23
NZ524120A (en) 2005-08-26
AR097445A2 (en) 2016-03-16
AU7349801A (en) 2002-01-30
CZ200369A3 (en) 2003-08-13
SK422003A3 (en) 2003-11-04
CA2416685C (en) 2008-10-07
US6960614B2 (en) 2005-11-01
NO20030249L (en) 2003-02-12
HUP0302781A2 (en) 2003-12-29
JP3811775B2 (en) 2006-08-23
GT200100141A (en) 2002-05-28
KR20030059077A (en) 2003-07-07
PL203387B1 (en) 2009-09-30
AR033542A1 (en) 2003-12-26
YU2503A (en) 2006-05-25
CN1219753C (en) 2005-09-21
UA76425C2 (en) 2006-08-15
AP2003002742A0 (en) 2003-03-31
NO20030249D0 (en) 2003-01-17
DZ3401A1 (en) 2002-01-24
IS6666A (en) 2002-12-31
BRPI0112584B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
EP1301472B1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
AU2001273498A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6770778B2 (en) N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
CN100335461C (en) Arylsulfonanilide ureas
US6891066B2 (en) N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
EP0126612A1 (en) 3,4-Dichloro-N-[2-(2,5-dihydro-1H-pyrrol-1-yl)cyclohexyl]-N-methylbenzeneacetamide
BE898219A (en) New amine derivatives, their salts, process for preparing them, and anti-ulcer agent containing them.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-25/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 153817

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2003-69

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2003/00348

Country of ref document: ZA

Ref document number: 422003

Country of ref document: SK

Ref document number: 200300348

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: DZP2003000021

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2416685

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037000810

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000591

Country of ref document: MX

Ref document number: 03003336

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2001273498

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20030072

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200300065

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P20030083A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2001952778

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018140599

Country of ref document: CN

Ref document number: 524120

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: AP/P/2003/002742

Country of ref document: AP

ENP Entry into the national phase

Ref document number: 10756401

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1200300161

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 6813

Country of ref document: GE

WWP Wipo information: published in national office

Ref document number: 2001952778

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10333399

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020037000810

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-69

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 524120

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524120

Country of ref document: NZ